cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"Based on mRNA TPM data profiling the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), where the patient is a white male with a bladder tumor and a tumor mutational burden of 18 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with supporting rationale.","Based on mRNA TPM data profiling the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), where the patient is a white male with a bladder tumor and a tumor mutational burden of 18 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with supporting rationale. Please load the transcriptomic data from the specified pickle file and analyze it using the Compass algorithm to estimate the patient's probability of responding to ICI therapy. Next, identify the top five immune-related concepts from the Compass results based on their significance scores. Combine these findings with the patient’s metadata to create a comprehensive overview of their immune profile. Then, using the Compass-predicted responder status together with the identified immune concepts, develop clear and detailed reasoning to support whether the patient is likely to respond or not respond to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"A 68-year-old White male with bladder urothelial carcinoma has mRNA TPM data characterizing his tumor immune microenvironment and a tumor mutational burden of 1.0 mutation/MB. Based on these findings, could you determine whether he is more likely to be a responder or non-responder to Atezolizumab, and please provide the rationale for your conclusion?","A 68-year-old White male with bladder urothelial carcinoma has mRNA TPM data characterizing his tumor immune microenvironment and a tumor mutational burden of 1.0 mutation/MB. Based on these findings, could you determine whether he is more likely to be a responder or non-responder to Atezolizumab, and please provide the rationale for your conclusion? Load the transcriptomic data from the designated pickle file and process it with the Compass algorithm to estimate the patient’s likelihood of benefiting from ICI therapy. Next, determine the top five immune-related features based on their significance scores from the Compass output and integrate these with the patient’s metadata to compile a detailed immune profile. Finally, using the Compass-predicted responder status along with the identified immune features, provide a clear and well-supported explanation regarding the patient’s potential response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tumor and a high tumor mutational burden of 44.0 mutations per megabase. Based on this information, can you provide an assessment of the patient's predicted response to Atezolizumab, including a detailed rationale for your conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tumor and a high tumor mutational burden of 44.0 mutations per megabase. Based on this information, can you provide an assessment of the patient's predicted response to Atezolizumab, including a detailed rationale for your conclusion? First, please load the transcriptomic data from the specified pickle file. Then, run the Compass algorithm to evaluate the patient’s probability of benefitting from immune checkpoint inhibitor (ICI) therapy. After that, identify the five most significant immune-related features from the Compass analysis and merge this information with the patient's metadata to create a comprehensive immune profile. Lastly, use the Compass-predicted responder status along with these key immune features to generate a clear, evidence-based explanation of the patient's potential response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment from a patient diagnosed with bladder urothelial carcinoma. The patient is a White female with lymph node tissue involvement and a tumor mutational burden of 2.0 mutations per megabase. Based on these findings, could you please evaluate and provide reasoning on whether this patient is likely to respond to Atezolizumab therapy?","I have processed mRNA TPM data reflecting the tumor immune microenvironment from a patient diagnosed with bladder urothelial carcinoma. The patient is a White female with lymph node tissue involvement and a tumor mutational burden of 2.0 mutations per megabase. Based on these findings, could you please evaluate and provide reasoning on whether this patient is likely to respond to Atezolizumab therapy? Begin by loading the transcriptomic data from the designated pickle file. Next, run the Compass algorithm to assess the patient’s likelihood of responding to immune checkpoint inhibitor (ICI) therapy. Once the analysis is complete, extract the top five immune-related features identified by the Compass analysis and integrate these with the patient’s metadata to form a comprehensive immune profile. Finally, use the Compass-derived responder status and these key immune features to craft a clear, evidence-based explanation of the patient’s potential response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"Given the patient's mRNA TPM data for bladder urothelial carcinoma, can you evaluate their predicted response to atezolizumab? The patient is male, White, with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 8.0 mutations per MB. Please conclude whether this patient is likely to be a responder or non-responder, and provide the reasoning behind your assessment.","Given the patient's mRNA TPM data for bladder urothelial carcinoma, can you evaluate their predicted response to atezolizumab? The patient is male, White, with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 8.0 mutations per MB. Please conclude whether this patient is likely to be a responder or non-responder, and provide the reasoning behind your assessment. First, load the transcriptomic data from the specified pickle file. Then, apply the Compass algorithm to evaluate the patient’s potential response to immune checkpoint inhibitor (ICI) therapy. After completing the analysis, identify the five most significant immune-related features determined by Compass and combine these with the patient’s metadata to create a detailed immune profile. Finally, using both the responder status provided by Compass and these key immune features, develop a clear, evidence-based explanation of the patient’s likely response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have a female patient with bladder urothelial carcinoma (BLCA) who is white and has a tumor mutational burden of 6.0 mutations per MB. We have processed mRNA TPM data representing her tumor immune microenvironment. Based on these data, could you please determine whether she is more likely to respond to Atezolizumab and explain the reasoning behind your conclusion?","I have a female patient with bladder urothelial carcinoma (BLCA) who is white and has a tumor mutational burden of 6.0 mutations per MB. We have processed mRNA TPM data representing her tumor immune microenvironment. Based on these data, could you please determine whether she is more likely to respond to Atezolizumab and explain the reasoning behind your conclusion? Begin by importing the transcriptomic data from the designated pickle file. Next, use the Compass algorithm to assess the patient’s likely response to immune checkpoint inhibitor therapy. Once the algorithm completes its analysis, extract the five most significant immune-related features it identifies and merge these with the patient’s metadata to construct a detailed immune profile. Finally, based on both the responder classification reported by Compass and these key immune features, formulate an evidence-based explanation regarding the patient’s potential response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"Based on mRNA TPM data from this patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA), could you assess their predicted responsiveness to Atezolizumab? The patient's clinical attributes are as follows: Male, White, tissue source is kidney, diagnosed with BLCA, and a tumor mutational burden of 11 mutations per MB. Please provide your conclusion regarding whether this patient is likely to respond to Atezolizumab, along with your rationale.","Based on mRNA TPM data from this patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA), could you assess their predicted responsiveness to Atezolizumab? The patient's clinical attributes are as follows: Male, White, tissue source is kidney, diagnosed with BLCA, and a tumor mutational burden of 11 mutations per MB. Please provide your conclusion regarding whether this patient is likely to respond to Atezolizumab, along with your rationale. First, load the transcriptomic data from the specified pickle file. Then, apply the Compass algorithm to evaluate the patient’s potential response to immune checkpoint inhibitor therapy. After the analysis is complete, identify and extract the five most significant immune-related features, and integrate these with the patient’s metadata to develop a comprehensive immune profile. Finally, use the responder classification provided by Compass along with these key immune features to construct an evidence-based assessment of the patient’s likely response to ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"Given the processed mRNA TPM data for a patient's tumor immune microenvironment with Bladder Urothelial Carcinoma (BLCA), alongside clinical information including male sex, white race, bladder tissue origin, and a tumor mutational burden of 18 mutations/MB, how would you assess the predicted responsiveness to Atezolizumab? Please specify whether this patient is likely a responder or non-responder and provide the supporting rationale for your conclusion.","Given the processed mRNA TPM data for a patient's tumor immune microenvironment with Bladder Urothelial Carcinoma (BLCA), alongside clinical information including male sex, white race, bladder tissue origin, and a tumor mutational burden of 18 mutations/MB, how would you assess the predicted responsiveness to Atezolizumab? Please specify whether this patient is likely a responder or non-responder and provide the supporting rationale for your conclusion. Begin by loading the transcriptomic data from the designated pickle file. Next, apply the Compass algorithm to assess the patient’s potential response to immune checkpoint inhibitor therapy. Once the analysis is complete, identify and extract the five most significant immune-related features, and combine these with the patient’s metadata to create a comprehensive immune profile. Finally, use the responder classification provided by Compass, along with these key features, to develop an evidence-based evaluation of the patient’s likely response to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"Based on processed mRNA TPM data from a patient's bladder tumor immune microenvironment with the following attributes—female, White, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), and with an unavailable tumor mutational burden—can you conclude if this patient is likely to respond to Atezolizumab and explain the rationale behind the prediction?","Based on processed mRNA TPM data from a patient's bladder tumor immune microenvironment with the following attributes—female, White, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), and with an unavailable tumor mutational burden—can you conclude if this patient is likely to respond to Atezolizumab and explain the rationale behind the prediction? First, load the transcriptomic data from the specified pickle file. Then, use the Compass algorithm to evaluate the patient's potential response to immune checkpoint inhibitor therapy. Once the analysis is complete, identify the five most significant immune-related features and merge them with the patient’s metadata to form a comprehensive immune profile. Finally, combine the responder classification from Compass with these critical features to generate an evidence-based assessment of the patient’s likely response to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"Based on processed mRNA TPM data from the tumor immune microenvironment of a male, white patient with Bladder Urothelial Carcinoma—and considering that details on tissue status and tumor mutational burden are unavailable—can we determine if this patient is likely to respond to Atezolizumab? Please provide your conclusion (responder or non-responder) along with the supporting rationale.","Based on processed mRNA TPM data from the tumor immune microenvironment of a male, white patient with Bladder Urothelial Carcinoma—and considering that details on tissue status and tumor mutational burden are unavailable—can we determine if this patient is likely to respond to Atezolizumab? Please provide your conclusion (responder or non-responder) along with the supporting rationale. Begin by loading the transcriptomic dataset from the designated pickle file. Next, apply the Compass algorithm to assess the patient's potential response to immune checkpoint inhibitor therapy. After completing this analysis, determine the five most significant immune-related features. Merge these features with the patient's metadata to build a comprehensive immune profile. Finally, integrate the responder classification produced by Compass with these key features to formulate an evidence-based evaluation of the patient’s likely response to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"Can you evaluate the predicted responsiveness to Atezolizumab for a male patient with Bladder Urothelial Carcinoma (BLCA) whose processed mRNA TPM data reflects his tumor immune microenvironment? The patient is white, his tissue sample was obtained from the kidney, and he has a tumor mutational burden of 2.0 mutations per megabase. Please provide your assessment on whether this patient is likely to respond to Atezolizumab, along with the supporting rationale for your conclusion.","Can you evaluate the predicted responsiveness to Atezolizumab for a male patient with Bladder Urothelial Carcinoma (BLCA) whose processed mRNA TPM data reflects his tumor immune microenvironment? The patient is white, his tissue sample was obtained from the kidney, and he has a tumor mutational burden of 2.0 mutations per megabase. Please provide your assessment on whether this patient is likely to respond to Atezolizumab, along with the supporting rationale for your conclusion. First, load the transcriptomic dataset from the specified pickle file. Then, apply the Compass algorithm to evaluate the patient's potential response to immune checkpoint inhibitor (ICI) therapy. Afterward, identify the five most significant immune-related features, and combine these with the patient's metadata to create a comprehensive immune profile. Finally, integrate the responder classification from the Compass algorithm with these key immune features to produce an evidence-based assessment of the patient’s likely response to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"Based on the available mRNA TPM data of the tumor immune microenvironment in a male, White patient diagnosed with Bladder Urothelial Carcinoma and a tumor mutational burden of 8.0 mutations per MB, could you please assess the predicted responsiveness to Atezolizumab and explain the reasoning behind classifying the patient as a responder or non-responder?","Based on the available mRNA TPM data of the tumor immune microenvironment in a male, White patient diagnosed with Bladder Urothelial Carcinoma and a tumor mutational burden of 8.0 mutations per MB, could you please assess the predicted responsiveness to Atezolizumab and explain the reasoning behind classifying the patient as a responder or non-responder? Begin by loading the transcriptomic dataset from the designated pickle file. Next, apply the Compass algorithm to assess the patient’s potential response to immune checkpoint inhibitor therapy. Then, identify the five most significant immune-related features and merge them with the patient’s metadata to construct a comprehensive immune profile. Finally, combine the responder classification from the Compass algorithm with these key immune features to generate an evidence-based evaluation of the patient’s likelihood of responding to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"Using mRNA TPM data from the tumor immune microenvironment for a patient with bladder urothelial carcinoma, how should we assess her potential responsiveness to Atezolizumab? The patient is a White female with disease involving the lymph node, and her tumor mutational burden data is unavailable. Could you provide a conclusion on whether she is likely to respond to treatment, supported by your analysis?","Using mRNA TPM data from the tumor immune microenvironment for a patient with bladder urothelial carcinoma, how should we assess her potential responsiveness to Atezolizumab? The patient is a White female with disease involving the lymph node, and her tumor mutational burden data is unavailable. Could you provide a conclusion on whether she is likely to respond to treatment, supported by your analysis? Step 1: Import the transcriptomic dataset from the specified pickle file. 

Step 2: Run the Compass algorithm to evaluate the patient’s potential responsiveness to immune checkpoint inhibitor (ICI) therapy.

Step 3: Identify the top five immune-related features from this analysis and integrate them with the patient’s existing metadata to develop a detailed immune profile.

Step 4: Combine the responder classification from the Compass algorithm with these key immune features to produce a comprehensive, evidence-based assessment of the patient’s likelihood of benefiting from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a  male, white individual with a tumor in the ureter and a tumor mutational burden of 9.0 (FMOne mutations per MB). Based on this information, could you please evaluate and detail whether the patient is likely to respond to Atezolizumab therapy, including your reasoning?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a  male, white individual with a tumor in the ureter and a tumor mutational burden of 9.0 (FMOne mutations per MB). Based on this information, could you please evaluate and detail whether the patient is likely to respond to Atezolizumab therapy, including your reasoning? 1. Begin by loading the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to assess the patient’s potential responsiveness to immune checkpoint inhibitor (ICI) therapy.  
3. Identify the five most relevant immune-related features from this analysis and merge them with the patient's existing metadata to create a detailed immune profile.  
4. Integrate the responder classification determined by the Compass algorithm with these key immune features to formulate a comprehensive, evidence-based assessment of the patient’s likelihood of benefiting from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"I have processed mRNA TPM data representing a patient’s tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and would like to assess the potential response to Atezolizumab. The patient is a white female with bladder tissue involvement, and her tumor mutational burden is 4.0 mutations per MB. Based on these findings, can you determine whether she is likely to be a responder or non-responder to Atezolizumab, and explain the clinical rationale behind your conclusion?","I have processed mRNA TPM data representing a patient’s tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and would like to assess the potential response to Atezolizumab. The patient is a white female with bladder tissue involvement, and her tumor mutational burden is 4.0 mutations per MB. Based on these findings, can you determine whether she is likely to be a responder or non-responder to Atezolizumab, and explain the clinical rationale behind your conclusion? 1. Load the transcriptomic dataset from the specified pickle file.  
2. Use the Compass algorithm to evaluate the patient’s potential responsiveness to immune checkpoint inhibitor (ICI) treatment.  
3. Identify the top five immune-related features from this analysis and combine them with the patient's existing metadata to establish a detailed immune profile.  
4. Merge the responder classification determined by the Compass algorithm with these key immune features to develop a comprehensive, evidence-based assessment of the patient’s likely benefit from ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"I have mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and need to assess predicted responsiveness to atezolizumab. The patient is a white male, with tumor tissue originating from the ureter, and exhibits a tumor mutational burden of 32 mutations per megabase. Could you help determine whether this patient is more likely to be classified as a responder or non-responder to atezolizumab, providing the supporting rationale for this assessment?","I have mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and need to assess predicted responsiveness to atezolizumab. The patient is a white male, with tumor tissue originating from the ureter, and exhibits a tumor mutational burden of 32 mutations per megabase. Could you help determine whether this patient is more likely to be classified as a responder or non-responder to atezolizumab, providing the supporting rationale for this assessment? 1. Begin by loading the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to assess the patient's likelihood of responding to immune checkpoint inhibitor (ICI) therapy.  
3. From the analysis, extract the five most relevant immune-related features and integrate them with the patient's existing clinical metadata to construct a detailed immune profile.  
4. Finally, combine the responder categorization provided by the Compass algorithm with these immune features to generate a comprehensive, evidence-based evaluation of the patient's potential benefit from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"I have mRNA TPM data profiling the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). This white male patient has a bladder tumor and a tumor mutational burden of 21.0 mutations per megabase. Based on these clinical and molecular characteristics, could you assess whether he is likely to respond to Atezolizumab and explain the reasoning behind your evaluation?","I have mRNA TPM data profiling the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). This white male patient has a bladder tumor and a tumor mutational burden of 21.0 mutations per megabase. Based on these clinical and molecular characteristics, could you assess whether he is likely to respond to Atezolizumab and explain the reasoning behind your evaluation? 1. Load the transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to evaluate the likelihood that the patient will respond to immune checkpoint inhibitor (ICI) therapy.
3. Identify the five most significant immune-related features from the analysis and merge these with the patient’s existing clinical data to create a detailed immune profile.
4. Integrate the responder classification derived from the Compass algorithm with the identified immune features to produce a comprehensive, evidence-based assessment of the patient’s potential benefit from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA). The patient is a 61-year-old White male with kidney tissue sampling and a tumor mutational burden of 10.0 mutations per MB. Based on these parameters, could you provide an evaluation of the patient’s predicted responsiveness to Atezolizumab, including the rationale for a responder or non-responder classification?","I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA). The patient is a 61-year-old White male with kidney tissue sampling and a tumor mutational burden of 10.0 mutations per MB. Based on these parameters, could you provide an evaluation of the patient’s predicted responsiveness to Atezolizumab, including the rationale for a responder or non-responder classification? 1. Retrieve the transcriptomic dataset from the designated pickle file.  
2. Employ the Compass algorithm to assess the probability that the patient will respond to immune checkpoint inhibitor (ICI) therapy.  
3. Select the top five most relevant immune-related features from the analysis and combine these with the patient’s existing clinical data to build a comprehensive immune profile.  
4. Merge the responder classification obtained from the Compass algorithm with the identified immune features to generate a detailed, evidence-based evaluation of the patient’s potential benefit from ICI treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a male white patient with bladder urothelial carcinoma (BLCA), who exhibits a high tumor mutational burden (38 mutations per MB). Based on this data, could you assess the patient's likely response to Atezolizumab? Please indicate whether he is expected to be a responder or non-responder, and provide the rationale for your conclusion.","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a male white patient with bladder urothelial carcinoma (BLCA), who exhibits a high tumor mutational burden (38 mutations per MB). Based on this data, could you assess the patient's likely response to Atezolizumab? Please indicate whether he is expected to be a responder or non-responder, and provide the rationale for your conclusion. 1. Begin by loading the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to determine the likelihood that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Identify and extract the five most significant immune-related features from the analysis, then integrate these features with the patient’s current clinical data to form a comprehensive immune profile.  
4. Finally, combine the patient’s responder classification (as determined by the Compass algorithm) with the selected immune features to create an evidence-based assessment of the patient’s prospective response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"Based on the mRNA TPM data reflecting the tumor immune microenvironment for Bladder Urothelial Carcinoma, with the following patient characteristics—female, White, bladder tissue involvement, and an FMOne mutational burden of 7 mutations per MB—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your reasoning for classifying the patient as a responder or non-responder.","Based on the mRNA TPM data reflecting the tumor immune microenvironment for Bladder Urothelial Carcinoma, with the following patient characteristics—female, White, bladder tissue involvement, and an FMOne mutational burden of 7 mutations per MB—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your reasoning for classifying the patient as a responder or non-responder. 1. Load the transcriptomic dataset from the indicated pickle file.  
2. Employ the Compass algorithm to evaluate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune-related features from the analysis, and incorporate these with the patient’s current clinical data to build a detailed immune profile.  
4. Integrate the responder classification, as determined by the Compass algorithm, with these selected immune features to generate an evidence-based prediction regarding the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a male patient with bladder urothelial carcinoma (BLCA) who is White and has a tumor mutational burden of 5 mutations/Mb, and whose mRNA TPM data reflecting the tumor immune microenvironment has been analyzed—what is your assessment of his likelihood to respond to Atezolizumab? Please provide the classification as a responder or non-responder along with your rationale.","For a male patient with bladder urothelial carcinoma (BLCA) who is White and has a tumor mutational burden of 5 mutations/Mb, and whose mRNA TPM data reflecting the tumor immune microenvironment has been analyzed—what is your assessment of his likelihood to respond to Atezolizumab? Please provide the classification as a responder or non-responder along with your rationale. 1. Begin by loading the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to determine the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. From your analysis, extract the five most relevant immune-related features and combine these with the patient’s current clinical data to construct a comprehensive immune profile.  
4. Finally, merge the responder classification provided by the Compass algorithm with the selected immune features to formulate an evidence-based prediction of the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"Given the mRNA TPM data for this patient's tumor immune microenvironment and the following clinical details: Male, White, diagnosed with bladder urothelial carcinoma (BLCA) with bladder tissue as the source, and a tumor mutational burden of 15.0 mutations per MB, could you please determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion.","Given the mRNA TPM data for this patient's tumor immune microenvironment and the following clinical details: Male, White, diagnosed with bladder urothelial carcinoma (BLCA) with bladder tissue as the source, and a tumor mutational burden of 15.0 mutations per MB, could you please determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion. 1. Start by importing the transcriptomic dataset contained in the designated pickle file.  
2. Utilize the Compass algorithm to evaluate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Identify the five key immune-related features from your analysis and integrate these with the patient’s current clinical data to develop a comprehensive immune profile.  
4. Finally, combine the immune profile with the responder classification provided by the Compass algorithm to create an evidence-based prediction of the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"Based on processed mRNA TPM data for the patient's tumor immune microenvironment and the following clinical details—male, white, kidney tissue, diagnosis of Bladder Urothelial Carcinoma, and an undefined tumor mutational burden (nan)—could you please assess the likelihood of response to Atezolizumab? Specifically, is there evidence to classify this patient as a responder or non-responder, and what is the rationale for this assessment?","Based on processed mRNA TPM data for the patient's tumor immune microenvironment and the following clinical details—male, white, kidney tissue, diagnosis of Bladder Urothelial Carcinoma, and an undefined tumor mutational burden (nan)—could you please assess the likelihood of response to Atezolizumab? Specifically, is there evidence to classify this patient as a responder or non-responder, and what is the rationale for this assessment? 1. Begin by loading the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to assess the likelihood of the patient responding to immune checkpoint inhibitor therapy.  
3. Determine the five critical immune-related features from your analysis, then merge these findings with the patient's existing clinical data to form an integrated immune profile.  
4. Lastly, use the combined immune profile and the response classification from the Compass algorithm to generate an evidence-based prediction regarding the patient's potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with a tissue sample from the lung, and the tumor mutational burden (FMO mutation burden per MB) is reported as not available (nan). Based on this information, could you provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting rationale?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with a tissue sample from the lung, and the tumor mutational burden (FMO mutation burden per MB) is reported as not available (nan). Based on this information, could you provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting rationale? 1. Load the transcriptomic dataset from the designated pickle file.  
2. Utilize the Compass algorithm to estimate the probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Identify the five key immune-related features revealed by this analysis and integrate them with the patient's clinical data to establish a comprehensive immune profile.  
4. Finally, combine the evidence from the integrated immune profile with the response prediction from the Compass algorithm to generate an informed forecast regarding the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in this male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 18 mutations/MB, could you determine whether the patient is likely to respond to Atezolizumab? Please include your rationale considering the clinical and molecular characteristics.","Based on the processed mRNA TPM data reflecting the tumor immune microenvironment in this male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 18 mutations/MB, could you determine whether the patient is likely to respond to Atezolizumab? Please include your rationale considering the clinical and molecular characteristics. 1. Retrieve the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to calculate the likelihood that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Determine the top five immune-related features identified by this analysis and merge them with the patient’s clinical data to create a detailed immune profile.  
4. Integrate the findings from the immune profile with the response prediction from the Compass algorithm to provide a well-informed forecast of the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and evaluated relevant clinical attributes (Sex: M, Race: Black or African American, Tissue: ureter, Tumor Mutational Burden: 7.0 mutations per MB). Could you help determine, based on these data, whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with the underlying rationale.","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and evaluated relevant clinical attributes (Sex: M, Race: Black or African American, Tissue: ureter, Tumor Mutational Burden: 7.0 mutations per MB). Could you help determine, based on these data, whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with the underlying rationale. 1. Access the transcriptomic dataset using the designated pickle file.  
2. Utilize the Compass algorithm to evaluate the probability that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Identify the top five immune-related markers from the analysis and combine them with the patient’s clinical data to construct a comprehensive immune profile.  
4. Integrate the immune profile with the response prediction from the Compass algorithm to generate an informed forecast of the patient’s potential response to immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"Based on the mRNA TPM data from this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical attributes (Sex: M, Race: WHITE, Tissue: bladder, Tumor Mutational Burden: 19.0 FMOne mutation burden per MB), could you evaluate the likelihood of a favorable response to Atezolizumab? Please provide a conclusion on whether the patient is predicted to be a responder or non-responder, along with the reasoning supporting this classification.","Based on the mRNA TPM data from this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical attributes (Sex: M, Race: WHITE, Tissue: bladder, Tumor Mutational Burden: 19.0 FMOne mutation burden per MB), could you evaluate the likelihood of a favorable response to Atezolizumab? Please provide a conclusion on whether the patient is predicted to be a responder or non-responder, along with the reasoning supporting this classification. 1. Retrieve the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. From the analysis, select the five most important immune-related markers; then, merge these markers with the patient's clinical data to develop a detailed immune profile.
4. Combine this immune profile with the response prediction from the Compass algorithm to generate a well-informed estimate of the patient's potential benefit from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"Based on mRNA TPM expression data that characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma—specifically a male, White patient with a bladder tumor and a tumor mutational burden of 5.0 mutations per MB—could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion.","Based on mRNA TPM expression data that characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma—specifically a male, White patient with a bladder tumor and a tumor mutational burden of 5.0 mutations per MB—could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion. 1. Retrieve the transcriptomic dataset from the designated pickle file.
2. Use the Compass algorithm to calculate the probability that the patient will have a positive response to immune checkpoint inhibitor therapy.
3. Identify the top five immune-related markers based on their importance, and then integrate these markers with the patient’s clinical information to create a comprehensive immune profile.
4. Combine the derived immune profile with the Compass algorithm prediction to formulate a robust estimation of the patient’s potential benefit from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"Based on an mRNA TPM profile of the patient's tumor immune microenvironment and the following clinical details: male, white, bladder tissue, a diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB, could you determine whether this patient is predicted to respond to Atezolizumab? Please provide your conclusion along with the supporting clinical rationale.","Based on an mRNA TPM profile of the patient's tumor immune microenvironment and the following clinical details: male, white, bladder tissue, a diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB, could you determine whether this patient is predicted to respond to Atezolizumab? Please provide your conclusion along with the supporting clinical rationale. 1. Begin by loading the transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune-related markers and merge these findings with the patient’s clinical data to construct a detailed immune profile.
4. Integrate the immune profile with the Compass algorithm’s outcome to generate a comprehensive assessment of the patient’s expected benefit from immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and given that the patient is male, White, with a bladder tumor and a tumor mutational burden of 8.0 mutations per MB, what is the predicted response to Atezolizumab? Please provide a conclusion on whether the patient is likely a responder or non-responder, along with supporting reasoning.","Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and given that the patient is male, White, with a bladder tumor and a tumor mutational burden of 8.0 mutations per MB, what is the predicted response to Atezolizumab? Please provide a conclusion on whether the patient is likely a responder or non-responder, along with supporting reasoning. 1. Load transcriptomic data from the provided pickle file.
2. Utilize the Compass algorithm to calculate the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Identify the top five immune-related markers and integrate these results with the patient’s clinical data to develop a comprehensive immune profile.
4. Combine the immune profile with the Compass algorithm’s results to form a detailed assessment of the patient’s potential benefit from immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), including details such as Female sex, White race, tumor tissue from the ureter, and a tumor mutational burden of 13.0 FMOne mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please provide the classification (responder or non-responder) along with a detailed explanation of your rationale.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), including details such as Female sex, White race, tumor tissue from the ureter, and a tumor mutational burden of 13.0 FMOne mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please provide the classification (responder or non-responder) along with a detailed explanation of your rationale. 1. Import the transcriptomic data contained in the specified pickle file.
2. Utilize the Compass algorithm to estimate the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune-related markers and merge this data with the patient’s clinical information to create a comprehensive immune profile.
4. Integrate the detailed immune profile with the Compass algorithm results to perform an in-depth assessment of the patient’s potential benefit from immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"Based on processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—male, White, kidney tissue, with a tumor mutational burden of 16 mutations per MB—does this patient appear likely to respond to Atezolizumab therapy? Please provide your conclusion along with the supporting rationale.","Based on processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—male, White, kidney tissue, with a tumor mutational burden of 16 mutations per MB—does this patient appear likely to respond to Atezolizumab therapy? Please provide your conclusion along with the supporting rationale. 1. Load the transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the likelihood of the patient responding favorably to immune checkpoint inhibitor therapy.
3. Select the top five immune-related markers and merge these with the patient’s clinical information to build an inclusive immune profile.
4. Combine the detailed immune profile with the results from the Compass algorithm to thoroughly evaluate the patient's potential benefit from immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"I have generated mRNA TPM data reflecting the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (using kidney tissue) and a tumor mutational burden of 2.0 mutations per MB. Based on these parameters, could you please assess whether this patient is likely to respond to atezolizumab and provide the rationale for your conclusion?","I have generated mRNA TPM data reflecting the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (using kidney tissue) and a tumor mutational burden of 2.0 mutations per MB. Based on these parameters, could you please assess whether this patient is likely to respond to atezolizumab and provide the rationale for your conclusion? 1. Begin by loading the transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to estimate the patient's likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Identify the top five immune-related markers and integrate these with the patient’s clinical data to construct a comprehensive immune profile.
4. Finally, combine the detailed immune profile with the outcomes of the Compass algorithm to assess the patient's potential benefit from immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data that characterize the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient details are as follows: Sex – female; Race – white; Tissue – bladder; Disease – Bladder Urothelial Carcinoma; Tumor Mutational Burden – not available (nan). Based on this information, could you provide a clinical assessment of whether the patient is likely to respond to Atezolizumab, including the supporting rationale for classifying her as a responder or non-responder?","I have processed mRNA TPM data that characterize the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient details are as follows: Sex – female; Race – white; Tissue – bladder; Disease – Bladder Urothelial Carcinoma; Tumor Mutational Burden – not available (nan). Based on this information, could you provide a clinical assessment of whether the patient is likely to respond to Atezolizumab, including the supporting rationale for classifying her as a responder or non-responder? 1. Load the transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy.
3. Identify the five most relevant immune-related markers and merge them with the patient's clinical data to build an integrated immune profile.
4. Combine this immune profile with the Compass algorithm outcomes to evaluate the patient’s potential benefit from the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"Based on the patient's processed mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with clinical details including male sex, white race, bladder tissue origin, and a tumor mutational burden of 7.0 mutations per MB, could you please evaluate whether this patient is likely to respond to Atezolizumab and provide the underlying rationale for your assessment?","Based on the patient's processed mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with clinical details including male sex, white race, bladder tissue origin, and a tumor mutational burden of 7.0 mutations per MB, could you please evaluate whether this patient is likely to respond to Atezolizumab and provide the underlying rationale for your assessment? 1. Begin by loading the transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to determine the patient's likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Identify the top five immune-related markers of relevance and integrate these with the patient’s clinical data to form a comprehensive immune profile.  
4. Finally, combine this immune profile with the results obtained from the Compass algorithm to assess the potential benefit of the therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"Based on the processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you please provide your clinical interpretation regarding the likelihood of response to Atezolizumab? The patient is a white male with bladder tissue involvement and has a tumor mutational burden of 20 mutations per MB. Please include your reasoning and any relevant supporting evidence for classifying the patient as a responder or non-responder.","Based on the processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you please provide your clinical interpretation regarding the likelihood of response to Atezolizumab? The patient is a white male with bladder tissue involvement and has a tumor mutational burden of 20 mutations per MB. Please include your reasoning and any relevant supporting evidence for classifying the patient as a responder or non-responder. 1. Load the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to evaluate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune-related markers and integrate these findings with the patient’s clinical information to develop a detailed immune profile.  
4. Finally, merge the immune profile with the Compass algorithm results to determine the potential benefit of the proposed therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,We have mRNA TPM expression data characterizing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and explain the rationale for your conclusion?,"We have mRNA TPM expression data characterizing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and explain the rationale for your conclusion? 1. Begin by loading the transcriptomic data from the specified pickle file.  
2. Next, apply the Compass algorithm to estimate the patient’s likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune-related markers and, using this information alongside the patient’s clinical data, construct a detailed immune profile.  
4. Finally, integrate the immune profile with the Compass algorithm results to assess the potential benefits of the proposed therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"I have mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 38-year-old male of White ethnicity, with a bladder tumor exhibiting a tumor mutational burden of 38.0 mutations per MB. Based on these factors, how would you assess the predicted responsiveness to Atezolizumab, and can you provide the supporting rationale for your conclusion?","I have mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 38-year-old male of White ethnicity, with a bladder tumor exhibiting a tumor mutational burden of 38.0 mutations per MB. Based on these factors, how would you assess the predicted responsiveness to Atezolizumab, and can you provide the supporting rationale for your conclusion? 1. First, load the transcriptomic dataset from the designated pickle file.
2. Then, use the Compass algorithm to evaluate the patient’s probability of responding well to immune checkpoint inhibitors.
3. Next, identify the top five immune-related biomarkers and combine these findings with the patient’s clinical information to develop a comprehensive immune profile.
4. Lastly, incorporate this immune profile with the Compass algorithm outcomes to determine the likely benefits of the proposed therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For a patient diagnosed with bladder urothelial carcinoma who has mRNA TPM data detailing the tumor immune microenvironment—considering the following attributes: male, White, tissue sample from kidney, and a tumor mutational burden of 6.0 mutations per MB—could you please provide a classification of the patient's predicted response to Atezolizumab (responder vs. non-responder) along with the rationale supporting that classification?","For a patient diagnosed with bladder urothelial carcinoma who has mRNA TPM data detailing the tumor immune microenvironment—considering the following attributes: male, White, tissue sample from kidney, and a tumor mutational burden of 6.0 mutations per MB—could you please provide a classification of the patient's predicted response to Atezolizumab (responder vs. non-responder) along with the rationale supporting that classification? 1. Begin by loading the transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to assess the patient's likelihood of responding well to immune checkpoint inhibitor therapy.
3. Identify the top five immune-related biomarkers and combine these results with the patient’s clinical data to develop a detailed immune profile.
4. Finally, integrate this immune profile with the Compass algorithm outcomes to evaluate the potential benefits of the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"Based on the processed mRNA TPM data assessing the tumor immune microenvironment for a male patient with bladder urothelial carcinoma (BLCA) — including details such as race (White), tissue (bladder), and a tumor mutational burden of 8.0 mutations/MB — what is the predicted therapeutic response to Atezolizumab (i.e., responder versus non-responder), and what evidence supports this conclusion?","Based on the processed mRNA TPM data assessing the tumor immune microenvironment for a male patient with bladder urothelial carcinoma (BLCA) — including details such as race (White), tissue (bladder), and a tumor mutational burden of 8.0 mutations/MB — what is the predicted therapeutic response to Atezolizumab (i.e., responder versus non-responder), and what evidence supports this conclusion? 1. Load the transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to determine the patient’s probability of a positive response to immune checkpoint inhibitor therapy.
3. Identify the five most critical immune-related biomarkers and merge these findings with the patient’s clinical information to create a comprehensive immune profile.
4. Combine the immune profile with the Compass results to assess the potential benefits of the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"Based on the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and considering his attributes—a white male with bladder tissue involvement and a tumor mutational burden of 13.0 mutations per megabase—could you assess his predicted responsiveness to Atezolizumab by indicating whether he is likely a responder or non-responder, and provide the supporting rationale?","Based on the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and considering his attributes—a white male with bladder tissue involvement and a tumor mutational burden of 13.0 mutations per megabase—could you assess his predicted responsiveness to Atezolizumab by indicating whether he is likely a responder or non-responder, and provide the supporting rationale? 1. Retrieve the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Identify the top five immune-related biomarkers and integrate these with the patient’s clinical data to develop a detailed immune profile.  
4. Combine the immune profile with the Compass algorithm results to evaluate the potential benefits of the proposed treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"Given the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following details (Male, White, kidney tissue, and a tumor mutational burden of 5 mutations/MB), can we determine if the patient is likely to respond to Atezolizumab? Please provide a conclusion with your supporting clinical rationale.","Given the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following details (Male, White, kidney tissue, and a tumor mutational burden of 5 mutations/MB), can we determine if the patient is likely to respond to Atezolizumab? Please provide a conclusion with your supporting clinical rationale. 1. Retrieve the transcriptomic dataset stored in the designated pickle file.  
2. Use the Compass algorithm to determine the probability that the patient will have a positive response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune-related biomarkers and merge these findings with the patient's clinical data to create a detailed immune profile.  
4. Integrate the comprehensive immune profile with the Compass algorithm's output to assess the potential benefits of the proposed treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"The patient is a female with White ethnicity diagnosed with bladder urothelial carcinoma (BLCA), and her tumor presents with a tumor mutational burden (TMB) of 5 mutations per megabase. Given this data and the mRNA TPM profile of her tumor immune microenvironment, could you please evaluate her likely response to Atezolizumab therapy? Specifically, is she more likely to be classified as a responder or non-responder, and what evidence supports this conclusion?","The patient is a female with White ethnicity diagnosed with bladder urothelial carcinoma (BLCA), and her tumor presents with a tumor mutational burden (TMB) of 5 mutations per megabase. Given this data and the mRNA TPM profile of her tumor immune microenvironment, could you please evaluate her likely response to Atezolizumab therapy? Specifically, is she more likely to be classified as a responder or non-responder, and what evidence supports this conclusion? Step 1: Load the transcriptomic dataset from the specified pickle file.  
Step 2: Apply the Compass algorithm to estimate the likelihood of the patient responding positively to immune checkpoint inhibitor therapy.  
Step 3: Identify the five key immune-related biomarkers and integrate these findings with the patient’s clinical data to develop a comprehensive immune profile.  
Step 4: Combine the detailed immune profile with the output of the Compass algorithm to evaluate the potential benefit of the proposed treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tissue sample from the kidney and a tumor mutational burden of 5.0 mutations per MB. Based on this information, could you please assess the predicted response to Atezolizumab and explain the rationale for classifying the patient as a responder or non-responder?","I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tissue sample from the kidney and a tumor mutational burden of 5.0 mutations per MB. Based on this information, could you please assess the predicted response to Atezolizumab and explain the rationale for classifying the patient as a responder or non-responder? 1. Begin by importing the transcriptomic dataset from the designated pickle file.  
2. Next, utilize the Compass algorithm to assess the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Then, pinpoint the five most significant immune-related biomarkers and integrate these results with the patient’s clinical data to construct a detailed immune profile.  
4. Finally, merge the comprehensive immune profile with the Compass algorithm's output to evaluate the potential benefits of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma to assess the tumor immune microenvironment. The patient is male, white, with tissue classification noted as “other,” and the tumor mutational burden (FMO mutation burden per MB) is not available (nan). Based on these parameters, could you provide a scientifically reasoned assessment on whether the patient is likely to respond to Atezolizumab?","I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma to assess the tumor immune microenvironment. The patient is male, white, with tissue classification noted as “other,” and the tumor mutational burden (FMO mutation burden per MB) is not available (nan). Based on these parameters, could you provide a scientifically reasoned assessment on whether the patient is likely to respond to Atezolizumab? 1. First, load the transcriptomic dataset from the specified pickle file.  
2. Then, apply the Compass algorithm to estimate the likelihood that the patient will have a positive response to immune checkpoint inhibitor therapy.  
3. Next, identify the five most relevant immune-related biomarkers and combine these findings with the patient's clinical data to develop a comprehensive immune profile.  
4. Finally, integrate this detailed immune profile with the output from the Compass algorithm to assess the potential effectiveness of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,Given mRNA TPM data indicating the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and the following attributes—Sex: Female; Race: White; tissue sampled from a lymph node; Tumor Mutational Burden: 12.0 mutations/MB—could you assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale based on the available data.,"Given mRNA TPM data indicating the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and the following attributes—Sex: Female; Race: White; tissue sampled from a lymph node; Tumor Mutational Burden: 12.0 mutations/MB—could you assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale based on the available data. 1. Begin by loading the transcriptomic dataset from the indicated pickle file.  
2. Next, run the Compass algorithm to estimate the patient's probability of responding to immune checkpoint inhibitor therapy.  
3. Then, determine the five most significant immune-related biomarkers and merge these results with the patient's clinical data to create a detailed immune profile.  
4. Finally, combine this comprehensive immune profile with the Compass algorithm's output to evaluate the potential effectiveness of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"Based on mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), where the patient is a male of Asian descent with bladder tissue involvement and a tumor mutational burden of 1.0 mutation per MB, could you assess the likelihood of a favorable response to Atezolizumab? Please provide your rationale for classifying this patient as a responder or non-responder.","Based on mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), where the patient is a male of Asian descent with bladder tissue involvement and a tumor mutational burden of 1.0 mutation per MB, could you assess the likelihood of a favorable response to Atezolizumab? Please provide your rationale for classifying this patient as a responder or non-responder. 1. Load the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to calculate the likelihood of the patient responding to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune-related biomarkers, and integrate these findings with the patient’s clinical data to generate a comprehensive immune profile.
4. Combine this detailed immune profile with the outputs from the Compass algorithm to assess the overall potential effectiveness of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a 6.0 FMOne mutation burden per MB, white male with bladder tissue involvement. Based on these parameters, how would you assess his predicted responsiveness to Atezolizumab, and what is the rationale for classifying him as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a 6.0 FMOne mutation burden per MB, white male with bladder tissue involvement. Based on these parameters, how would you assess his predicted responsiveness to Atezolizumab, and what is the rationale for classifying him as a responder or non-responder? 1. Begin by loading the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Select the top five immune-related biomarkers and combine these findings with the patient’s clinical data to construct a comprehensive immune profile.
4. Integrate the detailed immune profile with the results from the Compass algorithm to evaluate the overall potential efficacy of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"For a female patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations per MB, whose mRNA TPM data reflects the tumor immune microenvironment, could you evaluate the likelihood of a positive response to Atezolizumab therapy? Please include the reasoning behind your assessment.","For a female patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations per MB, whose mRNA TPM data reflects the tumor immune microenvironment, could you evaluate the likelihood of a positive response to Atezolizumab therapy? Please include the reasoning behind your assessment. 1. Load the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to gauge the patient's predicted response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune-related biomarkers and integrate these with the patient's clinical data to develop a comprehensive immune profile.  
4. Combine this detailed immune profile with the Compass algorithm’s findings to assess the overall potential effectiveness of the treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"Based on mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a white male, with a tissue sample from the kidney, a diagnosis of BLCA, and a tumor mutational burden of 6.0 mutations per megabase. Please provide your conclusion and the supporting rationale for classifying the patient as a responder or non-responder to Atezolizumab.","Based on mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a white male, with a tissue sample from the kidney, a diagnosis of BLCA, and a tumor mutational burden of 6.0 mutations per megabase. Please provide your conclusion and the supporting rationale for classifying the patient as a responder or non-responder to Atezolizumab. 1. Begin by loading the transcriptomic dataset from the specified pickle file.
2. Utilize the Compass algorithm to predict the patient’s response to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune-related biomarkers and merge these findings with the patient’s clinical data to create an integrated immune profile.
4. Finally, combine the comprehensive immune profile with the Compass algorithm results to evaluate the overall potential effectiveness of the treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"A male, white patient with Bladder Urothelial Carcinoma has mRNA TPM data from his tumor immune microenvironment and a Tumor Mutational Burden of 22.0 mutations per MB. Could you assess the predicted responsiveness to Atezolizumab and determine whether this patient is likely to be a responder or non-responder, including the rationale for your conclusion?","A male, white patient with Bladder Urothelial Carcinoma has mRNA TPM data from his tumor immune microenvironment and a Tumor Mutational Burden of 22.0 mutations per MB. Could you assess the predicted responsiveness to Atezolizumab and determine whether this patient is likely to be a responder or non-responder, including the rationale for your conclusion? 1. Load the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient's response to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune-related biomarkers and integrate these markers with the patient’s clinical data to construct a comprehensive immune profile.
4. Combine the detailed immune profile with the Compass algorithm outcomes to assess the overall potential effectiveness of the treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"Based on the mRNA TPM data of the tumor immune microenvironment for a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 1.0 mutations per megabase, would you classify this patient as likely to respond to Atezolizumab? Please provide your conclusion along with the underlying reasoning.","Based on the mRNA TPM data of the tumor immune microenvironment for a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 1.0 mutations per megabase, would you classify this patient as likely to respond to Atezolizumab? Please provide your conclusion along with the underlying reasoning. 1. First, load the transcriptomic dataset from the specified pickle file.  
2. Next, use the Compass algorithm to predict the patient's response to immune checkpoint inhibitor therapy.  
3. Then, determine the five most important immune-related biomarkers and merge these with the patient’s clinical data to create a detailed immune profile.  
4. Finally, combine the comprehensive immune profile with the outcomes from the Compass algorithm to assess the overall potential efficacy of the treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"I have processed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and need to assess the likelihood of response to Atezolizumab. The patient is a White female with a ureter tissue sample, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on this information, can you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment?","I have processed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and need to assess the likelihood of response to Atezolizumab. The patient is a White female with a ureter tissue sample, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on this information, can you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment? 1. Begin by loading the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient’s likely response to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune-related biomarkers and integrate them with the patient’s clinical data to construct a detailed immune profile.
4. Finally, merge the immune profile with the Compass algorithm’s results to evaluate the overall potential effectiveness of the treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the setting of Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with tumor tissue sampled from the kidney, and a tumor mutational burden (TMB) of 2.0 mutations per MB. Based on these findings, could you please determine whether this patient is likely to respond to Atezolizumab, and provide the scientific rationale underlying your conclusion?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the setting of Bladder Urothelial Carcinoma (BLCA). The patient is a white male, with tumor tissue sampled from the kidney, and a tumor mutational burden (TMB) of 2.0 mutations per MB. Based on these findings, could you please determine whether this patient is likely to respond to Atezolizumab, and provide the scientific rationale underlying your conclusion? 1. Load the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to predict the patient's response to immune checkpoint inhibitor therapy.
3. Determine the top five significant immune-related biomarkers, then combine these with the patient’s clinical data to develop a comprehensive immune profile.
4. Finally, integrate this immune profile with the Compass algorithm outcomes to assess the potential effectiveness of the treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"A male, white patient diagnosed with Bladder Urothelial Carcinoma has been profiled using mRNA TPM data from bladder tissue, and his tumor mutational burden is 11.0 mutations per megabase. Based on these parameters, can you assess his predicted responsiveness to Atezolizumab and explain the rationale behind classifying him as a responder or non-responder?","A male, white patient diagnosed with Bladder Urothelial Carcinoma has been profiled using mRNA TPM data from bladder tissue, and his tumor mutational burden is 11.0 mutations per megabase. Based on these parameters, can you assess his predicted responsiveness to Atezolizumab and explain the rationale behind classifying him as a responder or non-responder? 1. Begin by importing the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to forecast the patient’s response to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune-related biomarkers and merge these findings with the patient’s clinical data to construct a detailed immune profile.
4. Finally, combine this immune profile with the Compass algorithm results to evaluate the potential effectiveness of the proposed treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"I have processed mRNA TPM data characterizing a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a White male with bladder involvement and a tumor mutational burden of 9.0 mutations per megabase. Based on this information, how would you predict his response to Atezolizumab, and what is the rationale behind classifying him as a responder or non-responder?","I have processed mRNA TPM data characterizing a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a White male with bladder involvement and a tumor mutational burden of 9.0 mutations per megabase. Based on this information, how would you predict his response to Atezolizumab, and what is the rationale behind classifying him as a responder or non-responder? 1. Load the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to predict the patient’s responsiveness to immune checkpoint inhibitor therapy.
3. Determine the five most critical immune biomarkers and integrate these results with the patient's clinical data to develop a comprehensive immune profile.
4. Evaluate the potential effectiveness of the treatment plan by combining the constructed immune profile with the output from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"Based on mRNA TPM expression data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), and considering that the patient is a  male of White race, with kidney tissue involved and an unspecified tumor mutational burden (FMOne mutation burden per MB: nan), can you determine whether this patient is likely to respond to Atezolizumab and explain the rationale behind your conclusion?","Based on mRNA TPM expression data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), and considering that the patient is a  male of White race, with kidney tissue involved and an unspecified tumor mutational burden (FMOne mutation burden per MB: nan), can you determine whether this patient is likely to respond to Atezolizumab and explain the rationale behind your conclusion? 1. Begin by loading the transcriptomic dataset from the provided pickle file.
2. Apply the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and incorporate these findings with the patient’s clinical data to construct a comprehensive immune profile.
4. Assess the potential effectiveness of the proposed treatment plan by evaluating this integrated immune profile alongside the Compass algorithm results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data has been processed to assess the tumor immune microenvironment, could you evaluate the predicted responsiveness to Atezolizumab? The patient is a white male with kidney tissue as the sample source and a tumor mutational burden of 14.0 mutations per MB. Please provide your conclusion on whether this patient is more likely to be a responder or non-responder, along with the supporting rationale.","For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data has been processed to assess the tumor immune microenvironment, could you evaluate the predicted responsiveness to Atezolizumab? The patient is a white male with kidney tissue as the sample source and a tumor mutational burden of 14.0 mutations per MB. Please provide your conclusion on whether this patient is more likely to be a responder or non-responder, along with the supporting rationale. 1. Import the transcriptomic data from the specified pickle file.
2. Utilize the Compass algorithm to calculate the probability that the patient will respond to immune checkpoint inhibitor therapy.
3. Determine the five most relevant immune biomarkers, and combine these results with the patient’s clinical information to develop a detailed immune profile.
4. Evaluate the likely success of the treatment plan by analyzing the comprehensive immune profile in conjunction with the Compass algorithm's output.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and considering his clinical profile (male, white, bladder tissue with a tumor mutational burden of 18 mutations per megabase), can you assess the likelihood of response to Atezolizumab and provide the supporting rationale for classifying him as a responder or non-responder?","Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and considering his clinical profile (male, white, bladder tissue with a tumor mutational burden of 18 mutations per megabase), can you assess the likelihood of response to Atezolizumab and provide the supporting rationale for classifying him as a responder or non-responder? 1. Load the transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the five key immune biomarkers and merge these findings with the patient’s clinical data to construct a comprehensive immune profile.
4. Assess the expected success of the treatment plan by analyzing this immune profile in combination with the results from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"Based on the patient's mRNA TPM profile for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the following details:
- Sex: Male
- Race: White
- Tissue: Bladder
- Tumor Mutational Burden: 13 mutations per MB

Can you provide an assessment of the likelihood of response to Atezolizumab, including the clinical rationale for categorizing the patient as a responder or non-responder?","Based on the patient's mRNA TPM profile for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the following details:
- Sex: Male
- Race: White
- Tissue: Bladder
- Tumor Mutational Burden: 13 mutations per MB

Can you provide an assessment of the likelihood of response to Atezolizumab, including the clinical rationale for categorizing the patient as a responder or non-responder? 1. Retrieve the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to estimate the patient’s probability of responding to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and integrate these findings with the patient’s clinical data to create a comprehensive immune profile.
4. Evaluate the likely success of the treatment plan by correlating the comprehensive immune profile with the Compass algorithm results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,Can you assess whether a Black female patient with bladder urothelial carcinoma—whose tumor immune microenvironment is characterized by processed mRNA TPM data and who has a tumor mutational burden of 8.0 mutations per MB—is likely to respond to Atezolizumab? Please provide a conclusion on her responder status along with the supporting rationale.,"Can you assess whether a Black female patient with bladder urothelial carcinoma—whose tumor immune microenvironment is characterized by processed mRNA TPM data and who has a tumor mutational burden of 8.0 mutations per MB—is likely to respond to Atezolizumab? Please provide a conclusion on her responder status along with the supporting rationale. 1. Load the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to calculate the probability that the patient will respond to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune biomarkers and combine these with the patient’s clinical data to develop a comprehensive immune profile.
4. Assess the potential success of the treatment by correlating the comprehensive immune profile with the Compass algorithm's results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"Given the mRNA TPM data for a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) with the following characteristics—female, White, bladder tissue, and a tumor mutational burden of 6.0 mutations per megabase—can you assess whether this patient is likely to be a responder to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Given the mRNA TPM data for a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) with the following characteristics—female, White, bladder tissue, and a tumor mutational burden of 6.0 mutations per megabase—can you assess whether this patient is likely to be a responder to Atezolizumab? Please provide your conclusion along with the supporting rationale. 1. Begin by loading the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to compute the probability that the patient will respond to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers and merge these findings with the patient’s clinical data to create a comprehensive immune profile.
4. Evaluate the treatment’s potential success by correlating the comprehensive immune profile with the results generated by the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,I have processed mRNA TPM data from the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma. The patient's tumor mutational burden (FMOne mutation burden per MB) is not available. Could you evaluate whether this patient is predicted to respond to Atezolizumab and provide the rationale behind your assessment?,"I have processed mRNA TPM data from the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma. The patient's tumor mutational burden (FMOne mutation burden per MB) is not available. Could you evaluate whether this patient is predicted to respond to Atezolizumab and provide the rationale behind your assessment? 1. Start by loading the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to estimate the probability that the patient will respond to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and integrate these with the patient’s clinical data to construct a detailed profile of their immune status.
4. Assess the likelihood of treatment success by comparing this comprehensive immune profile with the output from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,Given the patient's mRNA TPM data of the tumor immune microenvironment and the following clinical details—a white male with bladder urothelial carcinoma and a tumor mutational burden of 23.0 mutations per MB—how would you predict the patient's responsiveness to Atezolizumab? Please include the rationale for classifying the patient as a responder or non-responder.,"Given the patient's mRNA TPM data of the tumor immune microenvironment and the following clinical details—a white male with bladder urothelial carcinoma and a tumor mutational burden of 23.0 mutations per MB—how would you predict the patient's responsiveness to Atezolizumab? Please include the rationale for classifying the patient as a responder or non-responder. 1. Begin by loading the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to calculate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers and merge these findings with the patient’s clinical data to develop a detailed profile of their immune status.  
4. Evaluate the potential success of the treatment by comparing this comprehensive immune profile with the Compass algorithm’s output.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient's details are: female, White, lymph node tissue involvement, BLCA diagnosis, and an unspecified tumor mutational burden. Based on these data, can you determine whether the patient is more likely to respond to Atezolizumab, and provide the rationale for your assessment?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient's details are: female, White, lymph node tissue involvement, BLCA diagnosis, and an unspecified tumor mutational burden. Based on these data, can you determine whether the patient is more likely to respond to Atezolizumab, and provide the rationale for your assessment? 1. Start by loading the transcriptomic dataset from the specified pickle file.  
2. Use the Compass algorithm to compute the probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Identify the five most critical immune biomarkers and integrate these with the patient’s clinical data to create a comprehensive immune profile.  
4. Assess the potential effectiveness of the treatment by comparing the constructed immune profile with the predictions from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"Based on the processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma, could you evaluate the predicted response to Atezolizumab? The patient's details are as follows: male, White, with a lymph node tissue sample and a tumor mutational burden of 2.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or a non-responder, along with your supporting rationale.","Based on the processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma, could you evaluate the predicted response to Atezolizumab? The patient's details are as follows: male, White, with a lymph node tissue sample and a tumor mutational burden of 2.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or a non-responder, along with your supporting rationale. 1. Begin by loading the transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  
3. Determine the five key immune biomarkers and merge these findings with the patient’s clinical data to generate a detailed immune profile.  
4. Finally, evaluate the potential efficacy of the treatment by comparing this immune profile against the predictions provided by the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I have analyzed a patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) to predict their response to Atezolizumab. The patient is a  male white individual with bladder tissue involvement, and the tumor mutational burden (measured as FMOne mutation burden per MB) is not available. Based on these attributes, can you determine if the patient is likely to respond to Atezolizumab, and please provide your supporting rationale?","I have analyzed a patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) to predict their response to Atezolizumab. The patient is a  male white individual with bladder tissue involvement, and the tumor mutational burden (measured as FMOne mutation burden per MB) is not available. Based on these attributes, can you determine if the patient is likely to respond to Atezolizumab, and please provide your supporting rationale? 1. Load the transcriptomic dataset from the specified pickle file.
2. Utilize the Compass algorithm to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the five key immune biomarkers and integrate these results with the patient’s clinical data to construct a comprehensive immune profile.
4. Compare this profile with the predictions generated by the Compass algorithm to assess the potential efficacy of the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"I have processed mRNA TPM data evaluating the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a 7.0 mutations/MB TMB male, identified as white, and with primary bladder involvement. Based on these attributes and the molecular profile, what is the predicted response to Atezolizumab, and what is the rationale behind this classification?","I have processed mRNA TPM data evaluating the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a 7.0 mutations/MB TMB male, identified as white, and with primary bladder involvement. Based on these attributes and the molecular profile, what is the predicted response to Atezolizumab, and what is the rationale behind this classification? 1. Import the transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to determine the patient’s probability of responding to immune checkpoint inhibitor therapy.
3. Identify the five primary immune biomarkers and combine these findings with the patient’s clinical data to develop a comprehensive immune profile.
4. Contrast this integrated profile with the Compass algorithm’s predictions to evaluate the likely effectiveness of the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"I have mRNA TPM data detailing the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a male of Asian descent with a bladder tumor and a tumor mutational burden of 1.0 mutation per MB. Based on these findings, could you assess whether this patient is likely to respond to Atezolizumab and provide the rationale for your conclusion?","I have mRNA TPM data detailing the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a male of Asian descent with a bladder tumor and a tumor mutational burden of 1.0 mutation per MB. Based on these findings, could you assess whether this patient is likely to respond to Atezolizumab and provide the rationale for your conclusion? 1. Begin by loading the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to calculate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and integrate these results with the patient’s clinical data to establish a comprehensive immune profile.
4. Finally, compare this integrated profile with the Compass algorithm’s predictions to assess the likely effectiveness of the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma, along with the clinical details provided (male, White, ureter tissue involvement, and a tumor mutational burden of 7.0 mutations per MB), could you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma, along with the clinical details provided (male, White, ureter tissue involvement, and a tumor mutational burden of 7.0 mutations per MB), could you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. 1. Load the transcriptomic dataset using the provided pickle file.  
2. Apply the Compass algorithm to estimate the patient’s probability of responding to immune checkpoint inhibitor therapy.  
3. Determine the five most significant immune biomarkers and merge these findings with the patient’s clinical data to construct a detailed immune profile.  
4. Compare this comprehensive profile with the predictions generated by the Compass algorithm to evaluate the potential effectiveness of the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,Could you help determine whether this bladder urothelial carcinoma patient is likely to respond to Atezolizumab therapy? The patient is a white male with a primary bladder tumor and a tumor mutational burden of 5 mutations per megabase. Please provide your assessment along with the rationale behind your conclusion.,"Could you help determine whether this bladder urothelial carcinoma patient is likely to respond to Atezolizumab therapy? The patient is a white male with a primary bladder tumor and a tumor mutational burden of 5 mutations per megabase. Please provide your assessment along with the rationale behind your conclusion. 1. Open the pickle file to load the transcriptomic dataset.  
2. Utilize the Compass algorithm to predict the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  
3. Identify the top five immune biomarkers and integrate these findings with the patient’s clinical information to create a detailed immune profile.  
4. Compare this comprehensive profile with the Compass algorithm’s predictions to assess the potential efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"I am evaluating a male patient of white race with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 mutations per megabase. Using mRNA TPM data from his tumor immune microenvironment, could you determine whether he is more likely to be a responder or non-responder to Atezolizumab and explain the rationale behind your conclusion?","I am evaluating a male patient of white race with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 mutations per megabase. Using mRNA TPM data from his tumor immune microenvironment, could you determine whether he is more likely to be a responder or non-responder to Atezolizumab and explain the rationale behind your conclusion? 1. Access and load the transcriptomic dataset by opening the designated pickle file.  
2. Apply the Compass algorithm to estimate the patient's probability of benefiting from immune checkpoint inhibitor therapy.  
3. Determine the five most significant immune biomarkers and combine these with the patient's clinical data to develop a comprehensive immune profile.  
4. Evaluate the therapy’s likely effectiveness by comparing the detailed immune profile with the Compass algorithm’s predictions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"I have mRNA TPM data profiling the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: Male, White, tissue sample obtained from lung, and tumor mutational burden data is unavailable. Based on this information, could you determine if the patient is likely to respond to Atezolizumab, and please provide the rationale for your conclusion?","I have mRNA TPM data profiling the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: Male, White, tissue sample obtained from lung, and tumor mutational burden data is unavailable. Based on this information, could you determine if the patient is likely to respond to Atezolizumab, and please provide the rationale for your conclusion? 1. Open the designated pickle file to load the transcriptomic dataset.
2. Use the Compass algorithm to calculate the likelihood that the patient will benefit from immune checkpoint inhibitor therapy.
3. Identify the five key immune biomarkers and merge these findings with the patient's clinical data to create a detailed immune profile.
4. Assess the predicted effectiveness of the therapy by comparing the immune profile with the results provided by the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"Based on the mRNA TPM analysis of the tumor immune microenvironment in this patient with Bladder Urothelial Carcinoma (BLCA)—a male, white individual with a lymph node biopsy and a tumor mutational burden of 2.0 mutations per MB—can you determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting clinical reasoning.","Based on the mRNA TPM analysis of the tumor immune microenvironment in this patient with Bladder Urothelial Carcinoma (BLCA)—a male, white individual with a lymph node biopsy and a tumor mutational burden of 2.0 mutations per MB—can you determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting clinical reasoning. 1. Retrieve the transcriptomic dataset by opening the specified pickle file.
2. Utilize the Compass algorithm to determine the patient's probability of responding to immune checkpoint inhibitor therapy.
3. Identify the five most critical immune biomarkers and integrate these with the patient's clinical data to construct a detailed immune profile.
4. Evaluate the anticipated effectiveness of the therapy by comparing the constructed immune profile with the output from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their likely response to Atezolizumab. The patient is a white male with a bladder tumor and a Tumor Mutational Burden of 44.0 mutations per MB. Based on this information, what is your evaluation of the patient’s potential responsiveness to Atezolizumab, and what is the rationale behind your conclusion?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their likely response to Atezolizumab. The patient is a white male with a bladder tumor and a Tumor Mutational Burden of 44.0 mutations per MB. Based on this information, what is your evaluation of the patient’s potential responsiveness to Atezolizumab, and what is the rationale behind your conclusion? 1. Please open the designated pickle file to retrieve the transcriptomic dataset.
2. Use the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune biomarkers and combine these with the patient’s clinical data to create a comprehensive immune profile.
4. Compare this immune profile to the results from the Compass algorithm to assess the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"Based on the patient's processed mRNA TPM data of the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following clinical details—male, white, tissue sample from the kidney, and a tumor mutational burden of 15.0 mutations per megabase—could you assess the predicted responsiveness to Atezolizumab and provide the supporting rationale for classifying this patient as either a responder or non-responder?","Based on the patient's processed mRNA TPM data of the tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and the following clinical details—male, white, tissue sample from the kidney, and a tumor mutational burden of 15.0 mutations per megabase—could you assess the predicted responsiveness to Atezolizumab and provide the supporting rationale for classifying this patient as either a responder or non-responder? 1. Retrieve the transcriptomic dataset by loading the specified pickle file.
2. Apply the Compass algorithm to assess the probability that the patient will benefit from immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and integrate these findings with the patient’s clinical data to construct a detailed immune profile.
4. Compare the constructed immune profile with the Compass algorithm’s output to evaluate the anticipated effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"In a patient diagnosed with bladder urothelial carcinoma (BLCA), we have mRNA TPM data characterizing the tumor immune microenvironment combined with the following clinical attributes: male sex, white race, lymph node tissue sample, and a tumor mutational burden of 17 mutations per MB. Based on this information, could you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab therapy? Please detail the rationale behind your evaluation.","In a patient diagnosed with bladder urothelial carcinoma (BLCA), we have mRNA TPM data characterizing the tumor immune microenvironment combined with the following clinical attributes: male sex, white race, lymph node tissue sample, and a tumor mutational burden of 17 mutations per MB. Based on this information, could you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab therapy? Please detail the rationale behind your evaluation. 1. Begin by loading the designated pickle file to access the transcriptomic dataset.

2. Use the Compass algorithm to calculate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.

3. Determine the five most significant immune biomarkers and merge these findings with the patient’s clinical data to create a comprehensive immune profile.

4. Finally, compare this immune profile with the Compass algorithm’s predictions to assess the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"Based on processed mRNA TPM data for the patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient’s profile includes the following details: Sex: M, Race: WHITE, Tissue: kidney, Disease: BLCA, and a tumor mutational burden of 11.0 mutations per megabase. Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting rationale.","Based on processed mRNA TPM data for the patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA), can you assess the predicted responsiveness to Atezolizumab? The patient’s profile includes the following details: Sex: M, Race: WHITE, Tissue: kidney, Disease: BLCA, and a tumor mutational burden of 11.0 mutations per megabase. Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting rationale. 1. Start by loading the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to predict the patient’s response probability to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and integrate these findings with the patient’s clinical data to develop a full immune profile.
4. Compare this profile with the Compass algorithm’s predictions to estimate the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"I have processed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) to evaluate the tumor immune microenvironment. The patient’s details are as follows: male, white, tumor tissue from the bladder, with an unspecified tumor mutational burden. Based on this information, could you assess whether the patient is more likely to be responsive or non-responsive to Atezolizumab, and provide the supporting rationale for this prediction?","I have processed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) to evaluate the tumor immune microenvironment. The patient’s details are as follows: male, white, tumor tissue from the bladder, with an unspecified tumor mutational burden. Based on this information, could you assess whether the patient is more likely to be responsive or non-responsive to Atezolizumab, and provide the supporting rationale for this prediction? 1. Begin by loading the transcriptomic dataset from the designated pickle file.
2. Use the Compass algorithm to predict the patient's probability of responding to immune checkpoint inhibitor therapy.
3. Determine the top five immune biomarkers and combine these results with the patient's clinical data to construct a comprehensive immune profile.
4. Compare this profile against the Compass algorithm's predictions to estimate how effective the therapy is likely to be.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I have processed the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) and would like to evaluate the predicted responsiveness to Atezolizumab. The patient is a white male with BLCA involving the bladder, and the reported tumor mutational burden (TMB) is not available. Based on these data, can you determine if the patient is likely to be a responder or a non-responder to Atezolizumab, and please provide your rationale?","I have processed the mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) and would like to evaluate the predicted responsiveness to Atezolizumab. The patient is a white male with BLCA involving the bladder, and the reported tumor mutational burden (TMB) is not available. Based on these data, can you determine if the patient is likely to be a responder or a non-responder to Atezolizumab, and please provide your rationale? 1. Load the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to calculate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers and integrate these with the patient’s clinical data to assemble a detailed immune profile.
4. Compare this immune profile with the predictions from the Compass algorithm to assess the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"A patient with Bladder Urothelial Carcinoma (BLCA) has been evaluated using processed mRNA TPM data reflecting the tumor immune microenvironment. The patient is a  male of White race, with bladder tissue involvement and a Tumor Mutational Burden of 12.0 mutations per MB. Based on these parameters, could you determine whether the patient is likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion?","A patient with Bladder Urothelial Carcinoma (BLCA) has been evaluated using processed mRNA TPM data reflecting the tumor immune microenvironment. The patient is a  male of White race, with bladder tissue involvement and a Tumor Mutational Burden of 12.0 mutations per MB. Based on these parameters, could you determine whether the patient is likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion? 1. Begin by loading the transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to calculate the probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers, and combine this information with the patient’s clinical data to create a comprehensive immune profile.  
4. Finally, compare this immune profile with the Compass algorithm's predictions to evaluate the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"Based on processed mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma, along with the following clinical details—Sex: Male; Race: White; Tissue: Bladder; and Tumor Mutational Burden: 6.0 FMOne mutation per megabyte—could you please assess the predicted responsiveness to Atezolizumab, providing a conclusion of responder or non-responder with supporting rationale?","Based on processed mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma, along with the following clinical details—Sex: Male; Race: White; Tissue: Bladder; and Tumor Mutational Burden: 6.0 FMOne mutation per megabyte—could you please assess the predicted responsiveness to Atezolizumab, providing a conclusion of responder or non-responder with supporting rationale? 1. Begin by loading the transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to calculate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.  
3. Identify the top five most significant immune biomarkers, and integrate these findings with the patient’s clinical data to construct a comprehensive immune profile.  
4. Finally, compare the constructed immune profile with the predictions made by the Compass algorithm to assess the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"I have processed mRNA TPM expression data to characterize the tumor immune microenvironment in a male, white patient with Bladder Urothelial Carcinoma (BLCA) originating in the bladder. The patient’s tumor mutational burden is reported as 5.0 FMOne mutations per MB. Based on this information, could you provide an assessment of whether this patient is likely to be a responder or non-responder to atezolizumab, along with the reasoning behind your conclusion?","I have processed mRNA TPM expression data to characterize the tumor immune microenvironment in a male, white patient with Bladder Urothelial Carcinoma (BLCA) originating in the bladder. The patient’s tumor mutational burden is reported as 5.0 FMOne mutations per MB. Based on this information, could you provide an assessment of whether this patient is likely to be a responder or non-responder to atezolizumab, along with the reasoning behind your conclusion? 1. Load the transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to determine the probability that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers and integrate these with the patient’s clinical data to develop a detailed immune profile.  
4. Compare this immune profile with the Compass algorithm predictions to evaluate the likely effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white race, with tissue sample details not available, and a tumor mutational burden of 8.0 mutations/MB. Based on these parameters, could you determine whether this patient is likely to respond to Atezolizumab, and please provide your rationale?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white race, with tissue sample details not available, and a tumor mutational burden of 8.0 mutations/MB. Based on these parameters, could you determine whether this patient is likely to respond to Atezolizumab, and please provide your rationale? 1. Begin by loading the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to calculate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Determine the top five immune biomarkers that show the greatest significance, then combine these with the patient’s clinical information to assemble a comprehensive immune profile.
4. Finally, compare the assembled immune profile with the predictions from the Compass algorithm to assess the probable efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations per MB, we have processed mRNA TPM data reflecting his tumor immune microenvironment. Could you assess his predicted response to Atezolizumab and explain whether he is likely to be classified as a responder or non-responder?","For a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0 mutations per MB, we have processed mRNA TPM data reflecting his tumor immune microenvironment. Could you assess his predicted response to Atezolizumab and explain whether he is likely to be classified as a responder or non-responder? 1. Load the transcriptomic dataset from the designated pickle file.
2. Use the Compass algorithm to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers and merge these findings with the patient’s clinical data to create a detailed immune profile.
4. Finally, compare the patient's immune profile with the Compass algorithm’s predictions to evaluate the potential efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) and would like to evaluate their predicted response to Atezolizumab. The patient is male, has an unknown racial background, the primary site is the bladder, and the tumor mutational burden is 0.0 mutations per MB. Based on this information, could you determine if the patient is likely to be a responder or non-responder to Atezolizumab and provide the supporting rationale?","I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) and would like to evaluate their predicted response to Atezolizumab. The patient is male, has an unknown racial background, the primary site is the bladder, and the tumor mutational burden is 0.0 mutations per MB. Based on this information, could you determine if the patient is likely to be a responder or non-responder to Atezolizumab and provide the supporting rationale? 1. Begin by loading the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to assess the patient's probability of responding to immune checkpoint inhibitor therapy.
3. Extract the top five immune biomarkers that are most relevant, and integrate these findings with the patient’s clinical data to construct a comprehensive immune profile.
4. Finally, compare the constructed immune profile with the predictions from the Compass algorithm to determine the likely efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"For a patient diagnosed with Bladder Urothelial Carcinoma, I have processed mRNA TPM data representing the tumor immune microenvironment. The patient is a White male, the tissue originates from the kidney, and the tumor mutational burden is 5.0 mutations per megabase. Based on these details, can you provide an assessment of whether the patient is predicted to respond to Atezolizumab, including the rationale for your conclusion?","For a patient diagnosed with Bladder Urothelial Carcinoma, I have processed mRNA TPM data representing the tumor immune microenvironment. The patient is a White male, the tissue originates from the kidney, and the tumor mutational burden is 5.0 mutations per megabase. Based on these details, can you provide an assessment of whether the patient is predicted to respond to Atezolizumab, including the rationale for your conclusion? 1. Load the transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient’s likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers of significance and combine these results with the patient’s clinical data to develop a comprehensive immune profile.
4. Compare this immune profile with the Compass algorithm’s predictions to assess the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"Based on the patient’s mRNA TPM data of the tumor immune microenvironment, can you determine whether this 6.0 FMOne mutation burden, White male with Bladder Urothelial Carcinoma (BLCA) is more likely to respond to Atezolizumab therapy, and please provide your reasoning for this clinical decision?","Based on the patient’s mRNA TPM data of the tumor immune microenvironment, can you determine whether this 6.0 FMOne mutation burden, White male with Bladder Urothelial Carcinoma (BLCA) is more likely to respond to Atezolizumab therapy, and please provide your reasoning for this clinical decision? 1. Retrieve the transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers and integrate these findings with the patient’s clinical data to create a detailed immune profile.
4. Compare the constructed immune profile with the predictions from the Compass algorithm to assess the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"Using the mRNA TPM data for the patient’s tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—female, white, kidney tissue sampled, BLCA diagnosis, and an unspecified tumor mutational burden—could you provide an evidence-based assessment of whether the patient is predicted to respond to Atezolizumab, along with your reasoning?","Using the mRNA TPM data for the patient’s tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—female, white, kidney tissue sampled, BLCA diagnosis, and an unspecified tumor mutational burden—could you provide an evidence-based assessment of whether the patient is predicted to respond to Atezolizumab, along with your reasoning? 1. Access the transcriptomic data stored in the designated pickle file.  
2. Apply the Compass algorithm to estimate the probability that the patient will exhibit a positive response to immune checkpoint inhibitor therapy.  
3. Determine the five most critical immune biomarkers and combine these results with the patient’s clinical information to develop a comprehensive immune profile.  
4. Evaluate the consistency between the patient’s immune profile and the Compass algorithm's predictions to gauge the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is male, of White race, with a ureter tissue sample and a tumor mutational burden of 59 mutations per megabase. Could you evaluate whether this patient is predicted to respond to Atezolizumab and explain the rationale behind your assessment?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is male, of White race, with a ureter tissue sample and a tumor mutational burden of 59 mutations per megabase. Could you evaluate whether this patient is predicted to respond to Atezolizumab and explain the rationale behind your assessment? 1. Retrieve the transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to calculate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Identify the top five critical immune biomarkers and integrate these findings with the patient's clinical data to construct a comprehensive immune profile.  
4. Compare the patient's immune profile with the Compass algorithm's predictions to assess the potential efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For a patient with Bladder Urothelial Carcinoma characterized by a tumor mutational burden of 13 mutations per MB, male sex, and white race, with mRNA TPM profiling of the tumor immune microenvironment obtained from kidney tissue, could you assess the likelihood of a positive response to Atezolizumab? Please include the rationale behind your evaluation.","For a patient with Bladder Urothelial Carcinoma characterized by a tumor mutational burden of 13 mutations per MB, male sex, and white race, with mRNA TPM profiling of the tumor immune microenvironment obtained from kidney tissue, could you assess the likelihood of a positive response to Atezolizumab? Please include the rationale behind your evaluation. 1. Please retrieve the transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to estimate the probability that the patient will have a positive response to immune checkpoint inhibitor therapy.  
3. Identify the five most critical immune biomarkers and combine these results with the patient’s clinical data to create a detailed immune profile.  
4. Finally, compare this comprehensive immune profile with the Compass algorithm’s predictions to evaluate the possible effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"I have processed mRNA TPM data for a patient diagnosed with bladder urothelial carcinoma (BLCA), with the following details: sex: F, race: other, tissue: ureter, and a tumor mutational burden (FMOne mutations per MB) of 12.0. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab and provide your rationale?","I have processed mRNA TPM data for a patient diagnosed with bladder urothelial carcinoma (BLCA), with the following details: sex: F, race: other, tissue: ureter, and a tumor mutational burden (FMOne mutations per MB) of 12.0. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab and provide your rationale? 1. Begin by extracting the transcriptomic dataset from the designated pickle file.  
2. Use the Compass algorithm to calculate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Determine the top five key immune biomarkers, and integrate these findings with the patient’s clinical data to develop a comprehensive immune profile.  
4. Finally, compare this immune profile with the predictions from the Compass algorithm to assess the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a  M, WHITE with a lymph node tissue sample, and a tumor mutational burden of 4.0 mutations per MB. Based on these clinical and molecular characteristics, can you determine whether the patient is predicted to be a responder or non-responder to Atezolizumab? Please include your reasoning supporting the assessment.","We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a  M, WHITE with a lymph node tissue sample, and a tumor mutational burden of 4.0 mutations per MB. Based on these clinical and molecular characteristics, can you determine whether the patient is predicted to be a responder or non-responder to Atezolizumab? Please include your reasoning supporting the assessment. 1. Extract the transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to estimate the patient's probability of a favorable response to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and combine these results with the patient's clinical data to create a thorough immune profile.
4. Compare the immune profile with the Compass algorithm's predictions to evaluate the anticipated effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For a patient with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue and a tumor mutational burden of 11.0 FMOne mutations per MB—and processed mRNA TPM data reflecting the tumor immune microenvironment, what is the predicted responsiveness to Atezolizumab? Please provide a conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting rationale.","For a patient with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue and a tumor mutational burden of 11.0 FMOne mutations per MB—and processed mRNA TPM data reflecting the tumor immune microenvironment, what is the predicted responsiveness to Atezolizumab? Please provide a conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting rationale. 1. Retrieve the transcriptomic data stored in the designated pickle file.  
2. Use the Compass algorithm to determine the likelihood of the patient responding positively to immune checkpoint inhibitor therapy.  
3. Select the top five immune biomarkers and integrate these findings with the patient’s clinical information to construct a comprehensive immune profile.  
4. Compare this immune profile against the predictions provided by the Compass algorithm to assess the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"Based on the mRNA TPM data of the tumor immune microenvironment for a male White patient with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations/Mb, can you assess and provide a conclusion on whether this patient is likely to respond to Atezolizumab, along with the underlying rationale for your prediction?","Based on the mRNA TPM data of the tumor immune microenvironment for a male White patient with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations/Mb, can you assess and provide a conclusion on whether this patient is likely to respond to Atezolizumab, along with the underlying rationale for your prediction? 1. Access the transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to evaluate the patient’s likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers and combine these findings with the patient’s clinical data to create a detailed immune profile.  
4. Assess the concordance between the constructed immune profile and the Compass predictions to estimate the therapy’s potential effectiveness.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"For a female patient with Bladder Urothelial Carcinoma (BLCA), who is of white race and whose tissue sample is from the kidney, the mRNA TPM data of the tumor immune microenvironment and a reported tumor mutational burden of ""nan"" have been analyzed. Based on these details, could you provide a conclusion on whether this patient is predicted to respond to Atezolizumab, along with the corresponding rationale?","For a female patient with Bladder Urothelial Carcinoma (BLCA), who is of white race and whose tissue sample is from the kidney, the mRNA TPM data of the tumor immune microenvironment and a reported tumor mutational burden of ""nan"" have been analyzed. Based on these details, could you provide a conclusion on whether this patient is predicted to respond to Atezolizumab, along with the corresponding rationale? 1. Retrieve the transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to predict the patient’s probability of a favorable response to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune biomarkers and integrate these markers with the patient’s clinical information to develop a comprehensive immune profile.
4. Compare the immune profile with the Compass algorithm’s predictions to evaluate the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"I have processed mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) to evaluate potential responsiveness to Atezolizumab. The patient is a white male with a tumor located in the ureter and a tumor mutational burden of 5 mutations per megabase. Based on these details, is the patient predicted to be a responder or non-responder to Atezolizumab? Please include your conclusion and supporting rationale.","I have processed mRNA TPM data from a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) to evaluate potential responsiveness to Atezolizumab. The patient is a white male with a tumor located in the ureter and a tumor mutational burden of 5 mutations per megabase. Based on these details, is the patient predicted to be a responder or non-responder to Atezolizumab? Please include your conclusion and supporting rationale. 1. Retrieve the transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to calculate the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and combine these with the patient’s clinical data to construct a detailed immune profile.
4. Compare this immune profile with the Compass algorithm's predictions to assess the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient’s details are as follows: male, Native Hawaiian or Other Pacific Islander ethnicity, a tissue sample categorized as “other,” and a tumor mutational burden of 19 mutations per megabase. Based on these characteristics, could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your evaluation?","A patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient’s details are as follows: male, Native Hawaiian or Other Pacific Islander ethnicity, a tissue sample categorized as “other,” and a tumor mutational burden of 19 mutations per megabase. Based on these characteristics, could you assess whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your evaluation? 1. Begin by accessing the transcriptomic dataset saved in the designated pickle file.
2. Utilize the Compass algorithm to estimate the patient's responsiveness to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune biomarkers and integrate these findings with the patient’s clinical information to generate a comprehensive immune profile.
4. Compare the constructed immune profile with the predictions from the Compass algorithm to evaluate the potential efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"I have processed the mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the likelihood of a favorable response to Atezolizumab. The patient's clinical details are as follows: Male, White, tumor site in the bladder, and an unspecified tumor mutational burden (FMOne mutation burden per MB is not available). Based on these data, can you help determine whether this patient would be expected to respond to Atezolizumab, and explain the reasoning behind the assessment?","I have processed the mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate the likelihood of a favorable response to Atezolizumab. The patient's clinical details are as follows: Male, White, tumor site in the bladder, and an unspecified tumor mutational burden (FMOne mutation burden per MB is not available). Based on these data, can you help determine whether this patient would be expected to respond to Atezolizumab, and explain the reasoning behind the assessment? 1. Retrieve the transcriptomic dataset from the specified pickle file. 
2. Apply the Compass algorithm to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and combine this information with the patient's clinical data to construct a detailed immune profile.
4. Compare this immune profile with the predictions generated by the Compass algorithm to assess the potential efficacy of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"Based on the processed mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the clinical details (female, white, bladder tissue origin, and unavailable tumor mutational burden data), how would you assess the likelihood of a favorable response to Atezolizumab? Please provide your conclusion on whether the patient is expected to be a responder or non-responder, including the supporting rationale.","Based on the processed mRNA TPM data reflecting this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with the clinical details (female, white, bladder tissue origin, and unavailable tumor mutational burden data), how would you assess the likelihood of a favorable response to Atezolizumab? Please provide your conclusion on whether the patient is expected to be a responder or non-responder, including the supporting rationale. 1. Access the transcriptomic dataset stored in the designated pickle file.
2. Use the Compass algorithm to evaluate the patient’s potential response to immune checkpoint inhibitor therapy.
3. Determine the five most significant immune biomarkers and integrate these findings with the patient’s clinical data to develop a comprehensive immune profile.
4. Compare the constructed immune profile with the Compass algorithm’s predictions to evaluate the likely effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a white male, with tissue samples obtained from the kidney, and has a tumor mutational burden of 33.0 mutations per megabase. Based on these clinical parameters, can you assess the predicted responsiveness to Atezolizumab and provide your rationale for classifying the patient as a responder or non-responder?","I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a white male, with tissue samples obtained from the kidney, and has a tumor mutational burden of 33.0 mutations per megabase. Based on these clinical parameters, can you assess the predicted responsiveness to Atezolizumab and provide your rationale for classifying the patient as a responder or non-responder? 1. Retrieve the transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to assess the patient’s likely response to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers and merge these findings with the patient’s clinical data to construct a detailed immune profile.
4. Compare this immune profile with the Compass algorithm’s predictions to assess the expected effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"Based on the processed mRNA TPM data from the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (non-traditional tissue type) and a tumor mutational burden of 32.0 mutations per megabase, could you please assess the predicted response to Atezolizumab therapy? I would appreciate a clear conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale for your determination.","Based on the processed mRNA TPM data from the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (non-traditional tissue type) and a tumor mutational burden of 32.0 mutations per megabase, could you please assess the predicted response to Atezolizumab therapy? I would appreciate a clear conclusion on whether this patient is likely to be a responder or non-responder, along with the supporting rationale for your determination. 1. Load the transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to evaluate how likely the patient is to respond to immune checkpoint inhibitor therapy.  
3. Determine the top five immune biomarkers and integrate these results with the patient's other clinical data to build a comprehensive immune profile.  
4. Compare the constructed immune profile with the predictions generated by the Compass algorithm to estimate the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"Based on the TPM mRNA data assessing the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations per MB, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the evidence and rationale for your conclusion.","Based on the TPM mRNA data assessing the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations per MB, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the evidence and rationale for your conclusion. 1. Begin by loading the patient's transcriptomic data from the designated pickle file.  
2. Utilize the Compass algorithm to assess the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Identify the top five immune biomarkers within this data and merge these findings with the patient’s other clinical information to construct a comprehensive immune profile.  
4. Finally, compare this detailed immune profile with the response predictions from the Compass algorithm to estimate the potential effectiveness of the therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"Based on this patient's profile—male, race categorized as OTHER, diagnosed with Bladder Urothelial Carcinoma (BLCA) involving bladder tissue, with a tumor mutational burden of 14 mutations/Mb—and the processed mRNA TPM data reflecting the tumor immune microenvironment, can you provide an assessment of his predicted response to Atezolizumab, including your supporting rationale?","Based on this patient's profile—male, race categorized as OTHER, diagnosed with Bladder Urothelial Carcinoma (BLCA) involving bladder tissue, with a tumor mutational burden of 14 mutations/Mb—and the processed mRNA TPM data reflecting the tumor immune microenvironment, can you provide an assessment of his predicted response to Atezolizumab, including your supporting rationale? 1. Start by loading the patient’s transcriptomic data from the specified pickle file.
2. Run the Compass algorithm on this data to evaluate the probability that the patient will benefit from immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers from the transcriptomic data and integrate these with the patient’s clinical information to develop a complete immune profile.
4. Compare this comprehensive immune profile against the predictions from the Compass algorithm to estimate the likely effectiveness of the proposed therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male; however, tissue details and tumor mutational burden data are not available. Based on this information, can you evaluate whether the patient is more likely to respond to atezolizumab and provide the rationale for your assessment?","I have analyzed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male; however, tissue details and tumor mutational burden data are not available. Based on this information, can you evaluate whether the patient is more likely to respond to atezolizumab and provide the rationale for your assessment? 1. Begin by importing the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to this data to calculate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.  
3. Determine the top five immune biomarkers from the transcriptomic dataset and combine these findings with the patient’s clinical details to construct a comprehensive immune profile.  
4. Evaluate this immune profile against the Compass algorithm’s predictions to assess the probable effectiveness of the proposed immune therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"We have processed mRNA TPM data from a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and we need to determine his likely response to Atezolizumab therapy. The patient’s characteristics are:

• Sex: Male  
• Race: White  
• Tissue: Bladder  
• Disease: BLCA  
• Tumor Mutational Burden: 9.0 mutations per megabase  

Based on these attributes, can you provide an assessment of whether this patient would be classified as a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion?","We have processed mRNA TPM data from a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and we need to determine his likely response to Atezolizumab therapy. The patient’s characteristics are:

• Sex: Male  
• Race: White  
• Tissue: Bladder  
• Disease: BLCA  
• Tumor Mutational Burden: 9.0 mutations per megabase  

Based on these attributes, can you provide an assessment of whether this patient would be classified as a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion? 1. Import the patient's transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to determine the probability of the patient responding to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers within the transcriptomic dataset and integrate these with the patient's clinical information to construct a detailed immune profile.  
4. Compare the immune profile with the predictions generated by the Compass algorithm to evaluate the potential effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"A 64-year-old Asian female with bladder urothelial carcinoma arising in the ureter has an mRNA TPM profile of her tumor immune microenvironment and a tumor mutational burden of 12.0 mutations per MB. Could you provide an assessment of her predicted response to Atezolizumab, and explain the rationale behind classifying her as a likely responder or non-responder?","A 64-year-old Asian female with bladder urothelial carcinoma arising in the ureter has an mRNA TPM profile of her tumor immune microenvironment and a tumor mutational burden of 12.0 mutations per MB. Could you provide an assessment of her predicted response to Atezolizumab, and explain the rationale behind classifying her as a likely responder or non-responder? 1. Load the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Extract the five most significant immune biomarkers from the transcriptomic data and integrate these with the patient's clinical information to create a detailed immune profile.  
4. Compare the resulting immune profile to the Compass algorithm's predictions to assess the potential effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,Based on the processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue and a Tumor Mutational Burden reported as nan—can we determine whether this patient is likely to respond to Atezolizumab? Please provide the classification (responder or non-responder) along with the underlying rationale.,"Based on the processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA)—a white male with bladder tissue and a Tumor Mutational Burden reported as nan—can we determine whether this patient is likely to respond to Atezolizumab? Please provide the classification (responder or non-responder) along with the underlying rationale. 1. Retrieve the patient’s transcriptomic dataset from the specified pickle file.
2. Utilize the Compass algorithm to determine the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Identify the top five immune biomarkers from the transcriptomic data and integrate these findings with the patient’s clinical information to generate a comprehensive immune profile.
4. Compare this immune profile with the predictions from the Compass algorithm to evaluate the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"Given the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) along with the following details: male sex, white race, bladder tissue origin, and a tumor mutational burden of 11.0 mutations per megabase—could you please determine whether this patient is likely to respond to Atezolizumab? Please include the supporting rationale for your conclusion.","Given the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) along with the following details: male sex, white race, bladder tissue origin, and a tumor mutational burden of 11.0 mutations per megabase—could you please determine whether this patient is likely to respond to Atezolizumab? Please include the supporting rationale for your conclusion. 1. First, access the patient's transcriptomic dataset stored in the designated pickle file.
2. Then, apply the Compass algorithm to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Next, identify the five most significant immune biomarkers within the transcriptomic data and combine these results with the patient’s clinical information to formulate a comprehensive immune profile.
4. Finally, compare this immune profile against the predictions provided by the Compass algorithm to assess the anticipated effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"Given the following patient details—a white male with Bladder Urothelial Carcinoma (BLCA), a liver tissue sample, and a tumor mutational burden of 10 mutations per MB—how would you assess his predicted responsiveness to atezolizumab, and what evidence supports this prediction?","Given the following patient details—a white male with Bladder Urothelial Carcinoma (BLCA), a liver tissue sample, and a tumor mutational burden of 10 mutations per MB—how would you assess his predicted responsiveness to atezolizumab, and what evidence supports this prediction? Step 1: Retrieve the patient's transcriptomic dataset from the specified pickle file.  
Step 2: Apply the Compass algorithm to calculate the probability that the patient will positively respond to immune checkpoint inhibitor therapy.  
Step 3: Identify the five most critical immune biomarkers in the transcriptomic data and integrate these findings with the patient’s clinical information to construct a comprehensive immune profile.  
Step 4: Compare this comprehensive immune profile with the predictions from the Compass algorithm to evaluate the anticipated effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"Using mRNA TPM data from a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 12.0 mutations per MB, could you please assess the likelihood of a favorable response to Atezolizumab and provide the rationale for your conclusion?","Using mRNA TPM data from a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 12.0 mutations per MB, could you please assess the likelihood of a favorable response to Atezolizumab and provide the rationale for your conclusion? Step 1: Retrieve the patient's transcriptomic data from the designated pickle file.  
Step 2: Use the Compass algorithm to determine the probability of a positive response to immune checkpoint inhibitor therapy.  
Step 3: Identify the top five significant immune biomarkers in the transcriptomic dataset and integrate this information with the patient’s clinical data to build a detailed immune profile.  
Step 4: Compare the constructed immune profile with the Compass algorithm’s predictions to assess the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"Based on mRNA TPM data evaluating the immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is female, with an unknown race, has bladder tissue involvement, and a tumor mutational burden of 13.0 mutations per megabase. Please classify the patient as either a responder or non-responder, and provide the supporting rationale for your assessment.","Based on mRNA TPM data evaluating the immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is female, with an unknown race, has bladder tissue involvement, and a tumor mutational burden of 13.0 mutations per megabase. Please classify the patient as either a responder or non-responder, and provide the supporting rationale for your assessment. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Determine the top five immune biomarkers from the transcriptomic dataset and combine these findings with the patient’s clinical information to develop a comprehensive immune profile.  
4. Compare the generated immune profile with the predictions from the Compass algorithm to evaluate the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"Given a male, white patient with bladder urothelial carcinoma (tissue sample from the kidney) and a tumor mutational burden of 6.0 mutations per MB, and having obtained mRNA TPM data representing the tumor immune microenvironment, what is your assessment of his likelihood of responding to atezolizumab? Please include your reasoning based on the available molecular and clinical data.","Given a male, white patient with bladder urothelial carcinoma (tissue sample from the kidney) and a tumor mutational burden of 6.0 mutations per MB, and having obtained mRNA TPM data representing the tumor immune microenvironment, what is your assessment of his likelihood of responding to atezolizumab? Please include your reasoning based on the available molecular and clinical data. 1. Retrieve the patient’s transcriptomic data from the indicated pickle file.  
2. Use the Compass algorithm to calculate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Identify the five key immune biomarkers from the transcriptomic data and integrate these findings with the patient’s clinical details to construct a thorough immune profile.  
4. Compare this immune profile with the Compass algorithm’s predictions to assess the potential effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"A male patient with bladder urothelial carcinoma has been profiled using mRNA TPM data to characterize his tumor immune microenvironment. The clinical details include a ureter tissue origin, white race, and a tumor mutational burden of 21.0 mutations per megabase. Based on this information, can we determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and what is the supporting rationale for this classification?","A male patient with bladder urothelial carcinoma has been profiled using mRNA TPM data to characterize his tumor immune microenvironment. The clinical details include a ureter tissue origin, white race, and a tumor mutational burden of 21.0 mutations per megabase. Based on this information, can we determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and what is the supporting rationale for this classification? 1. Begin by retrieving the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to predict the patient’s likelihood of responding favorably to immune checkpoint inhibitor therapy.  
3. Extract and analyze the five key immune biomarkers from the transcriptomic data, and integrate these results with the patient’s clinical information to develop a comprehensive immune profile.  
4. Finally, compare the comprehensive immune profile with the predictions generated by the Compass algorithm to evaluate the potential effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"Based on mRNA TPM data reflecting the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), along with clinical details (Male, White, bladder tissue, and a tumor mutational burden of 14.0 mutations/MB), what is the predicted responsiveness to Atezolizumab? Please provide a detailed rationale supporting whether the patient is likely to be classified as a responder or non-responder.","Based on mRNA TPM data reflecting the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), along with clinical details (Male, White, bladder tissue, and a tumor mutational burden of 14.0 mutations/MB), what is the predicted responsiveness to Atezolizumab? Please provide a detailed rationale supporting whether the patient is likely to be classified as a responder or non-responder. 1. Retrieve the patient's transcriptomic dataset from the designated pickle file.  
2. Use the Compass algorithm to estimate the patient's probability of responding favorably to immune checkpoint inhibitor therapy.  
3. Identify and evaluate the five key immune biomarkers from the transcriptomic data, then combine these findings with the patient's clinical information to construct a comprehensive immune profile.  
4. Finally, compare this integrated immune profile with the Compass algorithm's prediction to assess the potential effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"I'm evaluating mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to predict their responsiveness to Atezolizumab. The patient is a 60-year-old white male with bladder tissue tumor origin, and his tumor exhibits a mutational burden of 9 mutations per megabase. Based on these attributes, could you provide your assessment regarding whether this patient is likely to respond to Atezolizumab, and please detail the rationale for your conclusion?","I'm evaluating mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to predict their responsiveness to Atezolizumab. The patient is a 60-year-old white male with bladder tissue tumor origin, and his tumor exhibits a mutational burden of 9 mutations per megabase. Based on these attributes, could you provide your assessment regarding whether this patient is likely to respond to Atezolizumab, and please detail the rationale for your conclusion? 1. Begin by accessing the patient's transcriptomic dataset stored in the designated pickle file.  
2. Apply the Compass algorithm to assess the patient’s likelihood of responding positively to immune checkpoint inhibitor therapy.  
3. Identify and analyze the five principal immune biomarkers from the transcriptomic data, then combine this information with the patient's clinical records to develop a comprehensive immune profile.  
4. Finally, compare this consolidated immune profile with the predictions generated by the Compass algorithm to evaluate the potential effectiveness of the planned immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tumor tissue mRNA TPM data have been processed to assess the immune microenvironment and with an FMOne mutation burden of 27.0 mutations per MB, can you provide an evaluation of his predicted response to Atezolizumab? Please include the rationale behind classifying him as either a likely responder or non-responder.","For a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tumor tissue mRNA TPM data have been processed to assess the immune microenvironment and with an FMOne mutation burden of 27.0 mutations per MB, can you provide an evaluation of his predicted response to Atezolizumab? Please include the rationale behind classifying him as either a likely responder or non-responder. 1. Retrieve the patient's transcriptomic dataset from the specified pickle file.  
2. Utilize the Compass algorithm to estimate the patient's probability of a favorable response to immune checkpoint inhibitor therapy.  
3. Extract and evaluate the top five immune-related biomarkers from the transcriptomic data, and integrate these findings with the patient's clinical records to form a detailed immune profile.  
4. Compare this integrated immune profile with the predictions provided by the Compass algorithm to assess the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"Can you determine if this female bladder urothelial carcinoma (BLCA) patient, whose mRNA TPM data was used to assess the tumor immune microenvironment from a lymph node sample and with an unspecified tumor mutational burden, is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the supporting reasoning.","Can you determine if this female bladder urothelial carcinoma (BLCA) patient, whose mRNA TPM data was used to assess the tumor immune microenvironment from a lymph node sample and with an unspecified tumor mutational burden, is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the supporting reasoning. 1. Load the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to predict the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy.  
3. Identify the top five immune-related biomarkers in the transcriptomic data and integrate these with the patient's clinical records to develop a comprehensive immune profile.  
4. Compare this detailed immune profile with the Compass algorithm predictions to evaluate the potential effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab? The patient is a white female with kidney tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Please provide your assessment on whether she is more likely to be a responder or non-responder, along with the supporting rationale.","Based on the processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab? The patient is a white female with kidney tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Please provide your assessment on whether she is more likely to be a responder or non-responder, along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to estimate the patient’s probability of a positive response to immune checkpoint inhibitor therapy.  
3. Determine the five most significant immune biomarkers in the transcriptomic data and consolidate this information with the patient’s clinical history to form a detailed immune profile.  
4. Review the immune profile alongside the Compass algorithm’s prediction to assess the likely benefit of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"In a patient with Bladder Urothelial Carcinoma (BLCA), I have processed mRNA TPM data reflecting the tumor immune microenvironment. The patient details are as follows: Male, White, bladder tissue affected, with tumor mutational burden unavailable (nan). Based on this molecular profile, how should we predict the likelihood of responsiveness to Atezolizumab, and what is the rationale supporting this prediction?","In a patient with Bladder Urothelial Carcinoma (BLCA), I have processed mRNA TPM data reflecting the tumor immune microenvironment. The patient details are as follows: Male, White, bladder tissue affected, with tumor mutational burden unavailable (nan). Based on this molecular profile, how should we predict the likelihood of responsiveness to Atezolizumab, and what is the rationale supporting this prediction? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to calculate the patient’s probability of responding favorably to immune checkpoint inhibitor therapy.
3. Identify the top five significant immune biomarkers within the transcriptomic dataset and integrate these findings with the patient’s clinical history to create a comprehensive immune profile.
4. Evaluate the detailed immune profile alongside the Compass algorithm’s prediction to determine the potential benefit of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"I have mRNA TPM data that characterizes the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). This patient is a White male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per MB (FMOne metric). Based on these data, can we determine if the patient is likely to respond to Atezolizumab? Please provide a conclusion on responder status along with the supporting rationale.","I have mRNA TPM data that characterizes the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). This patient is a White male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per MB (FMOne metric). Based on these data, can we determine if the patient is likely to respond to Atezolizumab? Please provide a conclusion on responder status along with the supporting rationale. 1. Obtain the patient’s transcriptomic data from the specified pickle file.
2. Utilize the Compass algorithm to determine the likelihood that the patient will respond well to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers from the transcriptomic dataset and combine these findings with the patient's clinical history to develop a comprehensive immune profile.
4. Review the detailed immune profile together with the Compass algorithm’s prediction to assess whether the proposed immunotherapy is likely to be beneficial for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the patient’s predicted response to Atezolizumab? The patient is male, White, with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 4.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you assess the patient’s predicted response to Atezolizumab? The patient is male, White, with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 4.0 mutations per megabase. Please provide a conclusion on whether this patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to evaluate the patient’s likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Select the five most significant immune biomarkers from the transcriptomic data and integrate these findings with the patient’s clinical history to construct a detailed immune profile.  
4. Review the comprehensive immune profile in conjunction with the Compass algorithm’s prediction to determine whether the proposed immunotherapy is likely to be beneficial for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a male, White patient with bladder urothelial carcinoma (BLCA), using a bladder tissue sample. With a tumor mutational burden of 5.0 mutations/MB, can you assess whether this patient is likely to respond to Atezolizumab? Please include your reasoning and any factors that contribute to your evaluation.","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a male, White patient with bladder urothelial carcinoma (BLCA), using a bladder tissue sample. With a tumor mutational burden of 5.0 mutations/MB, can you assess whether this patient is likely to respond to Atezolizumab? Please include your reasoning and any factors that contribute to your evaluation. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to determine the patient’s probability of responding well to immune checkpoint inhibitor therapy.
3. Identify the five most important immune biomarkers from the transcriptomic data and combine these findings with the patient's clinical history to develop a comprehensive immune profile.
4. Evaluate this detailed immune profile alongside the Compass algorithm’s prediction to assess whether the proposed immunotherapy is likely to be effective for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"A female patient of white race with bladder urothelial carcinoma (BLCA) has been evaluated, with mRNA TPM data reflecting her tumor immune microenvironment and a tumor mutational burden of 15 mutations per megabase. Based on these findings, can you provide an assessment of whether she is likely to respond to Atezolizumab, including the rationale supporting that determination?","A female patient of white race with bladder urothelial carcinoma (BLCA) has been evaluated, with mRNA TPM data reflecting her tumor immune microenvironment and a tumor mutational burden of 15 mutations per megabase. Based on these findings, can you provide an assessment of whether she is likely to respond to Atezolizumab, including the rationale supporting that determination? 1. Obtain the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Extract the top five immune biomarkers from the transcriptomic data and integrate these results with the patient's clinical history to construct a detailed immune profile.  
4. Assess the constructed immune profile in conjunction with the Compass algorithm's prediction to determine the potential effectiveness of the proposed immunotherapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"In a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male, White individual with bladder tissue and a tumor mutational burden of 13 mutations per MB, how does the mRNA TPM data of the tumor immune microenvironment inform the predicted response to Atezolizumab? Please provide an assessment of whether the patient is likely to respond to the therapy, along with the supporting rationale.","In a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male, White individual with bladder tissue and a tumor mutational burden of 13 mutations per MB, how does the mRNA TPM data of the tumor immune microenvironment inform the predicted response to Atezolizumab? Please provide an assessment of whether the patient is likely to respond to the therapy, along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to predict the probability of a positive response to immune checkpoint inhibitor therapy.
3. Identify the five most significant immune biomarkers from the transcriptomic data and combine these findings with the patient’s clinical history to create a comprehensive immune profile.
4. Evaluate this immune profile together with the Compass algorithm’s prediction to assess the potential efficacy of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female with bladder tissue involvement and a tumor mutational burden of 14 mutations per megabase. Based on these clinical details, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female with bladder tissue involvement and a tumor mutational burden of 14 mutations per megabase. Based on these clinical details, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for your conclusion? 1. Access the patient’s transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to estimate this patient’s probability of achieving a favorable response to immune checkpoint inhibitor therapy.
3. From the transcriptomic data, identify the top five immune biomarkers and merge these findings with the patient’s clinical history to construct a comprehensive immune profile.
4. Review the integrated immune profile in conjunction with the Compass algorithm’s prediction to evaluate the anticipated effectiveness of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the clinical profile—including male sex, Black or African American race, bladder tissue origin, and a tumor mutational burden of 17 mutations per MB—can you determine if this patient is likely to respond to Atezolizumab? Please provide your assessment along with supporting clinical and molecular rationale.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the clinical profile—including male sex, Black or African American race, bladder tissue origin, and a tumor mutational burden of 17 mutations per MB—can you determine if this patient is likely to respond to Atezolizumab? Please provide your assessment along with supporting clinical and molecular rationale. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Utilize the Compass algorithm to estimate the likelihood of this patient responding favorably to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, and combine these findings with the patient’s clinical history to create a detailed immune profile.  
4. Assess this integrated immune profile along with the Compass algorithm’s prediction to determine the potential effectiveness of the proposed immunotherapy treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a 7.0 mutation/MB FMOne tumor, male, and White, with bladder tissue involvement. Could you provide an interpretation of whether this patient is likely a responder or non-responder to Atezolizumab therapy, and explain your rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a 7.0 mutation/MB FMOne tumor, male, and White, with bladder tissue involvement. Could you provide an interpretation of whether this patient is likely a responder or non-responder to Atezolizumab therapy, and explain your rationale? 1. Access the patient’s transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient’s probability of responding to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the top five immune biomarkers and integrate these results with the patient’s clinical history to develop a comprehensive immune profile.
4. Evaluate this combined immune profile along with the Compass algorithm prediction to assess the potential effectiveness of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"For a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tumor tissue exhibits a mutational burden of 5.0 mutations per megabase, and with processed mRNA TPM data available for the tumor immune microenvironment, could you please assess and explain whether this patient is expected to respond to atezolizumab treatment?","For a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tumor tissue exhibits a mutational burden of 5.0 mutations per megabase, and with processed mRNA TPM data available for the tumor immune microenvironment, could you please assess and explain whether this patient is expected to respond to atezolizumab treatment? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.
3. Examine the transcriptomic data to determine the top five immune biomarkers, and then integrate these findings with the patient's clinical history to create a detailed immune profile.
4. Review the combined immune profile along with the Compass algorithm’s prediction to evaluate the potential effectiveness of the suggested immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"Based on mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following attributes—male, white, lung tissue sample, and an FMOne tumor mutational burden of 20 mutations per MB—could you determine whether this patient is more likely to respond or not respond to atezolizumab? Please include the supporting rationale for your assessment.","Based on mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following attributes—male, white, lung tissue sample, and an FMOne tumor mutational burden of 20 mutations per MB—could you determine whether this patient is more likely to respond or not respond to atezolizumab? Please include the supporting rationale for your assessment. 1. Please load the patient’s transcriptomic data from the indicated pickle file.
2. Apply the Compass algorithm to estimate the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the top five immune biomarkers, and then incorporate these results with the patient’s clinical history to develop a comprehensive immune profile.
4. Finally, review both the detailed immune profile and the Compass algorithm’s prediction to assess the likely effectiveness of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"I am reviewing mRNA TPM data from a BLCA patient’s tumor immune microenvironment to evaluate potential responsiveness to Atezolizumab. The patient is a white male with bladder involvement and a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, can you determine whether the patient is likely to be a responder or non-responder, and please provide the rationale for your conclusion.","I am reviewing mRNA TPM data from a BLCA patient’s tumor immune microenvironment to evaluate potential responsiveness to Atezolizumab. The patient is a white male with bladder involvement and a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, can you determine whether the patient is likely to be a responder or non-responder, and please provide the rationale for your conclusion. 1. Retrieve the patient’s transcriptomic dataset from the specified pickle file.
2. Utilize the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic data to identify the five most significant immune biomarkers, then integrate these findings with the patient’s clinical history to formulate a comprehensive immune profile.
4. Review the detailed immune profile in conjunction with the Compass algorithm's prediction to determine the anticipated effectiveness of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I'm reviewing mRNA TPM data from a bladder urothelial carcinoma (BLCA) patient with a lymph node tissue specimen. The patient is a Black/African American male, and their tumor mutational burden is currently unavailable. Based on this information, could you help assess whether this patient is likely to respond to Atezolizumab, and explain the rationale for your assessment?","I'm reviewing mRNA TPM data from a bladder urothelial carcinoma (BLCA) patient with a lymph node tissue specimen. The patient is a Black/African American male, and their tumor mutational burden is currently unavailable. Based on this information, could you help assess whether this patient is likely to respond to Atezolizumab, and explain the rationale for your assessment? 1. Access the patient’s transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to predict the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the top five immune biomarkers, and combine these findings with the patient’s clinical history to build a detailed immune profile.
4. Examine both the constructed immune profile and the Compass algorithm’s prediction to assess the likely effectiveness of the proposed immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have processed mRNA TPM data that reflects the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma. The available patient information includes: Sex: Male, Race: White, Tissue: bladder, and a reported tumor mutational burden (FMOne mutation burden per MB) that is not available (nan). Based on these data, could you determine whether the patient is more likely to respond to Atezolizumab, and please provide the underlying rationale for your conclusion?","I have processed mRNA TPM data that reflects the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma. The available patient information includes: Sex: Male, Race: White, Tissue: bladder, and a reported tumor mutational burden (FMOne mutation burden per MB) that is not available (nan). Based on these data, could you determine whether the patient is more likely to respond to Atezolizumab, and please provide the underlying rationale for your conclusion? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will positively respond to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, and integrate these results with the patient’s clinical history to develop a comprehensive immune profile.
4. Review both the detailed immune profile and the Compass algorithm’s outcome to determine the anticipated effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have analyzed the mRNA TPM data representing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tumor mutational burden of 8.0 mutations per megabase. Based on these clinical and molecular findings, how would you classify her predicted response to Atezolizumab (i.e., responder or non-responder), and what evidence supports this conclusion?","I have analyzed the mRNA TPM data representing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female with a tumor mutational burden of 8.0 mutations per megabase. Based on these clinical and molecular findings, how would you classify her predicted response to Atezolizumab (i.e., responder or non-responder), and what evidence supports this conclusion? 1. Access and load the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to estimate the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy.  
3. Examine the transcriptomic profile to identify the top five key immune biomarkers and combine these findings with the patient's clinical history to construct a detailed immune profile.  
4. Evaluate the comprehensive immune profile alongside the Compass algorithm’s results to assess the expected effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"For a male Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6 mutations per MB and mRNA TPM data from kidney tissue representing the tumor immune microenvironment, how would you assess his predicted response to Atezolizumab? Please provide a conclusion on whether he is likely to be a responder or non-responder, including your supporting rationale.","For a male Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6 mutations per MB and mRNA TPM data from kidney tissue representing the tumor immune microenvironment, how would you assess his predicted response to Atezolizumab? Please provide a conclusion on whether he is likely to be a responder or non-responder, including your supporting rationale. 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Utilize the Compass algorithm to predict the patient's potential response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to determine the five most significant immune biomarkers, and integrate these results with the patient’s clinical history to create a comprehensive immune profile.  
4. Review the complete immune profile in combination with the Compass algorithm’s predictions to evaluate the likely efficacy of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"A male, white patient with bladder urothelial carcinoma (BLCA) has mRNA TPM data detailing his tumor immune microenvironment and a tumor mutational burden of 17 mutations per MB. Could you assess his likely response to atezolizumab therapy, providing support based on these molecular and clinical features?","A male, white patient with bladder urothelial carcinoma (BLCA) has mRNA TPM data detailing his tumor immune microenvironment and a tumor mutational burden of 17 mutations per MB. Could you assess his likely response to atezolizumab therapy, providing support based on these molecular and clinical features? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Run the Compass algorithm on this data to predict the patient's potential response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic dataset to identify the five most significant immune biomarkers, and combine these findings with the patient’s clinical history to assemble a comprehensive immune profile.
4. Review the complete immune profile alongside the Compass algorithm’s predictions to determine the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"Given the mRNA TPM data of the tumor immune microenvironment and the patient’s profile—a 6.0 mutation/MB tumor mutational burden in a male, White patient with kidney tissue affected by Bladder Urothelial Carcinoma (BLCA)—can you assess whether this patient is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the supporting rationale.","Given the mRNA TPM data of the tumor immune microenvironment and the patient’s profile—a 6.0 mutation/MB tumor mutational burden in a male, White patient with kidney tissue affected by Bladder Urothelial Carcinoma (BLCA)—can you assess whether this patient is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the supporting rationale. 1. Please locate and extract the patient’s transcriptomic data from the specified pickle file.
2. Next, process this data using the Compass algorithm to generate predictions about the patient's response to immune checkpoint inhibitor therapy.
3. Subsequently, analyze the transcriptomic dataset to identify the top five immune biomarkers, and integrate these results with the patient’s clinical history to construct a detailed immune profile.
4. Finally, evaluate the constructed immune profile in conjunction with the Compass algorithm’s predictions to assess the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"Based on the patient's data—a white male with bladder urothelial carcinoma, a lymph node sample, and a tumor mutational burden of 1.0 mutations per megabase—can you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please explain your reasoning.","Based on the patient's data—a white male with bladder urothelial carcinoma, a lymph node sample, and a tumor mutational burden of 1.0 mutations per megabase—can you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please explain your reasoning. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Process the extracted data using the Compass algorithm to predict the patient’s response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic dataset to identify the top five immune biomarkers, and then merge these findings with the patient’s clinical history to develop a comprehensive immune profile.
4. Lastly, review the immune profile alongside the Compass algorithm’s predictions to evaluate the anticipated effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"Based on processed mRNA TPM data reflecting the patient's tumor immune microenvironment, could you help determine whether this male, white patient with bladder urothelial carcinoma (BLCA) and a kidney tissue sample—despite an unavailable tumor mutational burden—would be predicted to respond to Atezolizumab treatment? Please provide your conclusion along with supporting reasoning.","Based on processed mRNA TPM data reflecting the patient's tumor immune microenvironment, could you help determine whether this male, white patient with bladder urothelial carcinoma (BLCA) and a kidney tissue sample—despite an unavailable tumor mutational burden—would be predicted to respond to Atezolizumab treatment? Please provide your conclusion along with supporting reasoning. 1. Begin by retrieving the patient’s transcriptomic data from the specified pickle file.  
2. Process this data using the Compass algorithm to forecast the patient’s response to immune checkpoint inhibitor therapy.  
3. Next, examine the transcriptomic dataset to identify the five most significant immune biomarkers, and then integrate these results with the patient’s clinical history to generate a detailed immune profile.  
4. Finally, compare the immune profile with the Compass algorithm’s predictions to assess the likely effectiveness of the intended immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"Given the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, with the following characteristics—female, White, kidney tissue sample, and a tumor mutational burden of 7.0 mutations per MB—can you evaluate this patient’s predicted response to Atezolizumab and clarify whether they are likely to be categorized as a responder or non-responder? Please include the supporting rationale for your conclusion.","Given the processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, with the following characteristics—female, White, kidney tissue sample, and a tumor mutational burden of 7.0 mutations per MB—can you evaluate this patient’s predicted response to Atezolizumab and clarify whether they are likely to be categorized as a responder or non-responder? Please include the supporting rationale for your conclusion. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Process this data with the Compass algorithm to predict the patient’s responsiveness to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic dataset to identify the five most relevant immune biomarkers, then combine these findings with the patient's clinical history to construct a comprehensive immune profile.  
4. Finally, compare the immune profile with the predictions generated by the Compass algorithm to evaluate the expected effectiveness of the planned immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"Based on the mRNA TPM data for the tumor immune microenvironment in a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 21 mutations per MB, would you consider this patient likely to be a responder to Atezolizumab? Please provide your conclusion along with the supporting rationale for your assessment.","Based on the mRNA TPM data for the tumor immune microenvironment in a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 21 mutations per MB, would you consider this patient likely to be a responder to Atezolizumab? Please provide your conclusion along with the supporting rationale for your assessment. 1. Begin by obtaining the patient’s transcriptomic data from the specified pickle file.
2. Process this data using the Compass algorithm to estimate the patient's potential response to immune checkpoint inhibitor therapy.
3. Examine the transcriptomic dataset to identify the five most relevant immune biomarkers, and then integrate these findings with the patient's clinical history to create a detailed immune profile.
4. Finally, compare this immune profile with the Compass algorithm’s predictions to assess the likely effectiveness of the proposed immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor exhibits an mRNA TPM profile and a tumor mutational burden of 7.0 mutations per MB, with demographic details as follows: male, White, and tumor tissue from the ureter—can you provide an assessment of their predicted responsiveness to Atezolizumab? Please include the rationale behind classifying the patient as a responder or non-responder based on these findings.","For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor exhibits an mRNA TPM profile and a tumor mutational burden of 7.0 mutations per MB, with demographic details as follows: male, White, and tumor tissue from the ureter—can you provide an assessment of their predicted responsiveness to Atezolizumab? Please include the rationale behind classifying the patient as a responder or non-responder based on these findings. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Process this data using the Compass algorithm to generate an estimate of the patient’s response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, then combine these findings with the patient’s clinical history to construct a comprehensive immune profile.  
4. Finally, compare this detailed immune profile with the predictions from the Compass algorithm to evaluate the expected effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White male, and the tissue sample analyzed is from the lung, with a tumor mutational burden of 6.0 mutations per megabase. Based on these details, could you provide an interpretation regarding his predicted responsiveness to Atezolizumab, including the rationale behind classifying him as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White male, and the tissue sample analyzed is from the lung, with a tumor mutational burden of 6.0 mutations per megabase. Based on these details, could you provide an interpretation regarding his predicted responsiveness to Atezolizumab, including the rationale behind classifying him as a responder or non-responder? 1. Access the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to this data to estimate the patient’s likely response to immune checkpoint inhibitor therapy.  
3. Identify the top five immune biomarkers from the transcriptomic data and integrate these findings with the patient’s clinical history to establish a detailed immune profile.  
4. Compare this immune profile with the Compass algorithm’s predictions to assess the anticipated efficacy of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"Based on the patient's processed mRNA TPM data of the tumor immune microenvironment and the following clinical details—a 6.0 mutations/MB tumor mutational burden in a male, White patient with a diagnosis of Bladder Urothelial Carcinoma (despite the kidney tissue specification)—could you assess the predicted response to Atezolizumab? Please indicate whether the patient is more likely to be a responder or non-responder, and provide the reasoning behind your assessment.","Based on the patient's processed mRNA TPM data of the tumor immune microenvironment and the following clinical details—a 6.0 mutations/MB tumor mutational burden in a male, White patient with a diagnosis of Bladder Urothelial Carcinoma (despite the kidney tissue specification)—could you assess the predicted response to Atezolizumab? Please indicate whether the patient is more likely to be a responder or non-responder, and provide the reasoning behind your assessment. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm on this dataset to predict the patient’s likely response to immune checkpoint inhibitor therapy.  
3. Identify the five most significant immune biomarkers from the transcriptomic analysis and combine these results with the patient’s clinical history to develop a comprehensive immunological profile.  
4. Compare this detailed immune profile with the Compass algorithm predictions to evaluate the expected efficacy of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with disease-specific information including tissue type (bladder) and an undefined tumor mutational burden (FMOne mutation burden per MB: nan). Based on these parameters, could you assess whether the patient is likely to respond to atezolizumab and provide evidence-based reasoning for your conclusion?","I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with disease-specific information including tissue type (bladder) and an undefined tumor mutational burden (FMOne mutation burden per MB: nan). Based on these parameters, could you assess whether the patient is likely to respond to atezolizumab and provide evidence-based reasoning for your conclusion? 1. Access the patient's transcriptomic data stored in the specified pickle file.  
2. Apply the Compass algorithm to this data to forecast the patient’s potential response to immune checkpoint inhibitor therapy.  
3. Determine the five most critical immune biomarkers from the transcriptomic analysis and integrate these findings with the patient’s clinical history to create a detailed immunological profile.  
4. Evaluate the predicted effectiveness of the immunotherapy by comparing the comprehensive immune profile with the outcomes from the Compass algorithm.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a male patient with Bladder Urothelial Carcinoma (BLCA) whose tumor mRNA TPM profile indicates the immune microenvironment status and an FMOne mutation burden of 3.0 mutations per megabase, can you assess the likelihood of a favorable response to Atezolizumab and explain the rationale behind your classification as a responder or non-responder?","For a male patient with Bladder Urothelial Carcinoma (BLCA) whose tumor mRNA TPM profile indicates the immune microenvironment status and an FMOne mutation burden of 3.0 mutations per megabase, can you assess the likelihood of a favorable response to Atezolizumab and explain the rationale behind your classification as a responder or non-responder? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Run the Compass algorithm on these data to estimate the patient’s potential response to immune checkpoint inhibitor therapy.  
3. Identify the top five immune biomarkers from the transcriptomic analysis and merge these findings with the patient’s clinical history to develop a comprehensive immunological profile.  
4. Compare the immune profile with the Compass algorithm’s prediction to assess the likely effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a 5.0 mutations per MB tumor mutational burden male of Asian descent, and the sample was taken from bladder tissue. Based on this data, can you assess whether the patient is likely to respond to Atezolizumab, and provide the supporting clinical rationale for your conclusion?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a 5.0 mutations per MB tumor mutational burden male of Asian descent, and the sample was taken from bladder tissue. Based on this data, can you assess whether the patient is likely to respond to Atezolizumab, and provide the supporting clinical rationale for your conclusion? 1. Access the patient's transcriptomic data using the specified pickle file.  
2. Utilize the Compass algorithm on these data to estimate the patient’s responsiveness to immune checkpoint inhibitor therapy.  
3. From the transcriptomic analysis, determine the five most significant immune biomarkers, and integrate these findings with the patient’s clinical history to construct a detailed immunological profile.  
4. Compare this immune profile with the Compass algorithm’s prediction to evaluate the potential effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"For a male white patient with bladder urothelial carcinoma, we have mRNA TPM data profiling the tumor immune microenvironment. Tumor mutational burden data is unavailable. Based on these details, how does the gene expression profile inform the predicted response to Atezolizumab, and could you provide your reasoning on whether this patient is likely to be classified as a responder or non-responder?","For a male white patient with bladder urothelial carcinoma, we have mRNA TPM data profiling the tumor immune microenvironment. Tumor mutational burden data is unavailable. Based on these details, how does the gene expression profile inform the predicted response to Atezolizumab, and could you provide your reasoning on whether this patient is likely to be classified as a responder or non-responder? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to this dataset to estimate the potential responsiveness to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, and combine these results with the patient’s clinical history to build a comprehensive immunological profile.  
4. Evaluate the congruence between the immunological profile and the Compass algorithm’s prediction to determine the likely effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and to predict the response to Atezolizumab therapy. The patient's details are as follows: Sex: Female, Race: White, Tissue: Ureter, and a tumor mutational burden of 12.0 mutations per megabase (FMOne). Based on these parameters, could you please determine whether this patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion?","I have processed mRNA TPM data to evaluate the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and to predict the response to Atezolizumab therapy. The patient's details are as follows: Sex: Female, Race: White, Tissue: Ureter, and a tumor mutational burden of 12.0 mutations per megabase (FMOne). Based on these parameters, could you please determine whether this patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion? 1. Please extract the patient’s transcriptomic data from the specified pickle file.  
2. Utilize the Compass algorithm on this dataset to predict the patient’s potential response to immune checkpoint inhibitor therapy.  
3. Examine the transcriptomic data to identify the top five significant immune biomarkers, and integrate these findings with the patient’s clinical history to develop a comprehensive immunological profile.  
4. Compare the immunological profile with the Compass algorithm’s prediction to assess the likely effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"Based on this patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you assess the predicted response to Atezolizumab? The patient is a white male with a tumor located in the ureter, and the reported tumor mutational burden is unavailable. Please provide your evaluation as to whether this patient is likely to respond to Atezolizumab, along with your reasoning.","Based on this patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you assess the predicted response to Atezolizumab? The patient is a white male with a tumor located in the ureter, and the reported tumor mutational burden is unavailable. Please provide your evaluation as to whether this patient is likely to respond to Atezolizumab, along with your reasoning. 1. Retrieve the patient's transcriptomic data from the provided pickle file.  
2. Apply the Compass algorithm to this dataset to predict the patient’s response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, and integrate these results with the patient’s clinical history to create a detailed immunological profile.  
4. Compare this immunological profile with the Compass algorithm’s prediction to evaluate the potential efficacy of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been profiled using mRNA TPM data, and with the following attributes: Sex: Female; Race: White; Tissue: Bladder; Tumor Mutational Burden: 5.0 mutations per MB, can you provide an evaluation of her predicted responsiveness to Atezolizumab, including a detailed explanation of your rationale?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been profiled using mRNA TPM data, and with the following attributes: Sex: Female; Race: White; Tissue: Bladder; Tumor Mutational Burden: 5.0 mutations per MB, can you provide an evaluation of her predicted responsiveness to Atezolizumab, including a detailed explanation of your rationale? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Process this data using the Compass algorithm to predict the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  
3. Evaluate the transcriptomic profile to identify the five most significant immune biomarkers, and combine these findings with the patient’s clinical history to formulate a comprehensive immunological profile.  
4. Compare the immunological profile with the Compass algorithm’s prediction to assess the potential effectiveness of the immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"Given mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likely response to Atezolizumab? The patient's clinical details are as follows:
• Sex: Male
• Race: White
• Tissue Sample: Lymph node
• Disease: Bladder Urothelial Carcinoma (BLCA)
• Tumor Mutational Burden: 4.0 mutations per megabase

Please indicate whether this patient is more likely to be a responder or non-responder, and provide the rationale for your conclusion.","Given mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), can you assess the likely response to Atezolizumab? The patient's clinical details are as follows:
• Sex: Male
• Race: White
• Tissue Sample: Lymph node
• Disease: Bladder Urothelial Carcinoma (BLCA)
• Tumor Mutational Burden: 4.0 mutations per megabase

Please indicate whether this patient is more likely to be a responder or non-responder, and provide the rationale for your conclusion. 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Process the data using the Compass algorithm to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile to identify the five most significant immune biomarkers, and integrate these results with the patient’s clinical history to create a comprehensive immunological profile.
4. Compare this immunological profile with the Compass algorithm's prediction to evaluate the potential effectiveness of the immune therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"I have evaluated mRNA TPM data from the tumor immune microenvironment of a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 8.0 FMOne mutations per megabase. Based on these data, could you please assess whether this patient is likely to respond to Atezolizumab and provide your rationale?","I have evaluated mRNA TPM data from the tumor immune microenvironment of a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 8.0 FMOne mutations per megabase. Based on these data, could you please assess whether this patient is likely to respond to Atezolizumab and provide your rationale? 1. Access the patient’s transcriptomic data contained in the designated pickle file.  
2. Apply the Compass algorithm to the extracted data to estimate the patient’s probability of responding to immune checkpoint inhibitor therapy.  
3. Examine the transcriptomic data to pinpoint the top five immune biomarkers and combine these findings with the patient’s clinical history to develop an integrated immunological profile.  
4. Compare this comprehensive immunological profile with the prediction from the Compass algorithm to assess the potential effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For a male, white patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM data has been analyzed for immune microenvironment profiling and with unavailable tumor mutational burden (NaN), what is the predicted response to Atezolizumab, and what is the rationale for classifying him as a responder or non-responder?","For a male, white patient with bladder urothelial carcinoma (BLCA) whose tumor mRNA TPM data has been analyzed for immune microenvironment profiling and with unavailable tumor mutational burden (NaN), what is the predicted response to Atezolizumab, and what is the rationale for classifying him as a responder or non-responder? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to this data to estimate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic information to identify the top five immune biomarkers, and integrate these findings with the patient’s clinical history to construct a comprehensive immunological profile.
4. Compare the resulting immunological profile with the prediction from the Compass algorithm to evaluate the potential effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"I have analyzed mRNA TPM expression data from the tumor immune microenvironment of a male African American patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 1.0 mutations per megabase. Based on this data, can we determine whether the patient is likely to respond to Atezolizumab, and what is the rationale for this classification?","I have analyzed mRNA TPM expression data from the tumor immune microenvironment of a male African American patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 1.0 mutations per megabase. Based on this data, can we determine whether the patient is likely to respond to Atezolizumab, and what is the rationale for this classification? 1. Access the patient’s transcriptomic dataset from the specified pickle file.
2. Process this dataset using the Compass algorithm to estimate the probability that the patient will respond to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the five most significant immune biomarkers, and combine these findings with the patient’s clinical history to develop a detailed immunological profile.
4. Compare the immunological profile with the Compass algorithm’s prediction to assess the likely effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA), we have analyzed mRNA TPM data of the tumor immune microenvironment. The patient is a  M of Asian descent, with kidney tissue involvement and a tumor mutational burden of 11.0 mutations per megabase. Based on this data, could you determine whether the patient is likely to respond to atezolizumab, and please provide the rationale behind your assessment?","For a patient with Bladder Urothelial Carcinoma (BLCA), we have analyzed mRNA TPM data of the tumor immune microenvironment. The patient is a  M of Asian descent, with kidney tissue involvement and a tumor mutational burden of 11.0 mutations per megabase. Based on this data, could you determine whether the patient is likely to respond to atezolizumab, and please provide the rationale behind your assessment? 1. Retrieve the patient’s transcriptomic dataset from the designated pickle file.  
2. Process the dataset through the Compass algorithm to calculate the probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Assess the transcriptomic data to pinpoint the five most significant immune biomarkers and integrate these findings with the patient’s clinical history to formulate a comprehensive immunological profile.  
4. Evaluate the immunological profile alongside the Compass algorithm’s prediction to determine the likely effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) who has been profiled using mRNA TPM data from the tumor immune microenvironment, a TMB of 8.0 mutations per MB, is a white male with kidney tissue involvement, how would you determine their likelihood of responding to atezolizumab? Please specify whether the patient would be classified as a responder or non-responder and outline the rationale behind your assessment.","For a patient with Bladder Urothelial Carcinoma (BLCA) who has been profiled using mRNA TPM data from the tumor immune microenvironment, a TMB of 8.0 mutations per MB, is a white male with kidney tissue involvement, how would you determine their likelihood of responding to atezolizumab? Please specify whether the patient would be classified as a responder or non-responder and outline the rationale behind your assessment. 1. Begin by retrieving the patient’s transcriptomic data from the specified pickle file.  
2. Next, analyze this data using the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Review the transcriptomic data to identify the top five immune biomarkers, and then integrate these findings with the patient’s clinical history to construct a detailed immunological profile.  
4. Finally, combine the insights from the immunological profile with the Compass algorithm prediction to assess the likely effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"Based on the processed mRNA TPM data for a female patient with Bladder Urothelial Carcinoma (BLCA) who is White, with bladder tissue involvement and a tumor mutational burden of 7 mutations per MB, could you please evaluate whether this patient is likely to respond to Atezolizumab? Additionally, please explain the rationale behind your assessment.","Based on the processed mRNA TPM data for a female patient with Bladder Urothelial Carcinoma (BLCA) who is White, with bladder tissue involvement and a tumor mutational burden of 7 mutations per MB, could you please evaluate whether this patient is likely to respond to Atezolizumab? Additionally, please explain the rationale behind your assessment. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to the data to estimate the patient's likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic profile to identify the five most significant immune biomarkers, and integrate these findings with the patient's clinical history to develop a comprehensive immunological assessment.  
4. Finally, merge the results from the immunological assessment with the Compass algorithm's output to evaluate the expected effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and would like to assess the predicted response to Atezolizumab. The patient details are as follows: Male, White, tissue unspecified, and the tumor mutational burden (FMO mutations per MB) is not available. Based on these parameters, could you provide an evaluation of whether the patient is likely to be a responder or non-responder to Atezolizumab, including your reasoning?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and would like to assess the predicted response to Atezolizumab. The patient details are as follows: Male, White, tissue unspecified, and the tumor mutational burden (FMO mutations per MB) is not available. Based on these parameters, could you provide an evaluation of whether the patient is likely to be a responder or non-responder to Atezolizumab, including your reasoning? 1. Access and retrieve the patient’s transcriptomic profile from the designated pickle file.
2. Process this data using the Compass algorithm to estimate the patient’s probability of a favorable response to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic profile to identify the five most significant immune biomarkers and incorporate these findings with the patient’s clinical history for a comprehensive immunological assessment.
4. Finally, combine the results of the immunological assessment with the Compass algorithm output to determine the expected effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5 mutations per megabase. Based on these attributes, what is the likelihood that this patient will respond to Atezolizumab, and what evidence supports this conclusion?","A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data to characterize the tumor immune microenvironment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5 mutations per megabase. Based on these attributes, what is the likelihood that this patient will respond to Atezolizumab, and what evidence supports this conclusion? 1. Retrieve the patient’s transcriptomic data from the specified pickle file. 
2. Process the data using the Compass algorithm to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy. 
3. Analyze the transcriptomic profile to identify the five key immune biomarkers, and integrate these findings with the patient’s clinical history for a thorough immunological evaluation. 
4. Combine the immunological evaluation with the Compass algorithm results to determine the predicted effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"Based on the patient's processed mRNA TPM data from the tumor immune microenvironment and the following clinical details—male, white, lung tissue sample, diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 8.0 mutations per MB—can you determine if the patient is likely to be a responder or non-responder to Atezolizumab, and please provide the rationale for your assessment?","Based on the patient's processed mRNA TPM data from the tumor immune microenvironment and the following clinical details—male, white, lung tissue sample, diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 8.0 mutations per MB—can you determine if the patient is likely to be a responder or non-responder to Atezolizumab, and please provide the rationale for your assessment? 1. Begin by extracting the patient’s transcriptomic data from the provided pickle file.  
2. Process this data using the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Assess the transcriptomic profile to identify the five major immune biomarkers, and correlate these findings with the patient’s clinical history for a comprehensive immunological evaluation.  
4. Integrate the results from the immunological assessment and the Compass algorithm to determine the predicted effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"Could you evaluate the likelihood of a favorable response to Atezolizumab in a patient with bladder urothelial carcinoma using the following data? The patient is a 14-mutations per megabase tumor mutational burden, white female with tumor tissue in the bladder. Please provide your clinical reasoning regarding whether she should be classified as a responder or non-responder based on these details.","Could you evaluate the likelihood of a favorable response to Atezolizumab in a patient with bladder urothelial carcinoma using the following data? The patient is a 14-mutations per megabase tumor mutational burden, white female with tumor tissue in the bladder. Please provide your clinical reasoning regarding whether she should be classified as a responder or non-responder based on these details. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Analyze this data with the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Examine the transcriptomic profile to pinpoint the five key immune biomarkers, and integrate these findings with the patient's clinical history for a thorough immunological assessment.  
4. Synthesize the outcomes from both the immunological evaluation and the Compass algorithm to predict the overall effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"Based on the mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical features—male sex, White race, bladder tissue origin, and a tumor mutational burden of 13.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide the conclusion along with your supporting rationale.","Based on the mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical features—male sex, White race, bladder tissue origin, and a tumor mutational burden of 13.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide the conclusion along with your supporting rationale. 1. Retrieve the patient's transcriptomic dataset from the specified pickle file.
2. Use the Compass algorithm to evaluate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Review the transcriptomic profile to identify the five principal immune biomarkers, and correlate these findings with the patient's clinical history for a comprehensive immunological evaluation.
4. Combine the results from the immunological analysis and the Compass algorithm to forecast the overall efficacy of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and the clinical details are as follows: male, Asian, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB. Could you evaluate the likelihood of a favorable response to Atezolizumab for this patient, and provide the clinical reasoning supporting your conclusion?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), and the clinical details are as follows: male, Asian, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB. Could you evaluate the likelihood of a favorable response to Atezolizumab for this patient, and provide the clinical reasoning supporting your conclusion? 1. Retrieve the patient's transcriptomic dataset from the indicated pickle file.
2. Apply the Compass algorithm to estimate the probability that the patient will respond well to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile to pinpoint the five key immune biomarkers, and integrate these findings with the patient’s clinical history for a thorough immunological evaluation.
4. Combine the insights from the immunological assessment with the Compass algorithm results to predict the overall effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"A patient with Bladder Urothelial Carcinoma has an mRNA TPM profile characterizing the tumor immune microenvironment. The patient is a 54-year-old white male with kidney tissue sampling and a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, can you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide your reasoning?","A patient with Bladder Urothelial Carcinoma has an mRNA TPM profile characterizing the tumor immune microenvironment. The patient is a 54-year-old white male with kidney tissue sampling and a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, can you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide your reasoning? 1. Begin by loading the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to calculate the probability that the patient will have a positive response to immune checkpoint inhibitor therapy.
3. Examine the transcriptomic profile to identify the five most significant immune biomarkers, correlating these results with the patient’s clinical history for a comprehensive immunological analysis.
4. Integrate the findings from the detailed immunologic assessment with the Compass algorithm's output to forecast the overall efficacy of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), can you determine if this patient is likely to respond to Atezolizumab? The patient is a White male with bladder tissue involvement and a tumor mutational burden of 6.0 mutations per megabase. Please provide your assessment of responder status along with the reasoning behind your conclusion.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), can you determine if this patient is likely to respond to Atezolizumab? The patient is a White male with bladder tissue involvement and a tumor mutational burden of 6.0 mutations per megabase. Please provide your assessment of responder status along with the reasoning behind your conclusion. 1. Load the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to determine the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile to pinpoint the five most critical immune biomarkers, and correlate these findings with the patient's clinical history.
4. Combine the detailed immunologic evaluation with the output from the Compass algorithm to predict the overall effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"Given the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and considering the following clinical attributes—Male, White, primary tissue from the kidney, and a tumor mutational burden of 6.0 mutations per MB—what is the predicted response to Atezolizumab? Please detail whether the patient is likely to respond or not, including your clinical reasoning.","Given the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and considering the following clinical attributes—Male, White, primary tissue from the kidney, and a tumor mutational burden of 6.0 mutations per MB—what is the predicted response to Atezolizumab? Please detail whether the patient is likely to respond or not, including your clinical reasoning. 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to assess the probability of the patient responding well to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic profile to identify the top five immune biomarkers that are most relevant, and cross-reference these findings with the patient’s clinical history.
4. Integrate the results from the immunologic assessment with the Compass algorithm output to estimate the overall potential effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"Can you assess whether a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 5.0 mutations per megabase and mRNA TPM data from his tumor immune microenvironment, is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Can you assess whether a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 5.0 mutations per megabase and mRNA TPM data from his tumor immune microenvironment, is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. 1. Retrieve the patient's transcriptomic profile from the designated pickle file.
2. Apply the Compass algorithm to calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to determine the top five immune biomarkers of interest, and verify these markers against the patient’s clinical history.
4. Combine the outcomes of the biomarker evaluation with the Compass algorithm results to gauge the overall potential effectiveness of the immune checkpoint treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"I have mRNA TPM data derived from tumor immune microenvironment profiling for a male patient with bladder urothelial carcinoma (BLCA), who presents with a tumor mutational burden of 49.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind your evaluation?","I have mRNA TPM data derived from tumor immune microenvironment profiling for a male patient with bladder urothelial carcinoma (BLCA), who presents with a tumor mutational burden of 49.0 mutations per MB. Could you assess whether this patient is likely to respond to Atezolizumab and explain the rationale behind your evaluation? 1. Access the patient’s transcriptomic data saved in the specified pickle file.  
2. Use the Compass algorithm to estimate this patient's likelihood of responding to immune checkpoint inhibitor therapy.  
3. Evaluate the transcriptomic profile to identify the top five immune biomarkers, and cross-check these findings with the patient's clinical history.  
4. Integrate the biomarker analysis with the Compass algorithm results to assess the overall potential success of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"A patient's tumor immune microenvironment has been profiled using mRNA TPM data for Bladder Urothelial Carcinoma (BLCA). The patient is a  M, identified as white, with bladder tissue involved, and presents with a tumor mutational burden of 12 mutations per MB. Based on this clinical profile, can you determine whether the patient is likely to respond to Atezolizumab, and provide your rationale for the classification?","A patient's tumor immune microenvironment has been profiled using mRNA TPM data for Bladder Urothelial Carcinoma (BLCA). The patient is a  M, identified as white, with bladder tissue involved, and presents with a tumor mutational burden of 12 mutations per MB. Based on this clinical profile, can you determine whether the patient is likely to respond to Atezolizumab, and provide your rationale for the classification? 1. Retrieve the patient’s transcriptomic dataset from the designated pickle file.
2. Apply the Compass algorithm to estimate the patient’s probability of responding to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile to identify the top five immune biomarkers, and compare these biomarkers with the patient’s clinical history.
4. Combine the biomarker findings with the Compass algorithm’s result to assess the overall potential effectiveness of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose processed mRNA TPM data reflects their tumor immune microenvironment, and with the following details—Sex: Male; Race: White; Tissue: Bladder; Tumor Mutational Burden (FMO mutation burden per MB): Not available—could you please assess the predicted response to Atezolizumab and provide the rationale for classifying this patient as a responder or non-responder?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose processed mRNA TPM data reflects their tumor immune microenvironment, and with the following details—Sex: Male; Race: White; Tissue: Bladder; Tumor Mutational Burden (FMO mutation burden per MB): Not available—could you please assess the predicted response to Atezolizumab and provide the rationale for classifying this patient as a responder or non-responder? 1. Open the specified pickle file to access the patient’s transcriptomic data.  
2. Use the Compass algorithm to calculate the likelihood that the patient will respond to immune checkpoint inhibitor treatment.  
3. Examine the transcriptomic data to determine the top five immune biomarkers and correlate these findings with the patient's clinical history.  
4. Integrate the results from both the biomarker analysis and the Compass algorithm to evaluate the overall potential efficacy of the immune checkpoint therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"Considering the processed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) and the following attributes: a white male, bladder tissue involvement, and a tumor mutational burden of 5.0 mutations per megabase, could you please assess the likelihood of this patient responding to Atezolizumab treatment and explain the reasoning behind classifying him as a responder or non-responder?","Considering the processed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) and the following attributes: a white male, bladder tissue involvement, and a tumor mutational burden of 5.0 mutations per megabase, could you please assess the likelihood of this patient responding to Atezolizumab treatment and explain the reasoning behind classifying him as a responder or non-responder? 1. Begin by loading the designated pickle file containing the patient’s transcriptomics data.  
2. Apply the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the top five immune-related biomarkers, and cross-reference these findings with the patient’s clinical background.  
4. Combine the insights gained from both the biomarker evaluation and the Compass-derived probability to assess the overall potential benefit of immune checkpoint therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"Given the mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA)—an African American male with kidney tissue involvement and a tumor mutational burden of 11.0 mutations per megabase—can you provide a detailed assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion?","Given the mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA)—an African American male with kidney tissue involvement and a tumor mutational burden of 11.0 mutations per megabase—can you provide a detailed assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion? 1. First, load the patient's transcriptomic data from the designated pickle file.  
2. Next, run the Compass algorithm to generate an estimate of the patient’s probability of responding to immune checkpoint inhibitor therapy.  
3. Then, review the transcriptomic dataset to pinpoint the top five immune-related biomarkers and compare these with the patient’s clinical history.  
4. Finally, integrate the biomarker findings with the Compass-derived probability to determine the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and I need to assess their predicted response to Atezolizumab. The patient is a  male of white race with a primary bladder tumor, and the tumor mutational burden data (FMOne mutation burden per MB) is not available. Could you provide your interpretation on whether this patient is likely to be a responder or non-responder, along with the rationale behind your prediction?","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and I need to assess their predicted response to Atezolizumab. The patient is a  male of white race with a primary bladder tumor, and the tumor mutational burden data (FMOne mutation burden per MB) is not available. Could you provide your interpretation on whether this patient is likely to be a responder or non-responder, along with the rationale behind your prediction? 1. Begin by loading the patient's transcriptomic data from the specified pickle file.  
2. Next, use the Compass algorithm to calculate an estimated probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Review the transcriptomic dataset to identify the five most significant immune-related biomarkers, and compare these findings with the patient’s clinical history.  
4. Finally, combine the biomarker analysis with the Compass-generated probability to assess the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"Given mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (sampled from the ureter) and an undefined tumor mutational burden, can we assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion and the rationale behind it.","Given mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (sampled from the ureter) and an undefined tumor mutational burden, can we assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion and the rationale behind it. 1. Load the patient's transcriptomic data from the designated pickle file.  
2. Utilize the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic dataset to identify the top five immune-related biomarkers and correlate these results with the patient’s clinical history.  
4. Integrate the biomarker assessment with the Compass-derived probability to evaluate the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"I have evaluated mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White male with a bladder tumor and a tumor mutational burden of 17 mutations per megabase. Based on these findings, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for classifying the patient as a responder or non-responder?","I have evaluated mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White male with a bladder tumor and a tumor mutational burden of 17 mutations per megabase. Based on these findings, could you provide an evidence-based assessment of whether this patient is likely to respond to Atezolizumab, including the rationale for classifying the patient as a responder or non-responder? 1. Open the patient's transcriptomic dataset from the specified pickle file.
2. Apply the Compass algorithm to calculate the probability that the patient will respond positively to immune checkpoint inhibitor therapy.
3. Examine the transcriptomic data to identify the five most significant immune-related biomarkers, then compare these findings with the patient's clinical history.
4. Combine the biomarker evaluation and the Compass probability score to determine the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"Based on the patient's processed mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma, could you assess the predicted responsiveness to Atezolizumab? The patient is a male of white race, with a bladder tumor, and an FMOne tumor mutational burden of 22.0 mutations/Mb. Please indicate whether the patient is likely to be classified as a responder or non-responder and provide your clinical reasoning.","Based on the patient's processed mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma, could you assess the predicted responsiveness to Atezolizumab? The patient is a male of white race, with a bladder tumor, and an FMOne tumor mutational burden of 22.0 mutations/Mb. Please indicate whether the patient is likely to be classified as a responder or non-responder and provide your clinical reasoning. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune-related biomarkers, and compare these results with the patient's clinical background.  
4. Integrate both the biomarker assessment and the Compass-derived probability to evaluate the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient details are: Male, White race, bladder tissue involvement, and an indeterminate tumor mutational burden (data unavailable). Based on this information, could you provide a clinically grounded assessment of whether the patient is predicted to respond to Atezolizumab, along with the supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient details are: Male, White race, bladder tissue involvement, and an indeterminate tumor mutational burden (data unavailable). Based on this information, could you provide a clinically grounded assessment of whether the patient is predicted to respond to Atezolizumab, along with the supporting rationale? 1. Access the patient’s transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to calculate the probability of a beneficial response to immune checkpoint inhibitor therapy.  
3. Evaluate the transcriptomic data to identify the top five immune-related biomarkers and correlate these findings with the patient’s clinical history.  
4. Integrate the biomarker profile with the Compass-derived probability to determine the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"Given the patient's mRNA TPM data for tumor immune microenvironment profiling in Bladder Urothelial Carcinoma (BLCA), along with the following attributes: Sex: Male, Race: Other, Tissue: Kidney, and a Tumor Mutational Burden of 18.0 mutations/Mb, could you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion?","Given the patient's mRNA TPM data for tumor immune microenvironment profiling in Bladder Urothelial Carcinoma (BLCA), along with the following attributes: Sex: Male, Race: Other, Tissue: Kidney, and a Tumor Mutational Burden of 18.0 mutations/Mb, could you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Run the Compass algorithm to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic data to identify the five most significant immune-related biomarkers and compare these biomarkers with the patient's clinical history.  
4. Combine the biomarker information with the Compass algorithm results to assess the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white ethnicity, with kidney tissue involvement and a tumor mutational burden of 5.0 mutations per MB. Based on these attributes, could you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale behind your assessment?","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white ethnicity, with kidney tissue involvement and a tumor mutational burden of 5.0 mutations per MB. Based on these attributes, could you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale behind your assessment? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the top five immune-related biomarkers and compare these with the patient's clinical history.
4. Integrate the biomarker analysis with the Compass results to evaluate the overall potential benefit of immune checkpoint therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"Based on the mRNA TPM profile of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, White, bladder tissue, and a tumor mutational burden of 4.0 mutations per megabase—could you evaluate the predicted responsiveness to atezolizumab and explain the rationale behind classifying this patient as a responder or non-responder?","Based on the mRNA TPM profile of the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, White, bladder tissue, and a tumor mutational burden of 4.0 mutations per megabase—could you evaluate the predicted responsiveness to atezolizumab and explain the rationale behind classifying this patient as a responder or non-responder? 1. Access the patient’s transcriptomic data from the specified pickle file.  
2. Employ the Compass algorithm to assess the probability that the patient will respond to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic profile to identify the five most significant immune-related biomarkers and correlate these findings with the patient’s clinical history.  
4. Integrate the results from the biomarker analysis with the Compass algorithm outcomes to determine the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"I have mRNA TPM data representing the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma. The patient's details are as follows: male, white, tissue origin—kidney, and a tumor mutational burden of 5 mutations per megabase. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and explain the rationale for your classification?","I have mRNA TPM data representing the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma. The patient's details are as follows: male, white, tissue origin—kidney, and a tumor mutational burden of 5 mutations per megabase. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and explain the rationale for your classification? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to evaluate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Analyze the transcriptomic profile to identify the top five immune-related biomarkers, correlating these findings with the patient’s clinical history.  
4. Integrate the biomarker analysis results with the outcomes from the Compass algorithm to assess the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"I have processed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white race with tissue from the kidney and a tumor mutational burden of 12.0 mutations per megabase. Based on these details, is the patient predicted to be a responder or non-responder to Atezolizumab, and what is the rationale for this classification?","I have processed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient is a  male of white race with tissue from the kidney and a tumor mutational burden of 12.0 mutations per megabase. Based on these details, is the patient predicted to be a responder or non-responder to Atezolizumab, and what is the rationale for this classification? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic data to identify the five most significant immune-related biomarkers, ensuring to correlate these findings with the patient's clinical history.
4. Combine the results from the Compass algorithm with the biomarker analysis to assess the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"For a patient with bladder urothelial carcinoma, for whom we have processed mRNA TPM data of the tumor immune microenvironment, could you assess the predicted response to atezolizumab? The patient’s details are as follows: male, white, tissue sample from the liver, and an unknown tumor mutational burden (FMOne mutation burden per MB reported as “nan”). Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the rationale supporting your assessment.","For a patient with bladder urothelial carcinoma, for whom we have processed mRNA TPM data of the tumor immune microenvironment, could you assess the predicted response to atezolizumab? The patient’s details are as follows: male, white, tissue sample from the liver, and an unknown tumor mutational burden (FMOne mutation burden per MB reported as “nan”). Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the rationale supporting your assessment. 1. First, extract the patient's transcriptomic data from the provided pickle file.
2. Next, use the Compass algorithm to estimate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.
3. Then, analyze the transcriptomic data to identify the five most significant immune-related biomarkers, taking into account the patient's clinical history.
4. Finally, integrate the results from the Compass algorithm with the biomarker analysis to determine the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"I have analyzed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient’s characteristics are as follows: female, white, tissue sample from kidney, and a reported FMOne mutation burden of nan. Based on these details, could you determine whether this patient is more likely to respond to Atezolizumab, and explain the reasoning behind this classification?","I have analyzed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient’s characteristics are as follows: female, white, tissue sample from kidney, and a reported FMOne mutation burden of nan. Based on these details, could you determine whether this patient is more likely to respond to Atezolizumab, and explain the reasoning behind this classification? 1. Retrieve the patient's transcriptomic data from the provided pickle file.
2. Use the Compass algorithm to evaluate the patient's likelihood of responding to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile, considering the patient's clinical history, to identify the top five immune-related biomarkers.
4. Combine the findings from the Compass algorithm with the biomarker analysis to assess the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"I have analyzed mRNA TPM data for a male white patient with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 10.0 mutations/MB. Based on this tumor immune microenvironment profile, can you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please elaborate on the factors that support your conclusion.","I have analyzed mRNA TPM data for a male white patient with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 10.0 mutations/MB. Based on this tumor immune microenvironment profile, can you assess whether this patient is likely to be a responder or non-responder to Atezolizumab? Please elaborate on the factors that support your conclusion. 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to determine the patient's probability of responding to immune checkpoint inhibitor therapy.
3. Review the transcriptomic profile in the context of the patient's clinical history to identify the five most significant immune-related biomarkers.
4. Integrate the results from the Compass algorithm with the biomarker analysis to evaluate the potential overall benefit of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"Based on the mRNA TPM data of her tumor immune microenvironment and considering her clinical profile—female, white, bladder tissue, Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per MB—can we determine whether this patient is likely to respond to Atezolizumab? Please provide a conclusion on her responder status along with the supporting reasoning.","Based on the mRNA TPM data of her tumor immune microenvironment and considering her clinical profile—female, white, bladder tissue, Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per MB—can we determine whether this patient is likely to respond to Atezolizumab? Please provide a conclusion on her responder status along with the supporting reasoning. 1. Access the patient's transcriptomic data from the designated pickle file.
2. Utilize the Compass algorithm to calculate the likelihood of this patient responding to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic profile alongside the patient’s clinical history to pinpoint the five most critical immune-related biomarkers.
4. Integrate the Compass algorithm results with your biomarker analysis to assess the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"I have processed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tumor, and the tumor mutational burden (FMOne mutations per MB) is not available. Based on this data, can you determine whether she is likely to respond to Atezolizumab and provide the supporting rationale?","I have processed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tumor, and the tumor mutational burden (FMOne mutations per MB) is not available. Based on this data, can you determine whether she is likely to respond to Atezolizumab and provide the supporting rationale? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Utilize the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.
3. Analyze the transcriptomic profile in conjunction with the patient's clinical history to identify the five most significant immune-related biomarkers.
4. Combine the insights from the Compass algorithm with your biomarker analysis to evaluate the overall potential benefit of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and I seek to evaluate the likelihood of a favorable response to Atezolizumab. The patient is a white female with bladder tissue involvement and a tumor mutational burden of 15.0 mutations per megabase. Could you provide an assessment of whether she is more likely to be a responder or a non-responder, along with the supporting rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and I seek to evaluate the likelihood of a favorable response to Atezolizumab. The patient is a white female with bladder tissue involvement and a tumor mutational burden of 15.0 mutations per megabase. Could you provide an assessment of whether she is more likely to be a responder or a non-responder, along with the supporting rationale? 1. Access the patient's transcriptomic information from the designated pickle file.
2. Apply the Compass algorithm to calculate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.
3. Review the transcriptomic data alongside the patient's clinical history to pinpoint the five most relevant immune-related biomarkers.
4. Integrate the probability estimate from the Compass analysis with your biomarker findings to determine the overall suitability of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"Given the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the following characteristics (male, white, lymph node tissue, and a tumor mutational burden of 8.0 mutations per megabase), can we determine if the patient is likely to respond to Atezolizumab treatment? Please include your reasoning in support of the classification as a responder or non-responder.","Given the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the following characteristics (male, white, lymph node tissue, and a tumor mutational burden of 8.0 mutations per megabase), can we determine if the patient is likely to respond to Atezolizumab treatment? Please include your reasoning in support of the classification as a responder or non-responder. 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to calculate the probability that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Examine both the transcriptomic data and the patient's clinical history to identify the five most pertinent immune-related biomarkers.  
4. Combine the Compass algorithm's probability score with your biomarker analysis to assess the overall suitability of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"Considering a male, White patient with bladder tissue and a diagnosis of bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0 mutations per megabase, how likely is this patient to respond to Atezolizumab based on the mRNA TPM data from the tumor immune microenvironment? Please provide your conclusion on whether the patient is classified as a responder or non-responder, along with the supporting rationale.","Considering a male, White patient with bladder tissue and a diagnosis of bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 6.0 mutations per megabase, how likely is this patient to respond to Atezolizumab based on the mRNA TPM data from the tumor immune microenvironment? Please provide your conclusion on whether the patient is classified as a responder or non-responder, along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Run the Compass algorithm on this data to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Review both the transcriptomic profile and the patient’s clinical history to identify the five most relevant immune-related biomarkers.
4. Integrate the probability score from the Compass algorithm with your biomarker analysis to evaluate the overall appropriateness of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"How likely is this patient to respond to Atezolizumab based on their tumor immune microenvironment profile? The patient is a White male diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 19 mutations per megabase. Please classify him as a predicted responder or non-responder and provide the rationale for your assessment.","How likely is this patient to respond to Atezolizumab based on their tumor immune microenvironment profile? The patient is a White male diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 19 mutations per megabase. Please classify him as a predicted responder or non-responder and provide the rationale for your assessment. 1. Access the patient's transcriptomic data from the designated pickle file.  
2. Process this data using the Compass algorithm to calculate the probability that the patient will respond well to immune checkpoint inhibitor therapy.  
3. Examine the transcriptomic profile in conjunction with the patient’s clinical history to identify the five most significant immune-related biomarkers.  
4. Combine the Compass algorithm’s probability score with your biomarker analysis to assess the overall suitability of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For a male, white patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0 mutations per megabase, can you evaluate the mRNA TPM data from the tumor immune microenvironment to determine whether he is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion?","For a male, white patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0 mutations per megabase, can you evaluate the mRNA TPM data from the tumor immune microenvironment to determine whether he is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Process the data using the Compass algorithm to determine the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Review the transcriptomic profile alongside the patient’s clinical history to pinpoint the top five immune-related biomarkers.
4. Integrate the probability score from the Compass analysis with your biomarker evaluation to assess the overall appropriateness of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"In a patient with bladder urothelial carcinoma (BLCA) characterized by processed mRNA TPM data of the tumor immune microenvironment, could you assess the predicted response to atezolizumab? The patient is a white male with kidney tissue involvement and an unquantifiable tumor mutational burden. Please provide a conclusion on whether this patient is likely to be a responder or non-responder, including the supporting reasoning.","In a patient with bladder urothelial carcinoma (BLCA) characterized by processed mRNA TPM data of the tumor immune microenvironment, could you assess the predicted response to atezolizumab? The patient is a white male with kidney tissue involvement and an unquantifiable tumor mutational burden. Please provide a conclusion on whether this patient is likely to be a responder or non-responder, including the supporting reasoning. 1. Extract the patient’s transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to analyze the data and calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Examine the transcriptomic data together with the patient’s clinical history to identify the five most relevant immune-related biomarkers.
4. Combine the Compass-derived probability score with your biomarker assessment to determine the suitability of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"I have processed mRNA TPM data from the tumor microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 3.0 FMOne mutations per MB. Could you assess his likely responsiveness to Atezolizumab and provide a detailed rationale for classifying him as either a responder or non-responder?","I have processed mRNA TPM data from the tumor microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 3.0 FMOne mutations per MB. Could you assess his likely responsiveness to Atezolizumab and provide a detailed rationale for classifying him as either a responder or non-responder? 1. Retrieve the patient’s transcriptomic information from the specified pickle file.
2. Analyze this data with the Compass algorithm to calculate the probability of the patient responding favorably to immune checkpoint inhibitor therapy.
3. Review the transcriptomic findings along with the patient’s clinical history to identify the five most pertinent immune-related biomarkers.
4. Integrate the Compass-derived probability score with your biomarker analysis to evaluate the appropriateness of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"I have analyzed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is a white male whose tumor sample was obtained from a lymph node, and his tumor mutational burden is 18.0 mutations per megabase. Could you please evaluate the likelihood of response to Atezolizumab in this case and provide your clinical reasoning?","I have analyzed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is a white male whose tumor sample was obtained from a lymph node, and his tumor mutational burden is 18.0 mutations per megabase. Could you please evaluate the likelihood of response to Atezolizumab in this case and provide your clinical reasoning? 1. Access the patient’s transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to compute the likelihood that the patient will respond well to immune checkpoint inhibitor therapy.
3. Review both the transcriptomic data and the patient’s clinical history to identify the five most relevant immune-related biomarkers.
4. Combine the probability score from the Compass analysis with your biomarker assessment to determine if immune checkpoint inhibitor therapy is a suitable treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"In a case of Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data profiling the tumor immune microenvironment. The patient is a white male with kidney tissue involvement and a tumor mutational burden of 15 mutations per megabase. Based on these factors, could you determine whether this patient is likely to respond to treatment with Atezolizumab, and please explain the rationale behind your conclusion?","In a case of Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data profiling the tumor immune microenvironment. The patient is a white male with kidney tissue involvement and a tumor mutational burden of 15 mutations per megabase. Based on these factors, could you determine whether this patient is likely to respond to treatment with Atezolizumab, and please explain the rationale behind your conclusion? 1. Retrieve the patient's transcriptomic information from the specified pickle file.  
2. Apply the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Examine both the transcriptomic profile and the patient's clinical background to identify the top five immune-related biomarkers relevant to their condition.  
4. Integrate the probability derived from the Compass analysis with your evaluation of the biomarkers to decide whether immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"I have mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma. The patient is a white male with disease involving a lymph node, and his tumor mutational burden is not available. Based on these data, could you assess whether this patient is more likely to respond to Atezolizumab and provide your supporting rationale?","I have mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma. The patient is a white male with disease involving a lymph node, and his tumor mutational burden is not available. Based on these data, could you assess whether this patient is more likely to respond to Atezolizumab and provide your supporting rationale? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will respond well to immune checkpoint inhibitor therapy.
3. Review both the transcriptomic data and the patient's clinical history to pinpoint the five most relevant immune-related biomarkers.
4. Integrate the probability from the Compass analysis with your assessment of these biomarkers to determine if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female, with bladder tissue involvement, and the tumor mutational burden data is unavailable (nan). Based on this information, could you evaluate and determine whether the patient is predicted to respond to Atezolizumab? Please include the reasoning behind your assessment.","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white female, with bladder tissue involvement, and the tumor mutational burden data is unavailable (nan). Based on this information, could you evaluate and determine whether the patient is predicted to respond to Atezolizumab? Please include the reasoning behind your assessment. 1. Access the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Examine both the transcriptomic data and the patient’s clinical history to identify the five most significant immune-related biomarkers.
4. Combine the probability derived from the Compass analysis with your biomarker evaluation to determine whether immune checkpoint inhibitor therapy is an appropriate treatment choice for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"A 62-year-old White male with Bladder Urothelial Carcinoma (BLCA) has been evaluated using mRNA TPM data from his tumor immune microenvironment, and his tumor mutational burden is 6.0 mutations per megabase. Considering this molecular profile and his clinical data, could you please assess whether this patient is predicted to respond to Atezolizumab, and provide your supporting rationale?","A 62-year-old White male with Bladder Urothelial Carcinoma (BLCA) has been evaluated using mRNA TPM data from his tumor immune microenvironment, and his tumor mutational burden is 6.0 mutations per megabase. Considering this molecular profile and his clinical data, could you please assess whether this patient is predicted to respond to Atezolizumab, and provide your supporting rationale? 1. Retrieve the patient's transcriptomic profile from the designated pickle file.  
2. Use the Compass algorithm to estimate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Review both the transcriptomic data and the patient's clinical history to identify the five most significant immune-related biomarkers.  
4. Integrate the probability from the Compass analysis with the findings from the biomarker evaluation to determine whether immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"I have a patient with Bladder Urothelial Carcinoma whose tumor immune microenvironment has been characterized using processed mRNA TPM data. The patient is a white female with disease affecting the kidney and an indeterminate tumor mutational burden. Could you assess her predicted responsiveness to Atezolizumab, and provide the clinical rationale for classifying her as either a responder or non-responder?","I have a patient with Bladder Urothelial Carcinoma whose tumor immune microenvironment has been characterized using processed mRNA TPM data. The patient is a white female with disease affecting the kidney and an indeterminate tumor mutational burden. Could you assess her predicted responsiveness to Atezolizumab, and provide the clinical rationale for classifying her as either a responder or non-responder? 1. Retrieve the patient's transcriptomic profile from the specified pickle file.
2. Apply the Compass algorithm to calculate the probability that the patient will benefit from immune checkpoint inhibitor therapy.
3. Examine both the transcriptomic dataset and the patient’s clinical history to pinpoint the five most relevant immune-related biomarkers.
4. Combine the probability result from the Compass analysis with the biomarker evaluation findings to decide if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a male, African American patient with Bladder Urothelial Carcinoma (BLCA), with a tissue sample from the ureter and unavailable tumor mutational burden data. Could you provide your assessment of the patient’s likelihood of responding to Atezolizumab, including your supporting rationale?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a male, African American patient with Bladder Urothelial Carcinoma (BLCA), with a tissue sample from the ureter and unavailable tumor mutational burden data. Could you provide your assessment of the patient’s likelihood of responding to Atezolizumab, including your supporting rationale? 1. Access the patient's transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Review the transcriptomic data alongside the patient's clinical history to identify the five most pertinent immune-related biomarkers.  
4. Synthesize the Compass algorithm's probability assessment with the biomarker evaluation to decide whether immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) to evaluate her predicted response to Atezolizumab. The patient is a white female with a bladder tumor, and the tumor mutational burden data is unavailable (nan). Based on these factors, could you please provide your clinical assessment of whether she is more likely to be a responder or non-responder to Atezolizumab, along with your reasoning?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) to evaluate her predicted response to Atezolizumab. The patient is a white female with a bladder tumor, and the tumor mutational burden data is unavailable (nan). Based on these factors, could you please provide your clinical assessment of whether she is more likely to be a responder or non-responder to Atezolizumab, along with your reasoning? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic data together with the patient’s clinical history to identify the five most clinically relevant immune-related biomarkers.
4. Integrate the Compass algorithm’s probability assessment with the biomarker analysis to determine the appropriateness of immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"Given the patient's processed mRNA TPM data representing the tumor immune microenvironment for bladder urothelial carcinoma—with characteristics including male sex, white race, tumor tissue originating from the ureter, and a tumor mutational burden of 4.0 mutations per MB—could you assess the predicted response to Atezolizumab? Specifically, based on these clinical and molecular parameters, does the evidence suggest that this patient would be classified as a responder or non-responder, and what is the supporting rationale?","Given the patient's processed mRNA TPM data representing the tumor immune microenvironment for bladder urothelial carcinoma—with characteristics including male sex, white race, tumor tissue originating from the ureter, and a tumor mutational burden of 4.0 mutations per MB—could you assess the predicted response to Atezolizumab? Specifically, based on these clinical and molecular parameters, does the evidence suggest that this patient would be classified as a responder or non-responder, and what is the supporting rationale? 1. Access the patient’s transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Review the transcriptomic data alongside the patient’s clinical history to pinpoint the five most clinically significant immune-related biomarkers.
4. Combine the Compass algorithm’s probability estimate with the biomarker findings to assess whether immune checkpoint inhibitor therapy is appropriate for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"I have analyzed the patient's mRNA TPM data from the tumor immune microenvironment for bladder urothelial carcinoma (BLCA) and would like to assess their likely response to Atezolizumab. The patient is a 14.0 mutations/MB male (White) with bladder cancer. Based on these parameters, is the patient likely to respond to Atezolizumab, and what is the rationale behind this prediction?","I have analyzed the patient's mRNA TPM data from the tumor immune microenvironment for bladder urothelial carcinoma (BLCA) and would like to assess their likely response to Atezolizumab. The patient is a 14.0 mutations/MB male (White) with bladder cancer. Based on these parameters, is the patient likely to respond to Atezolizumab, and what is the rationale behind this prediction? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.
3. Evaluate the transcriptomic information in conjunction with the patient’s clinical history to identify the five most clinically relevant immune biomarkers.
4. Integrate the Compass algorithm’s probability estimate with the biomarker evaluation to determine if immune checkpoint inhibitor therapy is appropriate for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"I have mRNA TPM data reflecting a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA). The patient's clinical details are as follows: male, White, tissue sampled from lung, and a tumor mutational burden of 7.0 mutations per MB. Based on this information, could you assess the likelihood of a positive response to Atezolizumab and explain the rationale behind your conclusion?","I have mRNA TPM data reflecting a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA). The patient's clinical details are as follows: male, White, tissue sampled from lung, and a tumor mutational burden of 7.0 mutations per MB. Based on this information, could you assess the likelihood of a positive response to Atezolizumab and explain the rationale behind your conclusion? 1. Access the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Combine the transcriptomic data with the patient’s clinical background to pinpoint the five most relevant immune biomarkers.
4. Synthesize the probability estimated by the Compass algorithm with the biomarker analysis to decide if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have processed mRNA TPM data from this patient’s tumor immune microenvironment in the context of bladder urothelial carcinoma. The patient is a White female with a primary lung tissue sample, diagnosed with bladder urothelial carcinoma, and a tumor mutational burden of 3.0 mutations per megabase. Based on this information, could you provide an evaluation of her predicted responsiveness to Atezolizumab, including the rationale for classifying her as a responder or non-responder?","I have processed mRNA TPM data from this patient’s tumor immune microenvironment in the context of bladder urothelial carcinoma. The patient is a White female with a primary lung tissue sample, diagnosed with bladder urothelial carcinoma, and a tumor mutational burden of 3.0 mutations per megabase. Based on this information, could you provide an evaluation of her predicted responsiveness to Atezolizumab, including the rationale for classifying her as a responder or non-responder? 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate this transcriptomic data with the patient’s clinical history to identify the five most significant immune biomarkers.  
4. Combine the probability derived from the Compass algorithm with the biomarker profile to determine if immune checkpoint inhibitor therapy is an appropriate treatment choice for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"I have mRNA TPM data assessing a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) with the following characteristics: Male patient, White, bladder tissue, with a tumor mutational burden of 11.0 mutations per megabase. Could you please determine whether this patient is likely to respond to Atezolizumab and provide the clinical reasoning behind your conclusion?","I have mRNA TPM data assessing a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) with the following characteristics: Male patient, White, bladder tissue, with a tumor mutational burden of 11.0 mutations per megabase. Could you please determine whether this patient is likely to respond to Atezolizumab and provide the clinical reasoning behind your conclusion? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Merge this transcriptomic information with the patient’s clinical history to identify the top five immune biomarkers of significance.  
4. Evaluate the combined data—both the Compass algorithm’s probability and the biomarker profile—to determine if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"Using mRNA TPM data from a patient's tumor immune microenvironment in bladder urothelial carcinoma, I am seeking to evaluate the predicted response to Atezolizumab. The patient is a white female with bladder tissue involvement and a tumor mutational burden of 4.0 mutations/Mb. Based on this information, could you determine whether she is likely to be a responder or non-responder to Atezolizumab, and explain your reasoning?","Using mRNA TPM data from a patient's tumor immune microenvironment in bladder urothelial carcinoma, I am seeking to evaluate the predicted response to Atezolizumab. The patient is a white female with bladder tissue involvement and a tumor mutational burden of 4.0 mutations/Mb. Based on this information, could you determine whether she is likely to be a responder or non-responder to Atezolizumab, and explain your reasoning? 1. Access the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to determine the probability that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Integrate this transcriptomic data with the patient’s clinical history to identify the five most significant immune biomarkers.  
4. Review the combined results—considering both the Compass probability and the immune biomarker profile—to assess whether immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment mRNA TPM data have been analyzed, could you assess the expected responsiveness to Atezolizumab? Notably, the patient is a White female with bladder tissue involvement, and the tumor mutational burden measurement is unavailable. Please provide a conclusion regarding whether she is likely to be a responder or a non-responder, including supportive reasoning.","For a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment mRNA TPM data have been analyzed, could you assess the expected responsiveness to Atezolizumab? Notably, the patient is a White female with bladder tissue involvement, and the tumor mutational burden measurement is unavailable. Please provide a conclusion regarding whether she is likely to be a responder or a non-responder, including supportive reasoning. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Combine the transcriptomic data with the patient’s clinical history to identify the five most relevant immune biomarkers.  
4. Evaluate the integrated findings—considering both the Compass-derived probability and the immune biomarker profile—to determine whether immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"I have analyzed mRNA TPM data representing the tumor immune microenvironment of a male, white patient with bladder urothelial carcinoma (BLCA), with unavailable tumor mutational burden data. Could you help determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind this assessment?","I have analyzed mRNA TPM data representing the tumor immune microenvironment of a male, white patient with bladder urothelial carcinoma (BLCA), with unavailable tumor mutational burden data. Could you help determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind this assessment? 1. Access the patient’s transcriptomic profile from the specified pickle file.  
2. Apply the Compass algorithm to determine the probability that the patient will have a positive response to immune checkpoint inhibitor therapy.  
3. Integrate the transcriptomic data with the patient's clinical history to pinpoint the five most significant immune-related biomarkers.  
4. Review the combined data—including the Compass-derived response probability and the detailed immune biomarker profile—to decide if immune checkpoint inhibitor therapy is a suitable treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"For a male, white patient with bladder urothelial carcinoma and a tumor mutational burden of 18 mutations per megabase, we have processed mRNA TPM data reflecting the tumor immune microenvironment. Based on these molecular and clinical characteristics, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your conclusion?","For a male, white patient with bladder urothelial carcinoma and a tumor mutational burden of 18 mutations per megabase, we have processed mRNA TPM data reflecting the tumor immune microenvironment. Based on these molecular and clinical characteristics, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.
3. Combine the transcriptomic data with the patient’s clinical history to identify the top five immune-related biomarkers.
4. Evaluate the aggregated information, including the Compass response probability and the biomarker profile, to determine whether immune checkpoint inhibitor therapy is an appropriate treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have a case involving a male White patient diagnosed with bladder urothelial carcinoma, presenting with a tumor mutational burden of 19 mutations per MB, and mRNA TPM data detailing the tumor immune microenvironment. Based on these parameters, could you determine whether the patient is likely to respond to Atezolizumab therapy and provide your rationale?","I have a case involving a male White patient diagnosed with bladder urothelial carcinoma, presenting with a tumor mutational burden of 19 mutations per MB, and mRNA TPM data detailing the tumor immune microenvironment. Based on these parameters, could you determine whether the patient is likely to respond to Atezolizumab therapy and provide your rationale? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Integrate the transcriptomic results with the patient’s clinical history to identify the five most relevant immune-related biomarkers.  
4. Review the combined information—the Compass response probability and the biomarker profile—to determine if immune checkpoint inhibitor therapy is a suitable treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"Based on the patient's mRNA TPM data of the tumor immune microenvironment for Bladder Urothelial Carcinoma, along with his clinical attributes (male, White) and a tumor mutational burden of 35.0 mutations per megabase, could you provide an assessment of his predicted response to Atezolizumab? Please include the rationale behind classifying him as a potential responder or non-responder.","Based on the patient's mRNA TPM data of the tumor immune microenvironment for Bladder Urothelial Carcinoma, along with his clinical attributes (male, White) and a tumor mutational burden of 35.0 mutations per megabase, could you provide an assessment of his predicted response to Atezolizumab? Please include the rationale behind classifying him as a potential responder or non-responder. 1. Begin by extracting the patient's transcriptomic data from the designated pickle file.  
2. Next, process this data using the Compass algorithm to calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Combine these transcriptomic findings with the patient’s clinical history to pinpoint the five most significant immune-related biomarkers.  
4. Finally, review both the calculated response probability and the identified biomarker profile to assess whether immune checkpoint inhibitor therapy is an appropriate treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"Based on the processed mRNA TPM data from this patient's tumor immune microenvironment in bladder urothelial carcinoma, could you determine if the patient is likely to respond to Atezolizumab? The patient is a white male with a kidney tissue sample, diagnosed with BLCA, and has a tumor mutational burden of 5.0 mutations per MB. Please provide your conclusion along with the supporting rationale.","Based on the processed mRNA TPM data from this patient's tumor immune microenvironment in bladder urothelial carcinoma, could you determine if the patient is likely to respond to Atezolizumab? The patient is a white male with a kidney tissue sample, diagnosed with BLCA, and has a tumor mutational burden of 5.0 mutations per MB. Please provide your conclusion along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Process this data with the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate the transcriptomic results with the patient’s clinical history to identify the five most critical immune-related biomarkers.  
4. Evaluate both the computed response likelihood and the biomarker profile to determine if immune checkpoint inhibitor therapy is a suitable treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"I have mRNA TPM data from a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: male, White, bladder tissue origin, and a tumor mutational burden of 5.0 mutations per megabase. Based on these parameters, could you provide your assessment on whether this patient is likely to respond to Atezolizumab, along with your rationale?","I have mRNA TPM data from a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: male, White, bladder tissue origin, and a tumor mutational burden of 5.0 mutations per megabase. Based on these parameters, could you provide your assessment on whether this patient is likely to respond to Atezolizumab, along with your rationale? 1. Access the patient’s transcriptomic data from the provided pickle file.  
2. Apply the Compass algorithm to this data to calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Combine these transcriptomic findings with the patient’s clinical history to identify the top five key immune-related biomarkers.  
4. Review both the computed response probability and the identified biomarker profile to determine whether immune checkpoint inhibitor therapy is an appropriate treatment choice for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"I have processed mRNA TPM data evaluating the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is male, White, with bladder tissue involvement and a tumor mutational burden of 16.0 mutations per MB. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the supporting rationale for your conclusion?","I have processed mRNA TPM data evaluating the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is male, White, with bladder tissue involvement and a tumor mutational burden of 16.0 mutations per MB. Based on this information, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the supporting rationale for your conclusion? 1. Retrieve the patient’s transcriptomic data from the supplied pickle file.
2. Use the Compass algorithm to evaluate this data and estimate the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Integrate the transcriptomic analysis with the patient’s clinical history to pinpoint the top five immune-related biomarkers.
4. Assess both the calculated response probability and the biomarker profile to decide if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"I have analyzed mRNA TPM data reflecting the immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is male, identified as OTHER race, with tumor tissue from the bladder and a tumor mutational burden of 8.0 FMOne mutations per MB. Based on these clinical and molecular characteristics, could you determine whether the patient is more likely to respond or not respond to Atezolizumab, and please provide your rationale?","I have analyzed mRNA TPM data reflecting the immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA). The patient is male, identified as OTHER race, with tumor tissue from the bladder and a tumor mutational burden of 8.0 FMOne mutations per MB. Based on these clinical and molecular characteristics, could you determine whether the patient is more likely to respond or not respond to Atezolizumab, and please provide your rationale? 1. Obtain the patient's transcriptomic data from the provided pickle file.
2. Apply the Compass algorithm to the data to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Combine the transcriptomic analysis with the patient's clinical history to identify the top five immune-related biomarkers.
4. Review both the estimated response probability and the biomarker profile to determine whether immune checkpoint inhibitor therapy is a suitable treatment option for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"Based on the mRNA TPM data from a male, white patient with Bladder Urothelial Carcinoma and a tumor mutational burden of 5.0 mutations per MB, can you evaluate whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the underlying rationale.","Based on the mRNA TPM data from a male, white patient with Bladder Urothelial Carcinoma and a tumor mutational burden of 5.0 mutations per MB, can you evaluate whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the underlying rationale. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Utilize the Compass algorithm on the data to calculate the probability of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate the transcriptomic findings with the patient's clinical history to pinpoint the top five immune-related biomarkers.  
4. Evaluate both the estimated response probability and the biomarker profile to decide if immune checkpoint inhibitor therapy is an appropriate treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"A 50-year-old female patient with Bladder Urothelial Carcinoma (BLCA), classified as White, has been evaluated using mRNA TPM data to characterize her tumor immune microenvironment. With a reported tumor mutational burden of 5.0 mutations per megabase, based on these molecular characteristics and considering treatment with Atezolizumab, is she more likely to be classified as a responder or non-responder? Please provide your assessment with supporting rationale.","A 50-year-old female patient with Bladder Urothelial Carcinoma (BLCA), classified as White, has been evaluated using mRNA TPM data to characterize her tumor immune microenvironment. With a reported tumor mutational burden of 5.0 mutations per megabase, based on these molecular characteristics and considering treatment with Atezolizumab, is she more likely to be classified as a responder or non-responder? Please provide your assessment with supporting rationale. 1. Access the patient's transcriptomic information from the specified pickle file.  
2. Apply the Compass algorithm to this data to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Combine these transcriptomic results with the patient’s clinical history to identify the five most relevant immune-related biomarkers.  
4. Use both the estimated response probability and the biomarker profile to determine whether immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"I have mRNA TPM data profiling the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white female with bladder tissue involvement and has a tumor mutational burden of 7.0 mutations per megabase. Based on these parameters, could you please provide your assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion?","I have mRNA TPM data profiling the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white female with bladder tissue involvement and has a tumor mutational burden of 7.0 mutations per megabase. Based on these parameters, could you please provide your assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Run the Compass algorithm on this data to calculate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate these results with the patient's clinical history to identify the five most pertinent immune-related biomarkers.  
4. Assess both the computed response probability and the biomarker profile to determine if immune checkpoint inhibitor therapy is a suitable treatment option for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment from a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) to assess the predicted response to Atezolizumab. The patient's details are as follows: male, white, primary bladder tissue, and tumor mutational burden data is not available (NaN). Could you please provide your interpretation on whether this patient is likely to be a responder or non-responder to Atezolizumab, including the rationale behind your assessment?","I have processed mRNA TPM data representing the tumor immune microenvironment from a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) to assess the predicted response to Atezolizumab. The patient's details are as follows: male, white, primary bladder tissue, and tumor mutational burden data is not available (NaN). Could you please provide your interpretation on whether this patient is likely to be a responder or non-responder to Atezolizumab, including the rationale behind your assessment? 1. Obtain the patient’s transcriptomic dataset from the specified pickle file.  
2. Apply the Compass algorithm to this dataset in order to estimate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Combine these computational results with the patient’s clinical history to pinpoint the top five immune-related biomarkers that are most relevant.  
4. Evaluate both the estimated response probability and the identified biomarker profile to decide whether immune checkpoint inhibitor therapy is an appropriate treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a male White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 9.0 mutations per MB, could you determine whether the patient is predicted to be a responder or non-responder to Atezolizumab? Please include the supporting clinical and molecular rationale for your conclusion.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a male White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 9.0 mutations per MB, could you determine whether the patient is predicted to be a responder or non-responder to Atezolizumab? Please include the supporting clinical and molecular rationale for your conclusion. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Run the Compass algorithm on the dataset to estimate the probability that the patient will respond to immune checkpoint inhibitors.  
3. Integrate these computational outcomes with the patient’s clinical history to identify the five most pertinent immune biomarkers.  
4. Assess both the estimated response probability and the biomarker profile to determine if immune checkpoint inhibitor therapy is a suitable treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the provided clinical attributes—sex (female), race (White), tissue (bladder), disease (BLCA), and a tumor mutational burden of 20 mutations per MB—could you please evaluate and explain whether this patient is likely to respond to Atezolizumab?","Based on the patient's tumor immune microenvironment mRNA TPM data for Bladder Urothelial Carcinoma (BLCA) and the provided clinical attributes—sex (female), race (White), tissue (bladder), disease (BLCA), and a tumor mutational burden of 20 mutations per MB—could you please evaluate and explain whether this patient is likely to respond to Atezolizumab? 1. Locate and load the patient’s transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to this dataset to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Combine the algorithm’s results with the patient’s clinical history to determine the five most relevant immune biomarkers.  
4. Evaluate the predicted response probability alongside the biomarker profile to decide whether immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"For a female, white patient with Bladder Urothelial Carcinoma, where mRNA TPM data from a lymph node sample indicates a tumor immune microenvironment and a tumor mutational burden of 10.0 mutations per MB, could you assess the likelihood of this patient responding to Atezolizumab and explain the reasoning behind the classification as a responder or non-responder?","For a female, white patient with Bladder Urothelial Carcinoma, where mRNA TPM data from a lymph node sample indicates a tumor immune microenvironment and a tumor mutational burden of 10.0 mutations per MB, could you assess the likelihood of this patient responding to Atezolizumab and explain the reasoning behind the classification as a responder or non-responder? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm on this dataset to estimate the patient's probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate these algorithm results with the patient's clinical history to identify the top five immune biomarkers of relevance.  
4. Assess the predicted response probability together with the biomarker profile to make an informed decision on the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's profile is as follows: male, white, with a bladder tissue origin of the malignancy and a tumor mutational burden of 35 mutations per megabase. Based on these clinical parameters, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the rationale supporting your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's profile is as follows: male, white, with a bladder tissue origin of the malignancy and a tumor mutational burden of 35 mutations per megabase. Based on these clinical parameters, could you please assess whether the patient is likely to respond to Atezolizumab, and provide the rationale supporting your conclusion? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to this dataset to calculate the patient’s likelihood of responding positively to immune checkpoint inhibitor therapy.
3. Combine the algorithm's findings with the patient’s clinical history to determine the five most relevant immune biomarkers.
4. Evaluate both the computed response probability and the identified biomarker profile to guide the decision on whether immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"I have analyzed the patient's mRNA TPM data, reflecting the tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white female with primary bladder tissue involvement and a tumor mutational burden of 6.0 mutations per megabase. Based on this molecular profile, could you please assess her likelihood of responding to Atezolizumab and provide the supporting rationale for your conclusion?","I have analyzed the patient's mRNA TPM data, reflecting the tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white female with primary bladder tissue involvement and a tumor mutational burden of 6.0 mutations per megabase. Based on this molecular profile, could you please assess her likelihood of responding to Atezolizumab and provide the supporting rationale for your conclusion? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Utilize the Compass algorithm on this dataset to estimate the patient’s probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm’s output with the patient’s clinical history to identify the five most pertinent immune biomarkers.  
4. Assess both the calculated response likelihood and the selected biomarker profile to determine the suitability for administering immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"Based on mRNA TPM data of the tumor immune microenvironment, I have a patient with bladder urothelial carcinoma who is a white female with bladder tissue involvement and a tumor mutational burden of 3.0 mutations per megabase. Could you assess the likelihood of this patient responding to Atezolizumab, and provide the supporting rationale for your conclusion?","Based on mRNA TPM data of the tumor immune microenvironment, I have a patient with bladder urothelial carcinoma who is a white female with bladder tissue involvement and a tumor mutational burden of 3.0 mutations per megabase. Could you assess the likelihood of this patient responding to Atezolizumab, and provide the supporting rationale for your conclusion? 1. Access the patient’s transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to this data to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Combine the algorithm’s results with the patient’s clinical history to pinpoint the five most relevant immune biomarkers.
4. Review both the response probability and the biomarker profile to determine whether proceeding with immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"Based on the patient's mRNA TPM data of the tumor immune microenvironment and the following clinical details—male sex, white race, bladder tissue origin, diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB—could you evaluate whether the patient is likely to respond to Atezolizumab? Please include the reasoning behind your assessment.","Based on the patient's mRNA TPM data of the tumor immune microenvironment and the following clinical details—male sex, white race, bladder tissue origin, diagnosis of Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 5.0 mutations/MB—could you evaluate whether the patient is likely to respond to Atezolizumab? Please include the reasoning behind your assessment. 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Run the Compass algorithm on this data to calculate their probability of responding favorably to immune checkpoint inhibitor therapy.
3. Integrate the algorithm's output with the patient's clinical history to identify the top five immune biomarkers that are most relevant.
4. Consider both the estimated response probability and the biomarker profile to decide if initiating immune checkpoint inhibitor therapy is the appropriate course of treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate their tumor immune microenvironment. The patient is a white male with a tumor mutational burden of 5.0 mutations per MB. Based on this information, can you help determine whether the patient is likely to respond to Atezolizumab, and explain your reasoning?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate their tumor immune microenvironment. The patient is a white male with a tumor mutational burden of 5.0 mutations per MB. Based on this information, can you help determine whether the patient is likely to respond to Atezolizumab, and explain your reasoning? 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Apply the Compass algorithm to assess the patient’s likelihood of responding well to immune checkpoint inhibitor therapy.  
3. Combine the algorithm output with the patient’s clinical history to determine the five most pertinent immune biomarkers.  
4. Evaluate the response probability and biomarker profile together to decide whether initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, White, bladder tissue origin, and a tumor mutational burden of 5.0 mutations per megabase—would you classify this patient as likely to respond or not respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and the following clinical details—male, White, bladder tissue origin, and a tumor mutational burden of 5.0 mutations per megabase—would you classify this patient as likely to respond or not respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. 1. Access the patient's transcriptomic data from the designated pickle file.
2. Run the Compass algorithm on this data to gauge the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Merge the algorithm's findings with the patient’s clinical history to identify the five most relevant immune biomarkers.
4. Assess the combined response probability and biomarker profile to determine if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"We have processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is male, White, with kidney tissue pathology, and a tumor mutational burden of 5.0 mutations per MB. Based on this information, could you please evaluate whether the patient is likely to respond to Atezolizumab and explain the rationale behind this assessment?","We have processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is male, White, with kidney tissue pathology, and a tumor mutational burden of 5.0 mutations per MB. Based on this information, could you please evaluate whether the patient is likely to respond to Atezolizumab and explain the rationale behind this assessment? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Process this data using the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Integrate the algorithm results with the patient’s clinical history to identify the five most relevant immune biomarkers.
4. Review the combined biomarker profile and response probability to decide if starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"I have processed mRNA TPM data to characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on these parameters, could you please determine whether the patient is likely to respond to Atezolizumab and explain the rationale behind your assessment?","I have processed mRNA TPM data to characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on these parameters, could you please determine whether the patient is likely to respond to Atezolizumab and explain the rationale behind your assessment? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Process this data using the Compass algorithm to calculate the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Combine the algorithm’s results with the patient’s clinical history to pinpoint the five most relevant immune biomarkers.
4. Evaluate the integrated biomarker profile and response probability to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA) and would like to evaluate their likelihood of responding to Atezolizumab. The patient's details are as follows: male, race categorized as other, primary tumor tissue from the bladder, and a tumor mutational burden of 3.0 FMOne mutations per MB. Could you please provide your assessment on whether this patient would be classified as a responder or non-responder to Atezolizumab, including your supporting rationale?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA) and would like to evaluate their likelihood of responding to Atezolizumab. The patient's details are as follows: male, race categorized as other, primary tumor tissue from the bladder, and a tumor mutational burden of 3.0 FMOne mutations per MB. Could you please provide your assessment on whether this patient would be classified as a responder or non-responder to Atezolizumab, including your supporting rationale? 1. Access the patient's transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to process the data and determine the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate these results with the patient's clinical history to identify the top five immune biomarkers of significance.  
4. Review the combined biomarker profile and response probability to decide on the appropriateness of initiating immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"Based on mRNA TPM data detailing the tumor immune microenvironment for a male patient with bladder urothelial carcinoma (BLCA)—with tissue from the ureter and an FMOne mutation burden of 10.0 mutations/MB—can you provide your assessment of the predicted responsiveness to Atezolizumab? Please include a conclusion regarding whether this patient is likely to be a responder or non-responder, along with your supporting rationale.","Based on mRNA TPM data detailing the tumor immune microenvironment for a male patient with bladder urothelial carcinoma (BLCA)—with tissue from the ureter and an FMOne mutation burden of 10.0 mutations/MB—can you provide your assessment of the predicted responsiveness to Atezolizumab? Please include a conclusion regarding whether this patient is likely to be a responder or non-responder, along with your supporting rationale. 1. Retrieve the patient's transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to analyze the data and estimate the probability of a favorable response to immune checkpoint inhibitor therapy.  
3. Combine these findings with the patient’s clinical history to identify the five most significant immune biomarkers.  
4. Evaluate the integrated biomarker profile alongside the estimated response probability to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment from a lymph node sample of a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per MB. Based on these details, could you assess whether this patient is likely to be a responder to Atezolizumab treatment and describe the rationale behind your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment from a lymph node sample of a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per MB. Based on these details, could you assess whether this patient is likely to be a responder to Atezolizumab treatment and describe the rationale behind your conclusion? 1. Begin by retrieving the patient's transcriptomic dataset from the specified pickle file.  
2. Next, analyze the dataset using the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate this analysis with the patient’s clinical history to pinpoint the five most relevant immune biomarkers.  
4. Finally, review the combined biomarker profile and response probability to decide if initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"Based on the following patient information, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a Caucasian male with bladder urothelial carcinoma (BLCA), with tumor tissue from the bladder and a tumor mutational burden of 3.0 mutations/MB. Please provide your conclusion along with your supporting rationale.","Based on the following patient information, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a Caucasian male with bladder urothelial carcinoma (BLCA), with tumor tissue from the bladder and a tumor mutational burden of 3.0 mutations/MB. Please provide your conclusion along with your supporting rationale. Step 1: Retrieve the patient's transcriptomic dataset from the designated pickle file.

Step 2: Apply the Compass algorithm to the dataset to determine the probability of a positive response to immune checkpoint inhibitor therapy.

Step 3: Combine the results from this analysis with the patient’s clinical history to identify the five most critical immune biomarkers.

Step 4: Evaluate the integrated biomarker profile and response probability to decide whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a Black or African American female with lung tissue involvement and a tumor mutational burden of 11.0 mutations per MB. Based on these findings, could you provide an assessment of whether the patient is likely to be a responder or a non-responder to Atezolizumab, along with the supporting rationale for your conclusion?","A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data of the tumor immune microenvironment. The patient is a Black or African American female with lung tissue involvement and a tumor mutational burden of 11.0 mutations per MB. Based on these findings, could you provide an assessment of whether the patient is likely to be a responder or a non-responder to Atezolizumab, along with the supporting rationale for your conclusion? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.

2. Process the data using the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.

3. Integrate the algorithm’s findings with the patient’s clinical history to identify the five most relevant immune biomarkers.

4. Review the combined biomarker profile and response probability to determine if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"I have processed mRNA TPM data assessing the tumor immune microenvironment for a male white patient with bladder urothelial carcinoma (BLCA), based on a lymph node tissue sample. The tumor mutational burden data is unavailable. Could you evaluate this patient's likely response to Atezolizumab and provide your reasoning for classifying them as a responder or non-responder?","I have processed mRNA TPM data assessing the tumor immune microenvironment for a male white patient with bladder urothelial carcinoma (BLCA), based on a lymph node tissue sample. The tumor mutational burden data is unavailable. Could you evaluate this patient's likely response to Atezolizumab and provide your reasoning for classifying them as a responder or non-responder? 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to process this data and estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.
3. Combine the algorithm’s output with the patient’s clinical history to identify the five immune biomarkers most relevant to their condition.
4. Assess the integrated biomarker profile alongside the response probability to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"Given mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, tissue sampled from the liver, and unavailable tumor mutational burden data (nan)—can you assess whether this patient is likely to respond to Atezolizumab therapy? Please include your reasoning in the conclusion.","Given mRNA TPM data characterizing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, tissue sampled from the liver, and unavailable tumor mutational burden data (nan)—can you assess whether this patient is likely to respond to Atezolizumab therapy? Please include your reasoning in the conclusion. 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Process this data using the Compass algorithm to estimate the probability of the patient responding to immune checkpoint inhibitor therapy.
3. Integrate the algorithm’s output with the patient's clinical history to identify the five immune biomarkers most pertinent to their clinical condition.
4. Evaluate the combined biomarker profile and response probability to determine if initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white female, with tumor tissue from the ureter and a tumor mutational burden of 26 mutations per megabase. Based on these data, could you please determine whether this patient is likely to respond to Atezolizumab and provide the clinical rationale for your assessment?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white female, with tumor tissue from the ureter and a tumor mutational burden of 26 mutations per megabase. Based on these data, could you please determine whether this patient is likely to respond to Atezolizumab and provide the clinical rationale for your assessment? 1. Access the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to analyze this data and estimate the likelihood that the patient will respond to immune checkpoint inhibitor therapy.
3. Combine the algorithm's output with the patient’s clinical history to identify the five most relevant immune biomarkers.
4. Review the overall biomarker profile and response probability to decide whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"Given mRNA TPM data for a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—sex: male; race: white; tissue: bladder; tumor mutational burden: 14 mutations/MB—can you provide an assessment of whether this patient is predicted to respond to Atezolizumab? Please include your reasoning and any supporting evidence.","Given mRNA TPM data for a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—sex: male; race: white; tissue: bladder; tumor mutational burden: 14 mutations/MB—can you provide an assessment of whether this patient is predicted to respond to Atezolizumab? Please include your reasoning and any supporting evidence. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to the data to estimate the patient's likelihood of responding to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm’s output with the patient's clinical history to identify the five most relevant immune biomarkers.  
4. Review the comprehensive biomarker profile and the estimated response probability to determine the appropriateness of initiating immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"Using processed mRNA TPM data from the tumor immune microenvironment of a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) — where the tissue sample originated from the lung and the reported tumor mutational burden is unavailable (nan) — can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with a detailed explanation supporting the classification as either a responder or non-responder.","Using processed mRNA TPM data from the tumor immune microenvironment of a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) — where the tissue sample originated from the lung and the reported tumor mutational burden is unavailable (nan) — can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion along with a detailed explanation supporting the classification as either a responder or non-responder. 1. Access the patient's transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to analyze the data and estimate the patient's probability of responding to immune checkpoint inhibitor therapy.  
3. Combine the algorithm's results with the patient's clinical history to identify the five key immune biomarkers.  
4. Evaluate the detailed biomarker profile along with the response likelihood to decide if starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white female with tumor tissue from the ureter and has a tumor mutational burden of 4.0 mutations per megabase. Based on these characteristics, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, and detail the reasoning behind that conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white female with tumor tissue from the ureter and has a tumor mutational burden of 4.0 mutations per megabase. Based on these characteristics, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, and detail the reasoning behind that conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to the data to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm's output with the patient's clinical history to identify the top five immune biomarkers of interest.  
4. Review the comprehensive biomarker profile alongside the response probability to determine if initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"Based on the patient's mRNA TPM data of the tumor immune microenvironment for Bladder Urothelial Carcinoma, can you determine whether this patient—with the following characteristics: Male, White, bladder as the tissue of origin, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 3.0 mutations per megabase—is predicted to be a responder or non-responder to Atezolizumab? Please explain your reasoning in detail.","Based on the patient's mRNA TPM data of the tumor immune microenvironment for Bladder Urothelial Carcinoma, can you determine whether this patient—with the following characteristics: Male, White, bladder as the tissue of origin, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 3.0 mutations per megabase—is predicted to be a responder or non-responder to Atezolizumab? Please explain your reasoning in detail. 1. Access the patient's transcriptomic profile from the specified pickle file.  
2. Use the Compass algorithm on this data to assess the probability that the patient will respond well to immune checkpoint inhibitor therapy.  
3. Combine the algorithm’s results with the patient’s clinical history to select the five most relevant immune biomarkers.  
4. Evaluate the full biomarker profile and the response likelihood to decide whether to start immune checkpoint inhibitor treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"Can you assess whether our male, White patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 22 FMOne mutations per megabase, and mRNA TPM data reflecting his tumor immune microenvironment is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting reasoning.","Can you assess whether our male, White patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 22 FMOne mutations per megabase, and mRNA TPM data reflecting his tumor immune microenvironment is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting reasoning. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to this data to estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm’s output with the patient’s clinical history to identify and prioritize the five most pertinent immune biomarkers.  
4. Review the comprehensive biomarker profile alongside the response probability to determine whether initiating immune checkpoint inhibitor treatment is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"In a white male patient with Bladder Urothelial Carcinoma and mRNA TPM data detailing the tumor immune microenvironment, how can we assess the likelihood of response to Atezolizumab, particularly given that the tumor mutational burden is unavailable? Please provide a conclusion on the expected responsiveness along with the supporting rationale.","In a white male patient with Bladder Urothelial Carcinoma and mRNA TPM data detailing the tumor immune microenvironment, how can we assess the likelihood of response to Atezolizumab, particularly given that the tumor mutational burden is unavailable? Please provide a conclusion on the expected responsiveness along with the supporting rationale. 1. Obtain the patient's transcriptomic data from the specified pickle file.
2. Run the Compass algorithm on the retrieved data to calculate the probability of a positive response to immune checkpoint inhibitor therapy.
3. Combine the algorithm’s results with the patient's clinical history to identify and rank the five most relevant immune biomarkers.
4. Evaluate the complete biomarker profile, along with the calculated response probability, to decide if starting immune checkpoint inhibitor therapy is justified.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a patient with Bladder Urothelial Carcinoma who has mRNA TPM data from a lymph node biopsy, a tumor mutational burden of 3.0 mutations per megabase, and who is a White female, how would you assess the likelihood of a favorable response to Atezolizumab? Please provide your evaluation along with the supporting rationale from the available data.","For a patient with Bladder Urothelial Carcinoma who has mRNA TPM data from a lymph node biopsy, a tumor mutational burden of 3.0 mutations per megabase, and who is a White female, how would you assess the likelihood of a favorable response to Atezolizumab? Please provide your evaluation along with the supporting rationale from the available data. 1. Retrieve the patient's transcriptomic data from the designated pickle file.  
2. Utilize the Compass algorithm to determine the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm's output with the patient's clinical history to identify and prioritize the five most relevant immune biomarkers.  
4. Review the complete biomarker profile alongside the calculated response probability to decide whether initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"Given mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma, how would you classify the patient's predicted response to Atezolizumab? The patient is a 62.0 mutation per MB TMB white male, and the sample was obtained from kidney tissue. Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with your supporting rationale.","Given mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma, how would you classify the patient's predicted response to Atezolizumab? The patient is a 62.0 mutation per MB TMB white male, and the sample was obtained from kidney tissue. Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with your supporting rationale. 1. First, extract the patient's transcriptomic information stored in the specified pickle file.  
2. Then, apply the Compass algorithm to predict the probability that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Next, combine the algorithm’s results with the patient’s clinical history to select and rank the top five most pertinent immune biomarkers.  
4. Finally, evaluate the entire biomarker profile in context with the predicted treatment response to determine if starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and would like to determine the likelihood of a favorable response to Atezolizumab. The patient's details are as follows: male, race reported as ""Other,"" tumor tissue classified as ""other,"" and a tumor mutational burden of 14 mutations per megabase. Based on this information, can you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and please explain your reasoning?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and would like to determine the likelihood of a favorable response to Atezolizumab. The patient's details are as follows: male, race reported as ""Other,"" tumor tissue classified as ""other,"" and a tumor mutational burden of 14 mutations per megabase. Based on this information, can you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and please explain your reasoning? 1. Begin by retrieving the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Integrate the algorithm's output with the patient’s clinical history to identify and rank the five immune biomarkers most relevant to this treatment.
4. Finally, assess the complete biomarker profile in light of the predicted treatment response to determine whether initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"Based on the patient's mRNA TPM data from the tumor immune microenvironment and the following clinical details—male, White, lymph node tissue sample, Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 7.0 mutations per MB—can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion on whether the patient is classified as a responder or non-responder along with the supporting rationale.","Based on the patient's mRNA TPM data from the tumor immune microenvironment and the following clinical details—male, White, lymph node tissue sample, Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 7.0 mutations per MB—can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion on whether the patient is classified as a responder or non-responder along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Run the Compass algorithm on this data to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Combine the algorithm output with the patient’s clinical history to identify and prioritize the five most relevant immune biomarkers for this treatment.  
4. Review the full biomarker profile in the context of the predicted treatment response to decide whether to proceed with initiating immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict response to Atezolizumab. The patient's clinical details are as follows: male, unknown race, primary tumor in the bladder, and a tumor mutational burden of 15.0 mutations per megabase. Based on these data, could you determine if the patient is likely to be a responder or non-responder to Atezolizumab, and provide the rationale for this determination?","I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict response to Atezolizumab. The patient's clinical details are as follows: male, unknown race, primary tumor in the bladder, and a tumor mutational burden of 15.0 mutations per megabase. Based on these data, could you determine if the patient is likely to be a responder or non-responder to Atezolizumab, and provide the rationale for this determination? 1. Access the patient's transcriptomic data stored in the designated pickle file.  
2. Apply the Compass algorithm to this dataset to calculate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm’s output with the patient’s clinical background, and then identify and rank the top five immune biomarkers most relevant to this treatment.  
4. Examine the complete biomarker profile within the context of the predicted treatment response to determine whether to initiate immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"Based on mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab using the following details: Sex—Male; Race—White; Tissue sample from kidney; Tumor mutational burden of 5.0 (FMOne mutation burden per MB)? Please provide your assessment as to whether this patient is more likely to be a responder or non-responder, including the supporting rationale for your conclusion.","Based on mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab using the following details: Sex—Male; Race—White; Tissue sample from kidney; Tumor mutational burden of 5.0 (FMOne mutation burden per MB)? Please provide your assessment as to whether this patient is more likely to be a responder or non-responder, including the supporting rationale for your conclusion. 1. Retrieve the patient’s transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm on these data to estimate the probability of a favorable response to immune checkpoint inhibitor therapy.  
3. Combine the algorithm’s results with the patient’s clinical history to determine and prioritize the top five immune biomarkers most relevant to this treatment.  
4. Review the full biomarker profile in relation to the predicted therapeutic response to make an informed decision about starting immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have analyzed mRNA TPM data from a bladder tumor biopsy reflecting the immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and tumor mutational burden data (FMO mutation burden per MB) is not available. Based on these findings, how would you assess this patient’s predicted responsiveness to Atezolizumab, and what evidence supports your classification as a responder or non-responder?","I have analyzed mRNA TPM data from a bladder tumor biopsy reflecting the immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male, and tumor mutational burden data (FMO mutation burden per MB) is not available. Based on these findings, how would you assess this patient’s predicted responsiveness to Atezolizumab, and what evidence supports your classification as a responder or non-responder? 1. Extract the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to these data to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate the algorithm’s findings with the patient’s clinical history to identify and rank the five most pertinent immune biomarkers in relation to this treatment.  
4. Evaluate the complete biomarker profile alongside the estimated therapeutic response to inform your decision regarding the initiation of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a White female with a tumor located in the ureter, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Could you please assess whether this patient is likely to be a responder or non-responder to Atezolizumab and provide the rationale behind this prediction?","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a White female with a tumor located in the ureter, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Could you please assess whether this patient is likely to be a responder or non-responder to Atezolizumab and provide the rationale behind this prediction? 1. Retrieve the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to assess the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Combine the algorithm's results with the patient's clinical history to identify and prioritize the five most relevant immune biomarkers associated with this treatment.
4. Review the complete biomarker profile along with the predicted treatment response to guide your decision on commencing immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"Given the patient's Bladder Urothelial Carcinoma (BLCA) profile—including mRNA TPM data of the tumor immune microenvironment, a tumor mutational burden of 24.0 mutations per MB, and clinical characteristics (male, white, bladder tissue)—can you determine whether this patient is likely to respond to Atezolizumab? Please include the clinical reasoning supporting your conclusion.","Given the patient's Bladder Urothelial Carcinoma (BLCA) profile—including mRNA TPM data of the tumor immune microenvironment, a tumor mutational burden of 24.0 mutations per MB, and clinical characteristics (male, white, bladder tissue)—can you determine whether this patient is likely to respond to Atezolizumab? Please include the clinical reasoning supporting your conclusion. 1. Retrieve the patient's transcriptomic profile from the designated pickle file.
2. Apply the Compass algorithm to estimate the probability that the patient will benefit from immune checkpoint inhibitor therapy.
3. Integrate the algorithm’s findings with the patient's clinical history to identify and rank the top five immune biomarkers most relevant to this treatment response.
4. Evaluate the complete biomarker profile alongside the predicted treatment outcome to inform your decision on initiating immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"Based on this patient's processed mRNA TPM data from the tumor immune microenvironment in BLCA, along with the following clinical details (Male, White, bladder tissue, and unavailable tumor mutational burden), could you determine whether the patient is more likely to respond to Atezolizumab? Please include the reasoning behind your assessment.","Based on this patient's processed mRNA TPM data from the tumor immune microenvironment in BLCA, along with the following clinical details (Male, White, bladder tissue, and unavailable tumor mutational burden), could you determine whether the patient is more likely to respond to Atezolizumab? Please include the reasoning behind your assessment. 1. Begin by extracting the patient’s transcriptomic information from the specified pickle file.
2. Next, apply the Compass algorithm to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Then, combine these algorithm results with the patient’s clinical background to pinpoint and rank the top five immune biomarkers that are most indicative of a treatment response.
4. Finally, review the entire biomarker profile in the context of the predicted treatment outcome to guide your decision regarding the initiation of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"Given processed mRNA TPM data from a bladder urothelial carcinoma patient's tumor immune microenvironment, and considering the following details—male, White, ureter tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase—how would you classify the patient's likelihood of responding to Atezolizumab? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting clinical rationale.","Given processed mRNA TPM data from a bladder urothelial carcinoma patient's tumor immune microenvironment, and considering the following details—male, White, ureter tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase—how would you classify the patient's likelihood of responding to Atezolizumab? Please provide your conclusion on whether the patient is likely to be a responder or non-responder, along with the supporting clinical rationale. 1. Retrieve the patient’s transcriptomic data from the provided pickle file.
2. Use the Compass algorithm to estimate the likelihood that the patient will respond well to immune checkpoint inhibitor therapy.
3. Integrate the algorithm’s outcome with the patient’s clinical history to identify and prioritize the top five immune biomarkers most strongly associated with a positive treatment response.
4. Assess the full biomarker profile in light of the predicted treatment outcome to inform your decision about initiating immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"Given the processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—a male, white patient with kidney tissue origin and a tumor mutational burden of 4.0 (FMOne mutations per MB)—could you assess the likelihood of response to Atezolizumab and provide your supporting rationale?","Given the processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—a male, white patient with kidney tissue origin and a tumor mutational burden of 4.0 (FMOne mutations per MB)—could you assess the likelihood of response to Atezolizumab and provide your supporting rationale? 1. Access the patient's transcriptomic data using the designated pickle file.  
2. Utilize the Compass algorithm to predict the patient’s likelihood of responding favorably to immune checkpoint inhibitor therapy.  
3. Combine the algorithm's output with the patient's clinical history to identify and rank the top five immune biomarkers most strongly linked to a positive treatment response.  
4. Review the complete biomarker profile in conjunction with the predicted treatment outcome to guide your decision on whether to proceed with immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"The patient, a white male with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 14 mutations/Mb, has had his tumor immune microenvironment characterized using mRNA TPM data. Based on this information, could you please provide an assessment of whether he is likely to respond to Atezolizumab, along with the supporting rationale?","The patient, a white male with bladder tissue affected by Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 14 mutations/Mb, has had his tumor immune microenvironment characterized using mRNA TPM data. Based on this information, could you please provide an assessment of whether he is likely to respond to Atezolizumab, along with the supporting rationale? 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Run the Compass algorithm to estimate the patient’s probability of responding well to immune checkpoint inhibitor therapy.  
3. Integrate this prediction with the patient’s clinical history to prioritize the five immune biomarkers most strongly associated with a positive response.  
4. Evaluate the complete biomarker profile alongside the predicted treatment outcome to decide whether to proceed with immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and would like to predict their response to atezolizumab. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these details, could you determine whether the patient is likely a responder or non-responder to atezolizumab, and explain the rationale behind your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA) and would like to predict their response to atezolizumab. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these details, could you determine whether the patient is likely a responder or non-responder to atezolizumab, and explain the rationale behind your conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Run the Compass algorithm to assess the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Combine the algorithm's prediction with the patient’s clinical history to identify the five immune biomarkers most strongly linked with a positive treatment outcome.
4. Review both the complete biomarker profile and the predicted treatment response to decide if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a patient with bladder urothelial carcinoma (BLCA) characterized by a male sex, white race, bladder tissue origin, and a tumor mutational burden of 10 mutations per megabase, based on processed mRNA TPM data of the tumor immune microenvironment, can you determine if this patient is likely to respond to Atezolizumab? Please include the rationale for classifying the patient as a responder or non-responder.","For a patient with bladder urothelial carcinoma (BLCA) characterized by a male sex, white race, bladder tissue origin, and a tumor mutational burden of 10 mutations per megabase, based on processed mRNA TPM data of the tumor immune microenvironment, can you determine if this patient is likely to respond to Atezolizumab? Please include the rationale for classifying the patient as a responder or non-responder. 1. Access the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to evaluate the probability that the patient will achieve a favorable response to immune checkpoint inhibitor therapy.
3. Integrate the Compass algorithm’s prediction with the patient’s clinical history to identify the top five immune biomarkers most strongly associated with a positive treatment outcome.
4. Consider the comprehensive biomarker profile alongside the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"Based on the mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma, along with demographic and clinical details (male, white ethnicity, kidney tissue origin, and an indeterminate tumor mutational burden), can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion with supporting reasoning.","Based on the mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma, along with demographic and clinical details (male, white ethnicity, kidney tissue origin, and an indeterminate tumor mutational burden), can we determine whether the patient is likely to respond to Atezolizumab? Please provide your conclusion with supporting reasoning. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to calculate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Combine the Compass prediction with the patient’s clinical history to pinpoint the five immune biomarkers most closely linked to a positive treatment outcome.  
4. Evaluate the full biomarker profile in conjunction with the predicted therapeutic response to decide if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"Based on the mRNA TPM data profiling the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of this patient’s likely response to Atezolizumab? The patient is a white male with a lymph node specimen, and his tumor mutational burden (FMOne mutation burden per MB) is reported as nan. Please include the rationale behind your conclusion on whether he is classified as a responder or non-responder.","Based on the mRNA TPM data profiling the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of this patient’s likely response to Atezolizumab? The patient is a white male with a lymph node specimen, and his tumor mutational burden (FMOne mutation burden per MB) is reported as nan. Please include the rationale behind your conclusion on whether he is classified as a responder or non-responder. 1. Retrieve the patient's transcriptomic dataset from the specified pickle file.  
2. Use the Compass algorithm to determine the probability that the patient will respond well to immune checkpoint inhibitor therapy.  
3. Integrate the Compass prediction with the patient's clinical history to identify the top five immune biomarkers most closely associated with a favorable treatment response.  
4. Assess the entire biomarker profile alongside the predicted therapeutic outcome to decide whether starting immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"Based on the patient's mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can we assess whether this  patient—a white male with bladder tissue involvement and a tumor mutational burden of 19 mutations per MB—is likely to respond to Atezolizumab? Please include the supporting rationale for classifying him as a responder or non-responder.","Based on the patient's mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can we assess whether this  patient—a white male with bladder tissue involvement and a tumor mutational burden of 19 mutations per MB—is likely to respond to Atezolizumab? Please include the supporting rationale for classifying him as a responder or non-responder. 1. Retrieve the patient’s transcriptomic dataset from the designated pickle file.  
2. Apply the Compass algorithm to estimate the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Combine the Compass prediction with the patient’s clinical history to identify the five immune biomarkers most strongly linked to favorable treatment outcomes.  
4. Evaluate the complete biomarker profile along with the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) characterized by an mRNA TPM profile of the tumor immune microenvironment, could you determine if they are likely to respond to atezolizumab therapy? The patient's details are as follows: female, race identified as ""other,"" tumor tissue from the ureter, and a tumor mutational burden of 5 mutations per MB. Please provide your conclusion along with the supporting rationale.","For a patient with bladder urothelial carcinoma (BLCA) characterized by an mRNA TPM profile of the tumor immune microenvironment, could you determine if they are likely to respond to atezolizumab therapy? The patient's details are as follows: female, race identified as ""other,"" tumor tissue from the ureter, and a tumor mutational burden of 5 mutations per MB. Please provide your conclusion along with the supporting rationale. 1. Retrieve the patient's transcriptomic data from the specified pickle file.  
2. Use the Compass algorithm to estimate the probability of a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate the Compass prediction with the patient’s clinical history to identify the five immune biomarkers most associated with positive treatment outcomes.  
4. Review the complete biomarker profile in combination with the predicted therapeutic response to determine if starting immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"Given the processed mRNA TPM data for a female patient with bladder urothelial carcinoma (BLCA) who is White, and noting a tumor mutational burden of 2.0 mutations per Mb, can you assess the likelihood of response to Atezolizumab? Please provide a conclusion on whether the patient is more likely to be a responder or non-responder, including the supporting rationale for your determination.","Given the processed mRNA TPM data for a female patient with bladder urothelial carcinoma (BLCA) who is White, and noting a tumor mutational burden of 2.0 mutations per Mb, can you assess the likelihood of response to Atezolizumab? Please provide a conclusion on whether the patient is more likely to be a responder or non-responder, including the supporting rationale for your determination. 1. Retrieve the patient's transcriptomic data from the provided pickle file.
2. Apply the Compass algorithm to calculate the likelihood that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Combine the Compass prediction with the patient’s clinical history to identify the five immune biomarkers that are most strongly correlated with positive treatment outcomes.
4. Review the complete immune biomarker profile alongside the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is recommended.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Based on these details, can you determine if he is likely to respond to Atezolizumab, and please provide the supporting rationale for your assessment?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 14.0 mutations per megabase. Based on these details, can you determine if he is likely to respond to Atezolizumab, and please provide the supporting rationale for your assessment? 1. Retrieve the patient's transcriptomic data from the assigned pickle file.
2. Use the Compass algorithm to quantify the probability of a favorable response to immune checkpoint inhibitor therapy.
3. Integrate the Compass prediction with the patient's clinical history to pinpoint the five immune biomarkers most strongly linked to positive treatment outcomes.
4. Evaluate the complete immune biomarker profile in conjunction with the predicted therapeutic response to decide if starting immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"Based on this patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with her clinical details—female sex, White race, unspecified tissue type, and a tumor mutational burden of 17.0 mutations per megabase—can we determine whether she is more likely to respond to Atezolizumab? Please include your reasoning behind classifying her as either a responder or non-responder.","Based on this patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with her clinical details—female sex, White race, unspecified tissue type, and a tumor mutational burden of 17.0 mutations per megabase—can we determine whether she is more likely to respond to Atezolizumab? Please include your reasoning behind classifying her as either a responder or non-responder. 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Combine the Compass output with the patient's clinical history to identify the five key immune biomarkers most strongly associated with positive treatment outcomes.
4. Assess the complete immunologic biomarker profile alongside the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma, along with their clinical attributes (male, white, bladder tissue involvement, and an unspecified tumor mutational burden), can we determine if this patient is more likely to respond or not respond to Atezolizumab therapy? Please include the supporting rationale for the classification.","Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma, along with their clinical attributes (male, white, bladder tissue involvement, and an unspecified tumor mutational burden), can we determine if this patient is more likely to respond or not respond to Atezolizumab therapy? Please include the supporting rationale for the classification. 1. Access the patient's transcriptomic information using the specified pickle file.
2. Utilize the Compass algorithm to estimate the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy.
3. Integrate the Compass output with the patient's clinical history to identify the top five immune biomarkers most strongly linked to positive treatment outcomes.
4. Review the full immunologic biomarker profile alongside the projected therapeutic response to decide if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"I have processed mRNA TPM data reflecting a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient's profile includes: Male sex, White race, bladder tissue sample, and a tumor mutational burden of 6.0 mutations per MB. Based on these clinical attributes, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the supporting rationale?","I have processed mRNA TPM data reflecting a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA). The patient's profile includes: Male sex, White race, bladder tissue sample, and a tumor mutational burden of 6.0 mutations per MB. Based on these clinical attributes, could you provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the supporting rationale? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to calculate the patient’s probability of a positive response to immune checkpoint inhibitor therapy.
3. Combine the Compass results with the patient's clinical history to determine the five immune biomarkers most strongly associated with beneficial treatment outcomes.
4. Evaluate the complete immunologic biomarker profile along with the estimated therapeutic response to decide whether immune checkpoint inhibitor therapy should be initiated.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tissue tumor and a tumor mutational burden of 9.0 mutations per megabase. Based on these details, could you please provide your assessment regarding her predicted response to Atezolizumab, including the rationale for classifying her as a likely responder or non-responder?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white female with a bladder tissue tumor and a tumor mutational burden of 9.0 mutations per megabase. Based on these details, could you please provide your assessment regarding her predicted response to Atezolizumab, including the rationale for classifying her as a likely responder or non-responder? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to estimate the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.
3. Integrate the Compass-derived probability with the patient's clinical history to identify the five immune biomarkers most strongly linked to favorable treatment outcomes.
4. Review the overall immunologic biomarker profile in conjunction with the predicted therapeutic response to determine if initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), can you help assess her predicted responsiveness to Atezolizumab? The patient’s clinical details are: Sex: Female; Race: White; Tissue: Kidney; Disease: BLCA; Tumor Mutational Burden (FMOne mutation burden per MB): 5.0. Based on these characteristics, would you classify her as a likely responder or non-responder, and could you provide the reasoning behind your assessment?","Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), can you help assess her predicted responsiveness to Atezolizumab? The patient’s clinical details are: Sex: Female; Race: White; Tissue: Kidney; Disease: BLCA; Tumor Mutational Burden (FMOne mutation burden per MB): 5.0. Based on these characteristics, would you classify her as a likely responder or non-responder, and could you provide the reasoning behind your assessment? 1. Begin by loading the patient's transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Combine this probability with the patient’s clinical history to identify the five immune biomarkers most strongly associated with positive treatment outcomes.
4. Finally, evaluate the complete immunologic biomarker profile alongside the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a 5.0 mutations per megabase tumor mutational burden, male, White, and has liver tissue involvement. Based on these details, can you determine whether this patient is likely to respond to atezolizumab, and please provide the rationale supporting your conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a 5.0 mutations per megabase tumor mutational burden, male, White, and has liver tissue involvement. Based on these details, can you determine whether this patient is likely to respond to atezolizumab, and please provide the rationale supporting your conclusion? 1. Start by importing the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to calculate the likelihood that the patient will have a favorable response to immune checkpoint inhibitor therapy.
3. Integrate this probability with the patient's clinical history to select the five immune biomarkers most predictive of a positive treatment outcome.
4. Review the complete immunologic biomarker profile in conjunction with the predicted therapeutic response to decide if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"Given the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma, along with the following details: Male, White, bladder tissue involved, and an indeterminate tumor mutational burden, can you determine whether this patient is likely to respond to Atezolizumab therapy? Please include the clinical reasoning behind your assessment.","Given the patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma, along with the following details: Male, White, bladder tissue involved, and an indeterminate tumor mutational burden, can you determine whether this patient is likely to respond to Atezolizumab therapy? Please include the clinical reasoning behind your assessment. 1. Begin by importing the patient’s transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to estimate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Combine this probability with the patient’s clinical history to identify the five immune biomarkers most strongly associated with a positive treatment outcome.
4. Evaluate the full immunologic biomarker profile alongside the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data representing a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a kidney tissue sample, and the tumor mutational burden data (FMOne per MB) is not available. Based on this information, can you assess whether the patient is likely to respond to atezolizumab treatment and provide your supporting reasoning?","I have processed mRNA TPM data representing a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a kidney tissue sample, and the tumor mutational burden data (FMOne per MB) is not available. Based on this information, can you assess whether the patient is likely to respond to atezolizumab treatment and provide your supporting reasoning? 1. Import the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to calculate the likelihood of a favorable response to immune checkpoint inhibitor therapy.
3. Integrate this probability with the patient’s clinical history to determine the five immune biomarkers most strongly linked to a positive response.
4. Review the complete profile of immunologic biomarkers together with the predicted therapeutic response to decide if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I have TPM mRNA data from a patient's tumor immune microenvironment in the setting of Bladder Urothelial Carcinoma (BLCA), and I would like to evaluate their predicted response to Atezolizumab. The patient is a White male with BLCA, the tissue sampled is from the kidney, and the tumor mutational burden is 7 mutations per megabase. Based on these details, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please explain the rationale behind your conclusion?","I have TPM mRNA data from a patient's tumor immune microenvironment in the setting of Bladder Urothelial Carcinoma (BLCA), and I would like to evaluate their predicted response to Atezolizumab. The patient is a White male with BLCA, the tissue sampled is from the kidney, and the tumor mutational burden is 7 mutations per megabase. Based on these details, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please explain the rationale behind your conclusion? 1. Load the patient’s transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to estimate the probability of a beneficial response to immune checkpoint inhibitors.
3. Combine this probability with the patient’s clinical history to identify the five immune biomarkers most strongly associated with a positive therapeutic outcome.
4. Evaluate the overall profile of immunologic biomarkers along with the predicted response to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"Based on the processed mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and the following clinical details: male sex, white race, bladder tissue involvement, and a tumor mutational burden of 1.0 FMOne mutation per MB, could you determine whether this patient is predicted to be a responder to Atezolizumab and explain the reasoning behind your conclusion?","Based on the processed mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) and the following clinical details: male sex, white race, bladder tissue involvement, and a tumor mutational burden of 1.0 FMOne mutation per MB, could you determine whether this patient is predicted to be a responder to Atezolizumab and explain the reasoning behind your conclusion? 1. Begin by loading the patient’s transcriptomic data from the designated pickle file.  
2. Use the Compass algorithm to estimate the likelihood that the patient will benefit from immune checkpoint inhibitor therapy.  
3. Integrate this estimated probability with the patient’s clinical history to identify the five immune biomarkers most closely correlated with a favorable outcome.  
4. Review the overall immunologic biomarker profile along with the predicted therapeutic response to determine whether initiating immune checkpoint inhibitor treatment is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) to evaluate their potential response to Atezolizumab. The patient is a  male of White ethnicity, with the tumor originating in the bladder, and the tumor mutational burden is reported as ""nan"" (not available). Based on this clinical and molecular profile, could you provide your assessment of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale for your conclusion?","I have analyzed mRNA TPM data for a patient with bladder urothelial carcinoma (BLCA) to evaluate their potential response to Atezolizumab. The patient is a  male of White ethnicity, with the tumor originating in the bladder, and the tumor mutational burden is reported as ""nan"" (not available). Based on this clinical and molecular profile, could you provide your assessment of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting rationale for your conclusion? 1. Start by loading the patient's transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to calculate the probability that the patient will benefit from immune checkpoint inhibitor therapy.
3. Combine this estimated probability with the patient's clinical history to identify the five immune biomarkers most strongly associated with a positive therapeutic outcome.
4. Evaluate the overall immune biomarker profile alongside the predicted response to decide if initiating immune checkpoint inhibitor treatment is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) who is male, Caucasian, and has a tumor mutational burden of 6.0 mutations per MB, mRNA TPM data representing the tumor immune microenvironment has been analyzed. Can you provide your assessment regarding the likelihood of a positive response to Atezolizumab, along with the supporting rationale for this conclusion?","For a patient with Bladder Urothelial Carcinoma (BLCA) who is male, Caucasian, and has a tumor mutational burden of 6.0 mutations per MB, mRNA TPM data representing the tumor immune microenvironment has been analyzed. Can you provide your assessment regarding the likelihood of a positive response to Atezolizumab, along with the supporting rationale for this conclusion? 1. Begin by retrieving the patient’s transcriptomic data from the designated pickle file.  
2. Next, utilize the Compass algorithm to determine the likelihood that the patient will experience a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate this probability estimate with the patient’s clinical history to pinpoint the five immune biomarkers most strongly linked to a positive treatment outcome.  
4. Finally, review the overall immune biomarker profile in conjunction with the predicted therapeutic response to decide whether starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"Based on the mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), and considering that she is a white female with a bladder tumor and a tumor mutational burden of 3.0 mutations per MB, can you determine whether she is likely to respond to Atezolizumab therapy? Please include the rationale for your assessment.","Based on the mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), and considering that she is a white female with a bladder tumor and a tumor mutational burden of 3.0 mutations per MB, can you determine whether she is likely to respond to Atezolizumab therapy? Please include the rationale for your assessment. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to calculate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.  
3. Combine this probability with the patient’s clinical history to identify the five immune biomarkers most strongly associated with a positive treatment outcome.  
4. Evaluate the overall immune biomarker profile alongside the predicted response to determine if initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"I have generated mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) who is being considered for Atezolizumab treatment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 7.0 mutations per megabase. Based on this information, could you please determine whether the patient is likely to respond to Atezolizumab and provide the rationale behind your prediction?","I have generated mRNA TPM data reflecting the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) who is being considered for Atezolizumab treatment. The patient is a white male with bladder tissue involvement and a tumor mutational burden of 7.0 mutations per megabase. Based on this information, could you please determine whether the patient is likely to respond to Atezolizumab and provide the rationale behind your prediction? 1. Access the patient’s transcriptomic data from the specified pickle file.  
2. Utilize the Compass algorithm to determine the likelihood that the patient will have a favorable response to immune checkpoint inhibitor therapy.  
3. Integrate this probability with the patient’s clinical history to pinpoint the five immune biomarkers most strongly linked to a positive treatment outcome.  
4. Assess the overall immune biomarker profile in conjunction with the predicted response to decide whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,Can you evaluate whether a white male patient with bladder urothelial carcinoma (BLCA) is likely to respond to Atezolizumab based on his mRNA TPM data from the tumor immune microenvironment? The patient’s tumor mutational burden is 14.0 mutations per MB. Please provide your assessment and the supporting rationale.,"Can you evaluate whether a white male patient with bladder urothelial carcinoma (BLCA) is likely to respond to Atezolizumab based on his mRNA TPM data from the tumor immune microenvironment? The patient’s tumor mutational burden is 14.0 mutations per MB. Please provide your assessment and the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Apply the Compass algorithm to calculate the probability that the patient will respond favorably to immune checkpoint inhibitor therapy.
3. Combine this probability with the patient’s clinical history to identify the five immune biomarkers most closely associated with a positive treatment outcome.
4. Review the overall immune biomarker profile alongside the predicted response to determine if initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"I have processed mRNA TPM data detailing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White ethnicity, with kidney tissue analysis and a tumor mutational burden of 2.0 mutations per MB. Based on this information, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your conclusion?","I have processed mRNA TPM data detailing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male of White ethnicity, with kidney tissue analysis and a tumor mutational burden of 2.0 mutations per MB. Based on this information, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your conclusion? 1. Retrieve the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm to estimate the likelihood that the patient will respond to immune checkpoint inhibitors.
3. Integrate this response probability with the patient’s clinical history to identify the five key immune biomarkers most strongly linked to a favorable outcome.
4. Evaluate the complete immune biomarker profile together with the predicted therapeutic response to decide whether starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (BLCA). The patient is White, with a bladder tissue sample and an indeterminate tumor mutational burden. Based on this information, can you provide a detailed assessment of whether the patient is likely to respond to Atezolizumab, including the rationale behind the classification as a responder or non-responder?","I have mRNA TPM data reflecting the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (BLCA). The patient is White, with a bladder tissue sample and an indeterminate tumor mutational burden. Based on this information, can you provide a detailed assessment of whether the patient is likely to respond to Atezolizumab, including the rationale behind the classification as a responder or non-responder? 1. Retrieve the patient’s transcriptomic data stored in the designated pickle file.
2. Run the Compass algorithm on this data to calculate the probability that the patient will benefit from immune checkpoint inhibitors.
3. Combine this probability with the patient’s clinical history to pinpoint the five key immune biomarkers most indicative of a favorable response.
4. Review the complete immune biomarker profile alongside the predicted therapeutic response to determine if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"Based on the patient's mRNA TPM data for tumor immune microenvironment profiling in Bladder Urothelial Carcinoma (BLCA)—with the following characteristics: male, White, lymph node tissue involvement, and an indeterminate tumor mutational burden—can we predict whether this patient is likely to be a responder or a non-responder to Atezolizumab? Please include your reasoning for this classification.","Based on the patient's mRNA TPM data for tumor immune microenvironment profiling in Bladder Urothelial Carcinoma (BLCA)—with the following characteristics: male, White, lymph node tissue involvement, and an indeterminate tumor mutational burden—can we predict whether this patient is likely to be a responder or a non-responder to Atezolizumab? Please include your reasoning for this classification. 1. Access the patient’s transcriptomic data from the specified pickle file.
2. Use the Compass algorithm on this data to determine the likelihood that the patient will respond well to immune checkpoint inhibitors.
3. Integrate this probability with the patient’s clinical history to identify the top five immune biomarkers most indicative of a positive treatment response.
4. Review the full immune biomarker profile along with the predicted therapeutic response to decide whether initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"Based on mRNA TPM data obtained from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), could you please assess whether the patient is likely to respond to Atezolizumab? Patient details include: male, white, tissue sampled from the lung, diagnosis of BLCA, and a tumor mutational burden of 1.0 mutations per megabase. Please provide your conclusion along with the supporting rationale.","Based on mRNA TPM data obtained from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), could you please assess whether the patient is likely to respond to Atezolizumab? Patient details include: male, white, tissue sampled from the lung, diagnosis of BLCA, and a tumor mutational burden of 1.0 mutations per megabase. Please provide your conclusion along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.  
2. Apply the Compass algorithm to the data to estimate the patient’s likelihood of responding favorably to immune checkpoint inhibitors.  
3. Combine this probability with the patient’s clinical history to determine the five most informative immune biomarkers that predict a positive treatment response.  
4. Review the comprehensive immune biomarker profile together with the predicted therapeutic response to decide if starting immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"Based on the mRNA TPM data assessing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine whether this patient is likely to respond to Atezolizumab? The patient’s details are as follows: Male, White, tissue sample from ureter, and a tumor mutational burden of 14.0 FMOne mutations per MB. Please provide your conclusion along with the supporting rationale.","Based on the mRNA TPM data assessing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), can you determine whether this patient is likely to respond to Atezolizumab? The patient’s details are as follows: Male, White, tissue sample from ureter, and a tumor mutational burden of 14.0 FMOne mutations per MB. Please provide your conclusion along with the supporting rationale. 1. Access the patient's transcriptomic data from the specified pickle file.
2. Use the Compass algorithm on the data to estimate the patient’s likelihood of a positive response to immune checkpoint inhibitors.
3. Integrate this probability with the patient's clinical history to identify the five most predictive immune biomarkers for treatment response.
4. Evaluate the overall immune biomarker profile in conjunction with the predicted therapeutic outcome to determine whether initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has mRNA TPM data profiling the tumor immune microenvironment (with data obtained from kidney tissue) and a tumor mutational burden of 14 mutations per MB, could you please assess the predicted responsiveness to Atezolizumab? Please provide your evaluation on whether the patient is likely to respond or not, along with the supporting rationale.","For a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has mRNA TPM data profiling the tumor immune microenvironment (with data obtained from kidney tissue) and a tumor mutational burden of 14 mutations per MB, could you please assess the predicted responsiveness to Atezolizumab? Please provide your evaluation on whether the patient is likely to respond or not, along with the supporting rationale. 1. Retrieve the patient’s transcriptomic data from the designated pickle file.
2. Run the Compass algorithm on the data to calculate the probability that the patient will respond positively to immune checkpoint inhibitors.
3. Integrate this probability with the patient’s clinical history to identify the five immune biomarkers most predictive of a favorable treatment outcome.
4. Review the overall immune biomarker profile together with the estimated therapeutic benefit to determine if initiating immune checkpoint inhibitor therapy is advisable.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"For a patient with Bladder Urothelial Carcinoma (BLCA) who is male, of African American descent, with a bladder tumor and a tumor mutational burden of 9.0 mutations per megabase, and given the available mRNA TPM data representing the tumor immune microenvironment, could you evaluate the likelihood of a positive response to Atezolizumab? Please include the rationale for classifying this patient as either a responder or non-responder.","For a patient with Bladder Urothelial Carcinoma (BLCA) who is male, of African American descent, with a bladder tumor and a tumor mutational burden of 9.0 mutations per megabase, and given the available mRNA TPM data representing the tumor immune microenvironment, could you evaluate the likelihood of a positive response to Atezolizumab? Please include the rationale for classifying this patient as either a responder or non-responder. 1. Extract the patient’s transcriptomic data from the specified pickle file.
2. Apply the Compass algorithm to this data to estimate the likelihood of a positive response to immune checkpoint inhibitors.
3. Combine this probability with the patient’s clinical history to identify the five key immune biomarkers that best predict a favorable treatment response.
4. Evaluate the overall profile of these immune biomarkers alongside the projected therapeutic benefit to determine whether initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"Based on the mRNA TPM data of the tumor immune microenvironment for this patient with bladder urothelial carcinoma (BLCA), who is a white male with a bladder tissue specimen and a tumor mutational burden of 8.0 mutations per megabase, could you please determine whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion?","Based on the mRNA TPM data of the tumor immune microenvironment for this patient with bladder urothelial carcinoma (BLCA), who is a white male with a bladder tissue specimen and a tumor mutational burden of 8.0 mutations per megabase, could you please determine whether this patient is likely to respond to Atezolizumab and provide the supporting rationale for your conclusion? 1. Retrieve the patient's transcriptomic data from the designated pickle file.
2. Use the Compass algorithm to analyze this data and estimate the likelihood of a positive response to immune checkpoint inhibitors.
3. Integrate the resulting probability with the patient’s clinical history to pinpoint the five key immune biomarkers that most strongly predict a favorable treatment outcome.
4. Assess the overall profile of these biomarkers in conjunction with the expected therapeutic benefit to determine whether starting immune checkpoint inhibitor therapy is warranted.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"Based on the patient’s mRNA TPM data from the tumor immune microenvironment and clinical details (female, white, bladder tissue, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 7 mutations per megabase), could you assess whether this patient is likely to respond to Atezolizumab immunotherapy and provide the supporting rationale for your conclusion?","Based on the patient’s mRNA TPM data from the tumor immune microenvironment and clinical details (female, white, bladder tissue, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 7 mutations per megabase), could you assess whether this patient is likely to respond to Atezolizumab immunotherapy and provide the supporting rationale for your conclusion? 1. Retrieve the patient’s transcriptomic profiling data from the designated pickle file.  
2. Apply the Compass algorithm to this data to estimate the probability of a positive response to immune checkpoint inhibitors.  
3. Integrate this probability with the patient’s clinical history to identify the five key immune biomarkers that most strongly predict a favorable treatment outcome.  
4. Review the overall biomarker profile and anticipated therapeutic benefit to determine if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"Based on this patient's profile—a female of Asian descent with Bladder Urothelial Carcinoma, assessed using mRNA TPM data from kidney tissue and a tumor mutational burden of 4.0 mutations per megabase—can you determine whether she is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the underlying rationale.","Based on this patient's profile—a female of Asian descent with Bladder Urothelial Carcinoma, assessed using mRNA TPM data from kidney tissue and a tumor mutational burden of 4.0 mutations per megabase—can you determine whether she is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the underlying rationale. 1. First, access the patient’s transcriptomic profiling data from the specified pickle file.  
2. Next, run the Compass algorithm on this data to generate an estimate of the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Then, combine this probability estimate with the patient’s clinical history to pinpoint the five immune biomarkers that most strongly predict a favorable outcome.  
4. Finally, evaluate the overall biomarker profile together with the anticipated therapeutic benefit to decide whether starting immune checkpoint inhibitor therapy is appropriate for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"I have evaluated mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, with kidney tissue involvement, and a tumor mutational burden of 7.0 (FMOne mutations per megabase). Based on these data, could you provide an assessment of whether the patient is likely to respond to Atezolizumab? Please include the rationale for your conclusion.","I have evaluated mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient is a white male, with kidney tissue involvement, and a tumor mutational burden of 7.0 (FMOne mutations per megabase). Based on these data, could you provide an assessment of whether the patient is likely to respond to Atezolizumab? Please include the rationale for your conclusion. 1. Begin by loading the patient’s transcriptomic profiling data from the designated pickle file.  
2. Apply the Compass algorithm to this dataset to obtain an estimated probability of the patient responding favorably to immune checkpoint inhibitor therapy.  
3. Integrate this probability with the patient's clinical history to identify the five immune biomarkers most strongly linked to a positive outcome.  
4. Finally, review the collective biomarker profile alongside the expected therapeutic benefit to determine whether initiating immune checkpoint inhibitor therapy is appropriate for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For a  patient with bladder urothelial carcinoma (BLCA), we have mRNA TPM data from the tumor immune microenvironment along with the following clinical details: Sex: male, Race: White, Tissue: bladder, and a reported tumor mutational burden of ""nan."" Based on these data, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","For a  patient with bladder urothelial carcinoma (BLCA), we have mRNA TPM data from the tumor immune microenvironment along with the following clinical details: Sex: male, Race: White, Tissue: bladder, and a reported tumor mutational burden of ""nan."" Based on these data, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. 1. Start by loading the patient’s transcriptomic profiling data from the specified pickle file.  
2. Run the Compass algorithm on this dataset to calculate the probability that the patient will respond well to immune checkpoint inhibitor therapy.  
3. Combine this probability with the patient's clinical history to determine the five immune biomarkers most strongly associated with a favorable response.  
4. Review the resulting biomarker profile together with the expected therapeutic benefits to decide if initiating immune checkpoint inhibitor therapy is appropriate for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For a male patient with bladder urothelial carcinoma (BLCA) who is White, with mRNA TPM data reflecting the tumor immune microenvironment and a tumor mutational burden of 5.0 mutations per megabase, could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include your reasoning regarding whether this patient is classified as a responder or non-responder.","For a male patient with bladder urothelial carcinoma (BLCA) who is White, with mRNA TPM data reflecting the tumor immune microenvironment and a tumor mutational burden of 5.0 mutations per megabase, could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include your reasoning regarding whether this patient is classified as a responder or non-responder. 1. Load the patient’s transcriptomic data from the designated pickle file.  
2. Process the data using the Compass algorithm to compute the likelihood of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate this likelihood with the patient’s clinical history to identify the five immune biomarkers most strongly linked to a favorable therapeutic outcome.  
4. Evaluate the identified biomarker profile alongside the anticipated treatment benefits to decide whether to proceed with immune checkpoint inhibitor therapy for this patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For a female patient diagnosed with Bladder Urothelial Carcinoma (BLCA) of white race and bladder tissue origin, with a tumor mutational burden of 7.0 FMOne mutations per MB, and having processed mRNA TPM data reflecting the tumor immune microenvironment, how would you classify her predicted response to Atezolizumab—responder or non-responder? Please explain the reasoning behind your assessment.","For a female patient diagnosed with Bladder Urothelial Carcinoma (BLCA) of white race and bladder tissue origin, with a tumor mutational burden of 7.0 FMOne mutations per MB, and having processed mRNA TPM data reflecting the tumor immune microenvironment, how would you classify her predicted response to Atezolizumab—responder or non-responder? Please explain the reasoning behind your assessment. 1. Begin by loading the patient’s transcriptomic data from the specified pickle file.  
2. Analyze the data with the Compass algorithm to determine the likelihood that the patient will respond positively to immune checkpoint inhibitor therapy.  
3. Combine this probability with the patient’s clinical history to pinpoint the five immune biomarkers most closely linked to a favorable treatment outcome.  
4. Review the resulting biomarker profile together with the expected benefits of treatment to decide if initiating immune checkpoint inhibitor therapy is appropriate for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, with the following characteristics—Male, White, non-specific tissue type, and a tumor mutational burden of 10.0 mutations per MB—what is the predicted likelihood of response to Atezolizumab? Please provide a conclusion regarding whether the patient is expected to be a responder or non-responder, including the supporting reasoning.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma, with the following characteristics—Male, White, non-specific tissue type, and a tumor mutational burden of 10.0 mutations per MB—what is the predicted likelihood of response to Atezolizumab? Please provide a conclusion regarding whether the patient is expected to be a responder or non-responder, including the supporting reasoning. 1. Load the patient’s transcriptomic data from the designated pickle file.  
2. Process this data using the Compass algorithm to estimate the probability of a positive response to immune checkpoint inhibitor therapy.  
3. Integrate the calculated probability with the patient’s clinical history to identify the five immune biomarkers most closely associated with a favorable treatment response.  
4. Discuss the identified biomarker profile and the anticipated benefits of treatment to determine if initiating immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
